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ABSTRACT 
FACULTY OF MEDICINE, HEALTH AND LIFE SCIENCES 
School of Medicine 
Doctor of Philosophy 
The role of the MAP Kinase Signal Integrating Kinases in the proliferation 
and survival of cancer cells 
By Matthew James Wheater 
Eukaryotic initiation factor 4E (eIF4E) is an oncogene over-expressed in a variety 
of cancers. It is responsible for regulation of synthesis of proteins involved in 
progression to the malignant phenotype, including cyclin D1, Mcl-1 and VEGF. The 
oncogenic activity of eIF4E has been shown to be dependent on phosphorylation 
at serine 209 by the mitogen-activating protein kinase signal integrating kinases 
(MNKs). 
This work investigates the role of the MNK proteins in the proliferation and survival 
of breast and kidney cancer cells. Inhibition of the MNKs with a chemical kinase 
inhibitor resulted in inhibition of proliferation through cell cycle arrest, with no 
induction of apoptosis. This is consistent with a reduction in cyclin D1 protein. 
Combination of mTOR inhibition and inhibition of the MNK proteins in kidney 
cancer cells resulted in an additive but not synergistic effect on inhibition of 
proliferation. siRNA knockdown of the MNKs resulted in a reduction in eIF4E 
phosphorylation but did not inhibit proliferation or induce cell cycle arrest in a renal 
cancer cell line. The generation of an eIF4E mutant with phospho-mimetic activity 
induced partial insensitivity to the MNK kinase inhibitor suggesting some specificity 
of activity of this agent through the MNK proteins. 
Inhibition of the MNKs resulted in a reduction in cyclin D1 mRNA with no reduction 
in transcription. An accumulation of cyclin D1 RNA was seen in the nuclear 
compartment following treatment with MNK inhibitor suggesting inhibition of 
nuclear export of cyclin D1 RNA and subsequent degradation. Gene expression 
array analysis revealed regulation of genes with key functions in cellular 
metabolism. 
The MNK kinases are thus worthy of further investigation as a therapeutic target in 
breast and renal cancer. More potent and specific inhibitors of the MNK kinases 
than CGP57380 are required for this to be clinically relevant.   3 
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1. Introduction 
An increasing understanding of the molecular characteristics underlying the 
development of cancer has led to a revolution in the development of cancer 
therapeutics, with many agents now in use designed to inhibit known signaling 
pathways critical to cancer cell proliferation and survival. Although these agents 
have improved the outlook for many with cancer, in the face of advanced disease, 
cure remains elusive for the majority. There is thus an imperative to investigate 
novel pathways involved in the development and maintenance of the malignant 
phenotype, and strategies for their inhibition. 
Many intracellular signaling events are controlled by post-translational modification 
of proteins including phosphorylation; indeed many of the cellular functions which 
become dysregulated as the hallmarks of cancer
1 are controlled by protein kinase 
signaling cascades. As such interest has developed in the understanding of protein 
kinases, and synthesis of specific inhibitors which are now starting to see 
widespread use in the clinical treatment of cancer.  
1.1. Eukaryotic Initiation Factor 4E (eIF4E) 
eIF4E is a translation factor involved in the preferential translation of a variety of 
proteins including many which regulate cell growth, proliferation and invasion. 
These include the cell cycle regulatory protein cyclin D1
2, the transcription factor c-
Myc and growth factors such as vascular endothelial growth factor (VEGF) and 
fibroblast growth factor 2 (FGF2)
3. eIF4E has dual functions, regulating translation 
through mRNA cap binding, and through control of mRNA nuclear export. 
 
eIF4E regulation of translation via mRNA cap binding 
Regulation of cap dependent translation is achieved through binding of eIF4E to 
the 7-methyl guanosine tri-phosphate (GTP) cap structure present at the 5’ end of 
all mRNA molecules. Following binding of eIF4E to the cap structure a scaffold 
protein eIF4G is recruited, leading to the further recruitment of eIF4A, a RNA 
helicase, to form the eIF4F complex. Poly-A binding protein (PABP) binds eIF4G to 
the poly-adenylated tail at the 3’ end of the mRNA creating a loop structure. 
Subsequent binding of the 40S ribosome subunit and methionyl tRNA leads to   15 
translation initiation on reaching the AUG initiation codon in the open reading frame 
(Fig 1:1). eIF4E is the rate limiting component of the eIF4F complex and thus 
translation is sensitive to the presence of increasing availability of eIF4E. 
A subset of mRNA molecules include a long and complex 5’ untranslated region 
(UTR) rich in cytosine and guanine, with features such as repeat stem loop 
structures. These mRNA molecules often code for proteins implicated in malignant 
transformation such as c-myc and VEGF as described above. Those mRNA 
molecules with a complex 5’ UTR are particularly sensitive to the presence of the 
helicase eIF4A for efficient translation. Most mRNAs have short 5’ UTRs and are 
efficiently translated at low levels of eIF4F, however in response to growth 
signaling, increasing amounts of eIF4E are available for formation of the eIF4F 
complex. This then allows increased translation of those mRNAs with complex 
5’UTRs.  
     16 
 
 
 
 
 
 
Figure 1:1 Structure of the eIF4F complex 
AAAAAAA!. Poly A tail; PABP Poly A Binding Protein; eIF4G eukaryotic initiation factor 
4G; eIF4E eukaryotic initiation factor 4E; MNK mitogen activating protein kinase signal 
integrating kinase; M
7GTP 7 methyl guanine triphosphate cap; eIF4A eukaryotic initiation 
factor 4A; 40SR 40S ribosomal subunit 
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eIF4E is essential for cell survival, with knockdown producing cell death in HeLa 
cells
3, and lethality in yeast
4. Overexpression however causes deregulated cell 
growth and malignant transformation
3,5; indeed patients with node positive breast 
cancer and high levels of eIF4E expression have a significant increase in relative 
risk for cancer recurrence
6. Increased expression has also been identified as an 
adverse prognostic factor in head and neck cancer
7, and lung cancer
8,9 and with 
progression from adenoma to carcinoma in colorectal cancer
9. Regulation of eIF4E 
is thus critical both to normal development and avoidance of a malignant 
phenotype. 
The activity of the eIF4F complex is regulated by competitive binding of eIF4E to 
4E binding proteins (4E-BPs) at the same binding site as eIF4G. Sequential 
phosphorylation of 4E-BP reduces its affinity for eIF4E allowing formation of the 
eIF4F complex. 4E-BP phosphorylation is under the control of the mammalian 
target of rapamycin complex 1 (mTORC1) and thus through the phosphoinositide 
3-kinase (PI3 kinase)/AKT pathway, such that a variety of mitogenic and growth 
stimulatory factors, signalling through receptor tyrosine kinases, cause up-
regulation of protein translation via eIF4E
10 .  
Further input to the eIF4E translation initiation factor is through phosphorylation by 
the mitogen activated protein kinase (MAPK) signal-integrating kinases (MNKs). 
The MNKs themselves undergo activating phosphorylation through both 
extracellular signal-regulated kinase (ERK) and p38 MAP-kinase, and are therefore 
downstream of the MAP-kinase pathway (Fig 1:2). 
 
eIF4E regulation of RNA nuclear export 
Additional control of gene expression at the post-transcriptional level can be 
achieved via the control of mRNA export, with enhanced nuclear export of mRNA 
messages facilitating increased ribosomal recruitment and hence enhanced 
translation. The majority of large mRNA molecules are transported through nuclear 
pore complexes following completion of splicing via the binding of an exporter 
complex, consisting of a heterodimer of Tap (NXF1) and NXT
11. An alternative 
export pathway, CRM1, predominantly regulates export of ribosomal RNA and 
small nuclear RNA (snRNA) prior to cytoplasmic incorporation into small nuclear 
ribonuclear proteins (snRNPs)   18 
The role of eIF4E in promoting nuclear export of mRNA appears related to its 
phosphorylation at serine 209 by MNKs, with phosphorylation promoting nuclear 
export and contributing to the transforming ability of eIF4E
12. 
In cytoplasmic fractions of whole cell lysates eIF4E is able to bind all mRNA 
molecules due to the presence of a 5’ m
7GTP cap on the mRNA molecule as 
described above. It appears however that eIF4E binding in nuclear fractions is 
restricted to a subset of mRNA molecules with specific characteristics. 
Experiments using eIF4E mutants deficient in particular functions have shown that 
binding to the mRNA cap is essential, however a mutant inactive in translation, and 
unable to bind the eIF4G scaffold, remains able to promote nuclear export. Using 
reporter constructs of the cyclin D1 3’UTR, a 100-nt region has been identified 
which is essential for nuclear export and is conserved between species. This 4E 
sensitivity element (4E-SE) appears to be the defining characteristic of mRNA 
molecules for which eIF4E regulates nuclear export
13, and is an example of the 
way in which coordinated regulation of expression of functionally related genes can 
occur at a post-transcriptional level. Such elements in the 5’ or 3’UTR of mRNA 
molecules have been termed untranslated sequence elements for regulation, or 
USER codes
14. 
The mechanism underlying nuclear export of mRNA as regulated by eIF4E 
appears specific, and independent of bulk mRNA transport via NXF1 (Tap). siRNA 
knockdown of NXF1 failed to affect the nuclear export of 4E-SE containing reporter 
constructs, however leptomycin B caused nuclear accumulation, suggesting CRM1 
to be the nuclear export mechanism through which eIF4E mediated mRNA export 
occurs
14. 
Whereas cytoplasmic regulation of eIF4E is predominantly through binding to 4E-
BPs, in the nucleus the export function of eIF4E is controlled through binding of the 
RING domain of promyelocytic leukaemia protein (PML)
15. A large portion of 
cellular eIF4E is located in the nucleus where it is associated with nuclear bodies. 
Whereas over-expression of eIF4E induces increased nuclear export of cyclin D1, 
over-expression of PML causes a reduction in cyclin D1 mRNA in the cytoplasmic 
compartment, suggesting a negative regulatory role of PML in eIF4E induced 
nuclear export. In addition PML can be detected by pull down of eIF4E by 
immunoprecipitation, suggesting a direct interaction between these two proteins
16.      19 
 
 
 
 
 
 
Figure 1:2 eIF4E is regulated by the PI3K and MAPK pathways 
Activation of receptor tyrosine kinases (RTK) through ligand binding leads to sequential 
activation of members of the PI3K/AKT/mTOR, or MAPK (RAS/RAF/MEK/ERK) pathways. 
Activation of mTOR leads to phosphorylation of 4E binding proteins (4EBP) and their 
dissociation from eIF4E allowing recruitment to the eIF4F complex. Activation of MNK1 via 
MAPK signaling leads to phosphorylation of eIF4E with a subsequent reduction in cap 
binding affinity and promotion of mRNA nuclear export.  
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eIF4E as a therapeutic target 
eIF4E has become a therapeutic target via its regulation by 4E-BP. mTOR 
inhibitors are now used in the clinic both as anti-neoplastic and 
immunosuppressant drugs. Both temsirolimus
17, and everolimus
18, analogues of 
the naturally occurring mTOR inhibitor rapamycin, have shown activity in advanced 
renal cancer and are licensed for use in the first and second line respectively. 
Alternative therapeutic strategies are being investigated with the clinical 
development of anti-sense technology targeted at eIF4E
19. 
Pre-clinical work has shown that inhibition of eIF4E with rapamycin can cause a 
paradoxical rise in eIF4E phosphorylation in a PI3K dependent fashion
20. The 
implication of this finding remains at present uncertain, but could represent a 
mechanism of resistance to mTOR inhibition in cancer therapy, however the further 
study of pathways controlling the activity of eIF4E is clearly warranted. 
 
1.2. Signalling pathways regulating eIF4E 
 
Growth and mitogenic signals, following transduction by transmembrane receptors, 
are relayed to their cytoplasmic and nuclear targets by a complex set of 
intracellular signaling molecules. Two molecular pathways define much of this 
signaling, namely the PI3K/mTOR and MAPK pathways. eIF4E is regulated by 
input from both the PI3K and MAPK signaling cascades, and is therefore 
potentially a critical node in the regulation of signalling inputs under many different 
conditions. 
 
PI3K/mTOR 
The best defined regulatory interaction of eIF4E is through the PI3K/mTOR 
pathway, via 4E-BP1. In its unphosphorylated form, 4E-BP1 binds eIF4E, 
preventing its interaction with the eIF4G scaffold protein and therefore preventing 
assembly of the eIF4F complex
21. The phosphorylation of 4E-BP1 is regulated by 
mTOR, in complex with raptor as mTORC1. 4E-BP1 undergoes four sequential 
phosphorylation events leading to its dissociation from eIF4E and up-regulation of 
translation of target mRNAs
22.   21 
mTOR exists as two complexes in mammals, mTORC1 in complex with raptor and 
mLST8, and mTORC2 together with rictor and mLST8
23. The function of mTORC1 
is the best defined and accounts for most of the knowledge of mTOR function. 
mTORC1 is able to integrate a variety of extracellular and intracellular signals 
including growth factors
24, amino acids
25, insulin
24 and intracellular energy supply 
in the form of ATP/ADP ratios
26. 
mTORC1 is directly activated by Rheb via binding to its catalytic domain. Rheb is a 
GTPase and only activates mTORC1 in the presence of GTP, having an inhibitory 
effect in its absence
27. Rheb is inactivated by tuberous sclerosis complex 2 
(TSC2), a GTPase activating protein (GAP) which forms a complex with TSC1, by 
converting Rheb from its GTP to its GDP bound form
28. TSC2 is itself inactivated 
by signalling from AKT, which phosphorylates TSC2, inhibiting its GAP activity
29. 
TSC also has inhibitory input from ERK, which inhibits the association of TSC1 and 
TSC2 in response to signaling from the MAPK pathway, ultimately resulting in 
activation of mTOR
30. 
AKT is recruited to the cell membrane by phosphotidylinositol-3,4,5–triphosphate 
(PIP3), and activated by phosphorylation at two sites
31. 3-phosphoinositide 
dependent kinase (PDK1), itself recruited and bound by PIP3, phosphorylates AKT 
at Thr 308 on the activation-loop
32. A second phosphorylation event at Ser 473 
occurs via mTORC2
33. 
Activation of cell surface receptor tyrosine kinases results in a conformational 
change through which tyrosine residues are phosphorylated, leading to the binding 
of PI3K via SH2 domains. PI3K consists of two subunits, p85, a regulatory unit, 
and p110 which has a catalytic function, phosphorylating phophotidylinositol-4,5-
bisphosphate (PIP2) to form PIP3. PI3K can also be directly activated by Ras, a 
further interaction between the MAPK and mTOR pathways
34. The action of PI3K 
in phosphorylating PIP2 is antagonised by the tumour suppressor phosphatase 
and tensin homolog (PTEN)
35. This phosphatase inhibits signalling through the 
PI3K/mTOR axis, and is mutated either in the germ line, or as a somatic mutation 
in a wide variety of cancers
36. 
Once activated mTORC1 up-regulates both eIF4E (via inhibitory phosphorylation of 
4EBP), and activates S6K. This results in both up-regulation of ribosomal 
synthesis, but also in an inhibitory negative feedback loop to PI3K (fig 1:3).   22 
PIP2 is involved in an additional intracellular signalling pathway, which can also be 
activated by receptor tyrosine kinases, as well as antigen receptors on the surface 
of cells of the immune system and phorbol esters. PIP2 can be converted, not only 
to PIP3 by PI3K, but also to inositol 1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG), by phospholipase C. IP3 binds receptors on the endoplasmic reticulum 
resulting in release of calcium, and the propagation of a signalling cascade through 
calcium flux. DAG however is an activator both of protein kinase C and of Ras 
GTPase. Activation of protein kinase C plays a critical role in control of immune 
function, in part through activation of NF-!B as well as through the interplay 
between the MAPK signalling cascade and the calmodulin, calcineurin pathway 
(reviewed in 
37).  
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Figure 1:3 PI3K/AKT signaling activates eIF4E via mTOR 
Activation of receptor tyrosine kinases via ligand binding leads to recruitment of the p85 
and p110 subunits of phosphatidylinositol 3-kinase (PI3K) and subsequent 
phosphorylation of phosphatidylinositol (3,4)-bisphosphate (PIP2) to phosphatidylinositol 
(3,4,5)-triphosphate (PIP3), a reaction antagonised by phosphatase and tensin homolog 
(PTEN). PIP3 recruits AKT to the inner cell membrane where it is phosphorylated and 
activated by 3-phosphoinositide dependent kinase (PDK1). Activated AKT phosphorylates 
tuberous sclerosis complex 2 (TSC2) preventing its inhibitory activity on Rheb, which also 
results from ERK activation preventing the binding of TSC2 and tuberous sclerosis 
complex 1. Rheb therefore remains in its activated form and activates mammalian target of 
rapamycin (mTOR) as mTOR complex 1 (mTORC1) bound to Raptor and mammalian 
LST8. This in turn results in phosphorylation of 4E-binding proteins (4E-BPs) preventing 
their association with eIF4E allowing recruitment to the eIF4F complex. mTOR additionally 
phosphorylates and activates ribosomal S6 kinase, which has a negative regulatory effect 
on PI3K. mTOR exists in a second complex (mTORC2) which has activity in promoting 
signaling through the PI3K/AKT pathway through activation of AKT.     24 
MAPK Signalling 
The MAPK signalling cascade is a complex system of sequential kinases that can 
be divided into three major cascades, with four main levels of signaling. The three 
major cascades include the ERK MAPK pathway which is involved in transduction 
of proliferative signaling, with activating mutations in several of its constituent 
kinases implicated in carcinogenesis
38,39. p38 and c-Jun N-terminal kinase (JNK) 
MAPK pathways are involved in stress response, with ERK and p38 shown to have 
activity in regulating eIF4E
40. 
Each of these signalling pathways has analogous levels of signaling, terminating in 
the MAPK molecules ERK, JNK and p38. These MAPK molecules are themselves 
activated by phosphorylation by a MAPK kinase (MAPKK). Moving up the chain of 
signaling molecules are also found MAPKK kinases (MAP3K) (fig 1:4). 
The best described of the MAPK pathways is the ERK pathway. Phosphorylation of 
receptor tyrosine kinases results in the activation of membrane bound RAS 
GTPase, through recruitment of adaptor proteins. Growth factor receptor-bound 
protein 2 (Grb2) is an adaptor protein, bound to Son of Sevenless (SOS) by a Src 
homology 3 (SH3) domain. Once the Grb2/SOS complex is bound to the activated 
receptor tyrosine kinase, SOS acts as a guanine exchange factor to Ras, switching 
it to its active GTP bound form
41. Three Ras genes exist in humans; K-Ras, H-Ras, 
and N-Ras, giving rise to four proteins; K-RAS4A, K-RAS4B, H-RAS and N-RAS. 
These are ubiquitously expressed with tissue specific variations in ratios of 
particular proteins
42. 
Activated Ras binds Raf-1, a serine/threonine kinase via two binding sites on Raf-
1, a cystein rich domain (CSD), and Ras binding domain (RBD). Raf-1 undergoes a 
conformational change during this binding process, leading to activation of its 
kinase function, and phosphorylation of MAPK/ERK kinase (MEK)
43. MEK, a family 
of dual specific tyrosine/threonine kinases in turn phosphorylate ERK1 and ERK2 
on both tyrosine and threonine residues
44. Co-ordination of this sequence of 
phosphorylation events is facilitated by the translocation of kinase suppressor of 
ras (KSR), a scaffold protein which binds Raf-1, MEK and ERK, to the plasma 
membrane
45. ERK 1 and 2 target a variety of effector molecules including protein 
kinases (MAPK activated protein kinases (MAPKAPK) I (p90RSK) and II)
46, and 
transcription factors such as the Ets family including Elk-1
47. 
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Figure 1:4 Signalling through the ERK MAPK pathway 
Activation of receptor tyrosine kinases (RTK) through ligand binding results in the 
recruitment of adaptor proteins Growth Factor Receptor-bound Protein 2 (Grb2) 
and Son of Sevenless (SOS). As a result Ras becomes activated leading to 
sequential phosphorylation of Raf (Mitogen Activating Protein Kinase Kinase 
Kinase (MAP3K)), Map/Erk Kinase (MEK) (Mitogen Activating Protein Kinase 
Kinase (MAPKK)) and Extracellular Regulated Signalling Kinase (ERK) (Mitogen 
Activating Protein Kinase (MAPK)). These phosphorylation events are facilitated by 
binding to the scaffold protein Kinase Suppressor of Ras (KSR). Activation of ERK 
leads to phosphorylation of Ribosomal S6 Kinase (RSK), Map Kinase Activating 
Protein Kinases (MAPKAPK) and activation of transcription factors within the 
nucleus.     26 
1.3.  Mitogen activated protein kinase (MAPK) signal-integrating 
Kinases 
Mitogen activated protein kinase (MAPK) signal-integrating Kinases (MNKs) 1 and 
2 are two protein kinases that phosphorylate eukaryotic initiation factor 4E (eIF4E) 
at serine 209. Murine Mnks 1 and 2, and human MNK1, were identified in 1997 as 
downstream targets of both the extracellular signal-regulated kinases (ERK) and 
p38 MAPK pathways, responsible for phosphorylation of eIF4E in response to 
extracellular mitogens or stress
40,48. Subsequently the human MNK2 gene was 
identified in 2000
49. Since then, despite extensive work on their role in both normal 
and deregulated cell function, uncertainty persists as to their function. 
The MNK proteins have similarity with other protein kinase targets of MAP kinases, 
the ribosomal S-6 kinase (RSK) proteins. They contain a C terminal ERK 
interacting domain, a T loop, which contains MAPK phosphorylation sites, and a 
catalytic domain, however unlike the RSKs they lack a second N terminal kinase 
domain
40. Two splice variants of both the MNK genes exist in humans; MNK1a and 
MNK1b
49,50. Both MNK1b and MNK2b are truncated proteins, lacking the C 
terminal MAPK binding domain, however they retain their ability to phosphorylate 
eIF4E in vitro (fig 1:5). 
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Figure 1:5 Domain structure of the MNK proteins 
MNK1 and MNK2 a isoforms consist of a nuclear localization sequence (NLS) at 
the N termini and a catalytic domain with two phosphorylation sites. MNK1a has a 
nuclear export sequence (NES) towards the C terminus and both MNK1a and 
MNK2a have MAPK binding sites at the C terminus. The b isoforms of both 
proteins have a truncated C terminus lacking the MAPK binding and NES motifs. 
     28 
There are differences in the binding affinity of MNK1 and MNK2 for MAP kinases. 
MNK1 is phosphorylated by both ERK and p38 MAPK but not Jun N-terminal 
kinases (JNKs). MNK2 is phosphorylated by ERK alone, suggesting a differential 
effect in the signaling pathways able to activate the MNKs
40. The regulation and 
activity of the two proteins also differ, related to multiple factors including their 
catalytic domains, and C termini
51. MNK1 has a low baseline level of activity that is 
readily inducible by activation of the MAPK pathway, and inhibited by blocking 
signalling through either the ERK or p38 MAPK pathways. MNK2 however has 
much greater basal activity, with little effect from either the induction of, or 
blockade of ERK signaling
52. 
Three phosphorylation sites have been identified in MNK1 and MNK2
52,53. Two of 
these, Thr 197 and Thr 202 are within the T-loop, the third, Thr 332, is close to the 
C terminus. All are within consensus MAPK phosphorylation sites. Alanine 
substitutions at Thr 197 and Thr 202 have shown these sites to be essential for 
activation, and kinase activity. Alanine substitution at Thr 332 in MNK1 surprisingly 
showed enhanced activation of MNK1, however the same substitution in MNK2 
inhibited kinase function. It may therefore be this site that is responsible for the 
high basal activity of MNK2. 
Both MNK1 and MNK2 contain an eIF4G binding domain in the N terminus which 
overlaps with a polybasic nuclear localisation sequence
53,54. Mutation of this 
sequence, preventing MNK1 from binding eIF4G inhibits the ability of MNK1 to 
phosphorylate eIF4E. In addition MNK1 must be phosphorylated through MAPK 
signalling for eIF4G binding to occur
55. Thus both eIF4E and activated MNKs bind 
to eIF4G as part of the eIF4F complex before eIF4E can be phosphorylated at 
serine 209
56. 
The cellular distribution of the full length and truncated MNK proteins is variable, as 
a consequence of the combination of effects of the nuclear localisation and nuclear 
export motifs (fig 1:5). Both MNK1a and MNK2a are cytoplasmic in distribution. In 
MNK1a this is due to the nuclear export sequence at the C terminus which 
facilitates exportin 1 (CRM1) mediated nuclear export. The N terminal domain 
binds importin !, and when nuclear export is blocked with leptomycin B, MNK1a 
localises to the nucleus, suggesting that it is able to shuttle from the nucleus to the 
cytoplasm
57. In the case of MNK2a a key amino acid in the nuclear export domain   29 
is substituted, suggesting that nuclear localisation should predominate. It has been 
shown however that the C terminal of MNK2a is able to interfere with access to the 
N terminal basic region, reducing access to the nuclear localisation domain, hence 
its cytoplasmic localisation
57. Both MNK1b and MNK2b lack the C terminal NES 
seen in the full length transcripts and as such predominantly localise to the 
nucleus
50. 
The impact of eIF4E phosphorylation on mRNA binding and translation remains 
controversial. Early in vitro assays investigating the phosphorylated form of eIF4E 
suggested enhanced binding affinity for the mRNA m7GTP cap structure. This was 
initially thought to account for increased protein synthesis and cellular growth in the 
context of phosphorylated eIF4E
58. More recently however data has suggested that 
phosphorylation may in fact reduce mRNA binding affinity, but that this may allow 
progression of the eIF4F complex beyond the mRNA cap structure, still allowing 
increased protein synthesis
59. Contrary to this model, a bicistronic reporter assay, 
allowing assessment of both cap-dependent and cap-independent translation in 
response to eIF4E phosphorylation has suggested a negative regulatory role of 
eIF4E phosphorylation on both global and cap-dependent translation
60. Further 
work on recovery from cellular stress has shown induction of 4E-BP and eIF4E 
phosphorylation, but that inhibition of the MNKs and subsequent reduction in eIF4E 
phosphorylation does not affect either formation of the eIF4F complex, or initiation 
of translation
61. 
Phosphorylated eIF4E plays an additional role in the control of mRNA export from 
the nucleus to cytoplasm. This was first defined with respect to cyclin D1 where 
enhanced eIF4E expression led to an increase in cytoplasmic cyclin D1 mRNA, but 
not total cyclin D1 mRNA levels
2. More recently it has been shown that eIF4E 
phosphorylation is required for this function, with introduction of a phospho-
resistant form of eIF4E (ST209/210AA) rendering cells resistant both to increases 
in cyclin D1 export and to transformation to the malignant phenotype
12. The 
transport function of phosphorylated eIF4E is important in the regulation of other 
proteins, including MDM2, where inhibition of eIF4E phosphorylation has also 
shown a reduction in nuclear export of mRNA
62. 
Data on the role of MNK1 driven phosphorylation of eIF4E in normal growth and 
development is conflicting. By generating a serine 251 to alanine mutation in eIF4E 
in Drosophila (the equivalent position to serine 209 in mammalian eIF4E), eIF4E   30 
was rendered resistant to phosphorylation as demonstrated by the uptake of 
radiolabelled phosphate. Flies containing the mutant eIF4E allele were rendered 
smaller, and developed more slowly than unmutated controls
63. This is contrary to 
a mouse model in which the MNK proteins were found not to be essential for 
normal growth or development. Both Mnk1 and Mnk2 single knockout, as well as 
double knockout mice have been developed, none of which show any phenotypic 
abnormality. Embryonic fibroblasts derived from these mice have confirmed that 
Mnk1 is responsible for inducible eIF4E phosphorylation, whereas Mnk2 is 
responsible for constitutive eIF4E phosphorylation, however in the complete 
absence of eIF4E phosphorylation, fibroblasts develop normally
64. A role for the 
Mnk proteins in induction of apoptosis has also been identified in fibroblasts 
derived from Mnk1 and Mnk2 double knockout mice. These fibroblasts had 
increasing sensitivity to apoptosis on serum withdrawal compared to wild-type 
cells, an effect which was replicated with an inhibitor of the MNK proteins applied 
to wild-type cells
65. 
Although eIF4E is the best described target of the MNKs, the MNK proteins have 
kinase activity towards additional proteins in addition to eIF4E. Sprouty2 is an 
antagonist of several receptor tyrosine kinases including fibroblast growth factor 
receptor and vascular endothelial growth factor receptor, and is involved in the 
negative feedback of RTK signaling. Phosphorylation of Sprouty2 at serines 112 
and 121 mediated by MNK1 result in its stabilisation and thus enhanced activity
66. 
Cytosolic phospholipase A2, which regulates eicosanoid synthesis from 
phospholipids during inflammatory responses, is activated both by increasing 
intracellular calcium, but also by phosphorylation at serine 727 by MNK1. This 
mode of activation has been implicated in thrombin stimulation of platelets
67. The 
heterogenous nuclear ribonuclear protein A1 (hnRNP A1) is one of three hnRNPs 
known to be targets of the MNKs, the others being hnRNP A0 and JKT BP. hnRNP 
binds the AU rich element (ARE) in the 3'UTR of TNF! mRNA, promoting mRNA 
stability, and thus the MNK proteins have been implicated in the control of TNF! 
biosynthesis
68, and are therefore implicated in the regulation of inflammatory 
processes. 
 
The MNK proteins have shown importance in tumour development in a mouse   31 
lymphoma model. Here, introduction of either wild type eIF4E or a phosphomimetic 
in which serine 209 was mutated to a positively charged aspartic acid (S209D), 
caused an increase in tumour formation. This effect was negated with the use of 
the phospho-resistant form in which serine 209 was mutated to alanine (S209A)
69. 
This model also identified Mcl-1 as a target for regulation by eIF4E 
phosphorylation. 
A second lymphoma model driven by PTEN knockout has confirmed the 
importance of the MNKs in tumourigenesis. In this model, conditional knockout of 
PTEN in T cells leads to the development of lymphoma by approximately 10 
weeks, with significant levels of eIF4E phosphorylation found in thymic tumours 
from these mice. When MNK 1 and 2 double knockout (MNK-DKO) mice were 
crossed with PTEN null mice to generate mice deficient both in MNK 1 and 2, and 
PTEN, tumours formed with increased latency, and at smaller size, with no 
measureable eIF4E phosphorylation in tumours derived from these mice
70. 
Equally the significance of phosopho-resistant eIF4E in impairing carcinogenesis 
has been confirmed in a second study using a pre-clinical prostate cancer model. 
Here knock-in mice expressing eIF4E S209A were crossed with a conditional 
knockdown of PTEN in prostate epithelium. The PTEN deficient mice with wild-type 
eIF4E developed prostate cancers by 5 to 8 months of age, however in mice 
crossed with eIF4E S209A knock-in, no invasive tumours were found, and pre-
invasive prostatic intraepithelial neoplasia was of a lower grade. Of note high levels 
of eIF4E phosphorylation were seen in the eIF4E wild-type tumours, with no 
phosphorylation seen in those from eIF4E S209A knock-in mice
71. 
Not only has eIF4E been implicated in carcinogenesis; by correlation of expression 
with outcome in clinical cases, phosphorylated eIF4E is also associated with 
clinical cancer progression. In a series of 300 patients with non-small cell lung 
cancer, high levels of eIF4E phosphorylation in the primary tumour was associated 
with shorter survival
72. Similarly in prostate cancer higher levels of phosphorylated 
eIF4E are associated both with increased pathological grading as defined by the 
Gleason score, and progression from normal prostate tissue, through prostatic 
intraepithelial neoplasia to invasive malignancy
71. 
The inhibition of eIF4E phosphorylation as a potential therapeutic target has been 
investigated in cell line models. Lung cancer cell lines
20 and a HER2 over-
expressing breast cancer line
73 have shown sensitivity to inhibition of proliferation   32 
by inhibition of the MNK proteins. Prostate cancer cell lines with wild type PTEN 
have also shown sensitivity to inhibition of MNKs with growth inhibition and 
accumulation of cells in G1 on cell cycle analysis
74. In addition inhibition of MNKs 
with CGP57380 in a murine primary CNS lymphoma xenograft model showed a 
significant reduction in tumour size compared with vehicle control treated 
animals
75. 
 
The effective regulation of cell signaling pathways not only involves 
phosphorylation events, but also in order to prevent continuous signaling following 
activation of a particular pathway, de-phosphorylation must occur. It is thus a 
balance between phosphorylation by kinases, and de-phosphorylation by 
phosphatases which regulates any particular signal. The phosphatase responsible 
for the de-phosphoryaltion of both eIF4E and MNK1 itself has recently been 
identified as phosphatase PP2A
76. PP2A is the phosphatase involved in the 
majority of serine-threonine de-phosphorylation in eukaryotic cells and thus 
regulates multiple pathways. Rather than being a single molecule it is a trimeric 
complex consisting of a scaffold and catalytic complex together with a third (B) 
subunit which provides specificity for localisation of the target and specificity of the 
substrate
77. Through a combination of different members of the scaffold, catalytic 
and B subunits over 75 different holo-enzymes can be formed leading to 
involvement in a diverse range of cellular functions
78. 
PP2A is regulated on a variety of different levels. PP2A can itself be 
phosphorylated on tyrosine 307, part of the catalytic subunit, by several kinases 
including the epidermal growth factor receptor, an event which leads to inactivation 
of phosphatase activity
79. PP2A can however act as an autophosphatase, and 
reactivate itself following de-activating phosphorylation. In addition phosphorylation 
of the B subunit can modify the target specificity of PP2A, providing another layer 
of regulation
80. 
PP2A can undergo additional post-translational modification by methylation of the 
carboxy group at leucine 309, within the same motif as tysrosine 307 within the C-
terminal of the catalytic motif
81. The role of carboxy methylation appears to be 
related to the binding of the catalytic subunit for particular B subunits, hence 
changing the specificity of phosphatase activity
82. 
Second messengers, such as the lipid second messenger ceramide have a role in   33 
regulation of PP2A. Ceramide may be formed by the hydrolysis of sphingomyelin in 
response to stress signaling, for example through tumour necrosis factor !. This 
subsequently activates ceramide-activated protein phosphatases (CAPPs), which 
include PP2A, and can result in activation of a variety of signaling molecules, for 
example protein kinase C! and c-Jun
83. Additionally c-Jun may be regulated by the 
interaction of one of two inhibitors of PP2A, I1
PP2A  and I2
PP2A, which increases c-
Jun concentration and DNA binding through inhibition of phosphorylation at serine 
63
84. 
Thus MNK activity is highly regulated in a complex fashion, both through activation 
via MAPK signaling and phosphorylation, but also through de-phosphorylation both 
of MNK itself and of its target, eIF4E, by PP2A. 
 
1.4. Regulated Targets of eIF4E phosphorylation 
Cyclin D1 
Cyclin D1 is a critical regulator of the cell cycle, where it translates mitogenic 
stimuli into progression through the cell cycle from G1
85. Upregulation of cyclin D1 
through chromosomal translocation and gene amplification has been implicated in 
several cancers including breast
86 and oesophageal cancer
87 and mantle cell 
lymphoma
88. 
Cyclin D1 is the binding partner of the two cyclin dependent kinases CDK4 and 
CDK6. Following binding to cyclin D1, CDK4 leads to phosphorylation of 
retinoblastoma protein (Rb), releasing E2F transcription factors, which up-regulate 
many genes involved in DNA synthesis and cell cycle progression, including 
cyclins and cyclin dependent kinases involved in subsequent stages of the cell 
cycle. The cyclin D/CDK4-6 complex also binds the cell cycle inhibitors p27 and 
p21, titrating them away from cyclin E/CDK2, facilitating complete phosphorylation 
of Rb and further progression through the cell cycle (fig 1:6)
89. Cyclin D1 has 
additional cell cycle independent functions including regulation of transcription 
factors with regulatory activity towards both the oestrogen
90 and androgen 
receptors
91 independent of binding to CDK4. 
A variety of approaches have been taken to investigate inhibition of cyclin D1 as an 
anti-cancer therapy. In pre-clinical models the histone deacetylase inhibitor 
trichostatin A causes reduced proliferation and cell cycle arrest as a consequence   34 
of cyclin D1 inhibition through regulation of NF-!B
92. Inhibition of cyclin D1 through 
enhanced degradation has shown cell cycle arrest in breast and colon cancer cell 
lines
93. In the clinical setting, inhibitors of the kinase activity of the cyclin D1/CKD 4 
complex have been developed. The cyclin dependent kinase inhibitor flavopiridol is 
being investigated in a variety of clinical settings and has shown both single agent 
and combination activity in leukaemia
94. In most cases it is the cell cycle regulatory 
function of cyclin D1 that has been investigated with respect to overexpression in 
cancer, however in a study of breast cancer tissue samples a gene expression 
profile independent of E2F activity, and consistent with inhibition of the 
transcription factor C/EBP!, was seen
95 suggesting the importance of both cell 
cycle regulatory and transcription control for cyclin D1 in cancer.  
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Figure 1:6 Cell cycle control. The role of cyclin D1 
Cyclin D1 binds cyclin dependent kinases (CDK) 4 and 6 and phosphorylates 
retinoblastoma protein (Rb). Phosphorylated Rb releases E2F transcription factors 
which activate transcription of Cyclin E, as well as other genes involved in cell 
cycle progression. Cyclin D1/CDK 4/6 bind and inhibit the inhibitors of cyclin 
E/CDK 2, p27 and p21, resulting in enhanced phosphorylation of Rb.     36 
1.5. Post translational modification of proteins 
Although the 20 amino acids that make up proteins provide an almost limitless 
variety of structure and function, following translation of the genetic code to 
formation of a protein, additional modifications may be made, further influencing 
the way in which a given protein may function. Perhaps the most common of these 
is phosphorylation; the addition of a phosphate group, usually to a tyrosine, serine 
or threonine amino acid, catalysed by a protein kinase. This addition is frequently 
involved in the activation or deactivation of enzymatic function and is described in 
detail below. 
Other modifications include the addition of polypeptides to larger proteins targeting 
them for degradation, such as ubiquitination leading to protein degradation via the 
proteosome. The addition of other small ubiquitin-like peptides which bind proteins 
but cause changes in function other than degradation have also been described. 
One example of this is the small ubiquitin-related modifier proteins (SUMO) of 
which eIF4E is a known target
96. 
Modification of histone proteins by either methylation or acetylation is a mechanism 
by which post-translational modification of a protein is able to influence 
transcription. Histone proteins provide the structure for chromatin by acting as a 
structural support around which the DNA molecule is packaged. Post translational 
modification of histone proteins results in changes in the conformation of chromatin 
and as such promoter regions of genes become more or less accessible to 
transcription factors, either up or down-regulating gene expression. This has been 
exploited clinically with the use of histone deacetylase (HDAC) inhibitors, which are 
able to induce cell cycle arrest and apoptosis in cancer cell models. For example 
the HDAC inhibitor vorinostat has shown clinical activity in the treatment of 
advanced cutaneous T cell lymphoma
97. 
Prenylation involves the addition of a hydrophobic prenyl moiety to the C terminal 
cystein of a protein and affects its location via either interaction with cell lipid 
membranes, or protein-protein interactions. A notable example is Ras, part of the 
MAPK and AKT signalling pathways, which must be membrane bound for 
oncogenic activity. Ras undergoes prenylation by an enzyme farnesyl-transferase 
for which inhibitors have been generated, and are currently in clinical testing
98.   37 
Over the last 10 years, small cell permeable molecules that are able to selectively 
target protein kinases have moved from laboratory tools, to having routine use in 
clinical practice. 
There are over 500 protein kinases in the human proteome
99. Many of these are 
membrane bound receptor tyrosine kinases, however others are soluble proteins 
which form signalling intermediates in the transduction of extracellular signals to a 
wide range of intracellular changes. All kinases belong to a superfamily of proteins 
with a common kinase catalytic domain. Within this domain have been described 
12 smaller subdomains which contain sequences of conserved amino-acids and 
are likely representative of the common function of these enzymes. The kinases 
have been further classified according to common structural and functional 
features. An initial classification by Hanks et al according to amino acid sequence 
homology established four groups of proteins which were named AGC (after 
constituent families protein kinase A, G and C), CaMK (calcium/calmodulin 
regulated kinases), CMGC (containing cyclin-dependent kinases, MAP kinases, 
glycogen synthase 3, and casein kinases) and PTK (‘conventional’ protein-tyrosine 
kinases)
100. This classification was updated in 2003 following an extensive search 
of the human genome for sequences with homology to the eukaryotic protein 
kinase domain. Four additional groups were added to give a total of ten. These 
were as follows: Tyrosine kinases, Tyrosine kinase-like, AGC, CAMK, CK1 (casein 
kinase 1), CMGC, STE (MAP kinase cascade kinases, homologs of yeast Ste 
kinases), RGC (receptor guanylate cyclase) and Atypical
99. 
Protein kinases catalyse the addition of a phosphate group to other proteins within 
the cell through the hydrolysis of adenosine triphosphate (ATP) to adenosine 
diphosphate, and the addition of a phosphate group at the hydroxyl moiety of 
tyrosine, serine and threonine amino acids. There are two broad groups based on 
the amino acid residue targeted for phosphorylation, with the majority of kinases 
either targeting tyrosine, or serine/threonine, and a minority able to target all three 
residues. This post-translational modification of the target gives rise to changes in 
activity, most commonly as a result of conformational change, and may result in 
enzymatic activation of the target
53, inhibition of the target
101, changes in 
distribution
102, or destruction of the target molecule through targeting for 
degradation
103.   38 
The basic structure of protein kinases is conserved such that each has an ATP 
binding pocket formed by the association of N and C terminal domains. The crystal 
structure of this catalytic domain was first identified during structural analysis of 
cyclic adenosine monophosphate-dependent protein kinase
104. Within this cleft are 
conserved amino acid sequences for nucleotide binding, protein binding and for the 
catalytic activity of the kinase
105. 
The activity of protein kinases is controlled via conformational change, often 
brought about by phosphorylation of additional sites within the protein molecule. 
The activation loop is typically located at the mouth of the catalytic domain, defined 
as spanning the region between two conserved sequences DFG and APE (using 
single letter amino acid notation). This loop can inhibit ATP and substrate binding 
when in its inactive conformation, however phosphorylation of the loop results in 
either ATP or the peptide substrate gaining access to the catalytic domain, and 
therefore increased function of the kinase
106. 
Activation of protein kinases may involve interaction with other proteins, and as 
such many kinases contain putative protein-protein interaction domains. Examples 
of these include the Src homology 2 (SH2)
107 and Src homology 3 (SH3)
108 
domains. These represent consensus sequences of amino acids which allow 
binding to phosphorylated tyrosine residues and proline-rich motifs respectively on 
interacting proteins which may result in activation or inactivation of the kinase 
through interaction with the activation loop as described above. Alternatively these 
sites may represent interactions within the kinase molecule such that the kinase 
function is altered by conformational changes brought about by association 
between phosphorylated residues within the molecule and SH2 domains. 
Crystal structure of the kinase domains of both MNK1
105 and MNK2
109 have been 
studied, following expression in E.coli and purification. The kinase fragments were 
shown to have kinase activity by phosphorylating eIF4E in response to ERK in 
vitro. The characteristic bilobar kinase structure was identified. The secondary 
structure of the N-terminal lobe consists of predominantly ! strands and is 
responsible for ATP binding. It contains a Glycine rich loop previously shown to 
interact with non-transferable phosphates within the ATP nucleotide. The majority 
of the secondary structure of the C-terminal lobe is " helices. It is here that the 
peptide substrate binds and the elements required for phosphate transfer are   39 
found. A magnesium binding loop, catalytic loop and activating loop are located in 
this region. 
The activating loop in the MNK proteins is extended by the insertion of additional 
amino-acids to the two ! helices EF and F. This results in a stable inhibitory 
conformation of the activating loop in the non-phosphorylated state, which crosses 
the kinase cleft and interacts with the !C helix of the N terminal lobe. Interaction of 
phenylalanine (Phe) 230 of the activation loop, with Phe 192 of the DFD motif in 
the magnesium loop results in Phe 192 occupying the ATP-binding pocket and 
inhibiting ATP binding. Interaction of arginine residues in helix !C and the 
activation loop stabilise the inhibitory conformation. When activating 
phosphorylation by ERK or p38 MAPK occurs, the phosphorylated residues in the 
activation loop engage with the RD pocket, also formed by arginine residues in the 
!C helix and a further arginine upstream of the catalytic loop. This releases the 
activating loop from the N terminal lobe, freeing up the ATP binding site, and 
allowing the substrate to access the catalytic cleft. 
 
1.6. Inhibition of protein kinases with small molecules 
The identification of a wide variety of protein kinases as oncogenes, with activating 
mutations found in many cancers, has led to interest in these as therapeutic 
targets. 
An early example of a naturally occurring kinase inhibitor is staurosporine, a 
natural product produced by the actinomycete Streptomyces identified during a 
screen for microbial alkaloids
110. Molecular characterisation identified 
staurosporine as an indolocarbazole compound with chemical synthesis achieved 
in 1996
111. During further investigation, staurosporine and its derivatives were 
found to be protein kinase inhibitors, initially as potent inhibitors of protein kinase 
C
112 and v-src
113 kinase, with anti-tumour properties in animal models
114, and 
subsequently as non-specific inhibitors of many other kinases
115. 
Identification of the crystal structure of staurosporine bound to the kinase domain 
of protein kinase C showed the tight binding of staurosporine to the adenosine 
binding pocket, and identified many of the interactions between the inhibitor and 
the surrounding residues of the kinase
116.   40 
Knowledge of the crystal structure of a variety of protein kinases, in many cases 
bound to inhibitors has allowed the generation of pharmacophore models in order 
to rationalise the structure of compounds developed through screening 
programmes
117. Several classes of compound with activity as protein kinase 
inhibitors have thus been identified and modified to induce specificity for particular 
kinase molecules. 
CIBA Geigy developed a kinase inhibitor screening programme, and identified 
CGP57148, a 2-phenylaminopyrimidine with activity against the Abl protein kinase 
and platelet-derived growth factor
118. This compound has growth inhibitory effects 
on cells containing the BCR-Abl fusion protein characteristic of chromic myeloid 
leukaemia (CML) 
119. Clinical trials of what by then was known as imatinib showed 
dramatic effects in CML. By switching off signalling through the fusion protein, 
responses were seen in 95% of patients treated with imatinib with clearance of the 
fusion protein by cytogenetic analysis in 74%
120. 
One major success of imatinib has been its specificity for a small number of protein 
kinases, a feature that has been difficult to achieve with other agents. One reason 
for this is likely to be the binding of imatinib to the inactive form of the kinase. The 
active, or open form of many kinases results in a similar conformation of the 
catalytic cleft
121, making the design of molecules to specifically recognise a 
particular kinase more difficult. When in the inactive form the conformation is much 
more specific to an individual protein and as such small molecules can be tailored 
to an individual kinase domain. 
A subset of patients has primary resistance to therapy with imatinib, or develops 
resistance during therapy. It has become apparent that a single amino acid 
mutation can result in a conformational change, preventing binding of the imatinib 
molecule to the catalytic cleft, for example by disruption of the inhibitory 
conformation
122. As a consequence alternative compounds which bind the active 
conformation have been developed to target such resistant cases
123. 
CGP57380 (4-amino-3-(p-fluorophenylamino)pyrazolo[3,4-d]pyrimidine) was 
identified in 2001 and described as a specific inhibitor of MNK1
60. The compound 
showed inhibition of MNK1 kinase activity with both in vitro kinase assays and 
cellular kinase activity with an IC50 of 2.2 µM and 3 µM respectively. It was found to 
have no inhibitory activity on other kinases including p38, JNK1, ERK1 and 2,   41 
protein kinase C and Src-like kinases. Additional analysis of the specificity of 
CGP57380 has shown both MNK1 and MNK2 inhibition with some inhibitory 
activity towards MKK1, ERK2, RSK1 and p38 MAPK!, but at significantly higher 
concentrations than those required for inhibition of MNK1/MNK2
68. Questions have 
been raised however as to how specific CGP57380 is in a broader kinase screen. 
When tested against a panel of 80 protein kinases, three other kinases were 
identified with inhibition at similar concentrations to MNK1, namely MAP Kinase 
Kinase 1 (MKK1), Casein Kinase 1 (CK1) and Brain selective kinase 2 (BRSK2)
124. 
Although some questions remain as to the specificity of CGP57380 as an inhibitor 
of the MNK proteins, it has been investigated in several models to demonstrate the 
importance of eIF4E phosphorylation in cancer cell survival. A lung cancer cell line 
model used CGP57380 at up to 5 µM to demonstrate modest inhibition of cell 
proliferation, with enhanced effects for the addition of CGP57380 to rapamycin
20. 
Similarly a single HER2 overexpressing breast cancer cell line showed growth 
inhibition in a long-term colony assay in a dose dependent fashion with CGP57380 
up to 50 µM
73. 
1.7. Cancer models for eIF4E regulation 
As HER2 signalling may be mediated via both the mTOR and MAPK signalling 
pathways then HER2 overexpressing breast cancer cells may be particularly 
sensitive to inhibition of the MNK proteins. 
mTOR inhibition has now become part of routine care for certain patients with 
advanced renal cancer, however this is not effective for all. The interesting cell line 
data suggesting an increase in eIF4E phosphorylation in response to inhibition of 
the MNK proteins
20 may therefore be particularly relevant to this patient cohort. 
Breast Cancer 
Breast cancer represents a major health problem. As the commonest malignancy 
in females, and the third most common malignancy overall, more than 40,000 
cases are diagnosed annually in the United Kingdom. 
Breast cancer has historically been at the forefront of biological research with an 
advanced understanding of the molecular pathogenesis underlying what is 
increasingly seen as a heterogeneous disease. The concept of therapy targeted at 
specific molecular pathways has been, perhaps unknowingly, in existence for over 
a century, since it was first discovered that performing an oophorectomy in a case   42 
of advanced breast cancer could lead to regression of metastatic disease
125. Since 
then it has become apparent that it is in fact a subset of breast cancers over-
expressing the oestrogen receptor that respond to oestrogen deprivation, and a 
variety of therapeutic manoeuvres have been designed to achieve this
126. 
The 1980s and 1990s saw the identification of the ERBB2 oncogene, and its 
protein product the HER2 cell surface receptor tyrosine kinase
127. This member of 
the EGFR family is overexpressed due to gene amplification in around 20% of 
breast cancers and accounts for a more aggressive pattern of disease with a worse 
prognosis
128. The production of a therapeutic monoclonal antibody targeting the 
external domain of the HER2 receptor (trastuzumab) has significantly changed the 
outlook for patients with this subtype of breast cancer, however as with other 
subtypes, in the face of metastatic disease breast cancer remains almost 
universally fatal
129. 
The advent of high throughput gene expression profiling has allowed further work 
to be carried out in characterising breast cancer and defining prognostic groups by 
their pattern of gene expression. Profiling of a number of breast cancers has 
defined signatures for 5 groups of patients, namely normal breast–like, luminal A, 
luminal B, basal and HER2
130. These groups differ in both their genetic and 
molecular signatures. Normal breast-like tumours are characterised on the basis of 
their similarity to normal breast ductal and adipose tissue. Luminal tumours have 
expression patterns similar to cells of the breast duct luminal epithelium, and 
typically have high expression of the oestrogen receptor (ER) gene, with a further 
subclassification into A and B partly reflecting the level of ER expression, p53 
mutation status and other luminal specific genes. Those classified as basal have 
similar expression patterns to the basal epithelium with low expression of ER and 
non-amplified ERBB2, and HER2 tumours have high levels of ERBB2 expression, 
with low levels of ER. Subsequent correlation of this genetic data with clinical 
outcome has revealed distinct patterns of survival dependent on the gene 
expression grouping
131. 
In order to allow clinical application of these subgroups attempts have been made 
to define these groups on the basis of protein expression, allowing conventional 
diagnostic immunohistochemical (IHC) tests to be used to classify tumours. In this 
way luminal cases are typically defined by high levels of ER on IHC with absence 
of HER2 over-expression. The HER2 group have consistently high levels of HER2   43 
overexpression, low levels of ER and are typically of a high nuclear grade. Basal-
like tumours include all tumours of the ‘triple negative’ class with absent ER and 
progesterone receptor (PR) staining on IHC and absence of HER2 over-
expression. These tumours are almost always of high nuclear grade, and respond 
poorly to conventional chemotherapy
132. 
In summary a great deal of information is available on the influence of a variety of 
molecular factors on breast cancer outcomes. Cell line models have been 
integrated into these classification systems such that the influence of specific 
pathways can be modeled on the clinical spectrum of breast cancers
133. 
 
Renal Cancer 
Renal Cancer represents the 8
th most common malignancy in the United Kingdom, 
and with just under 8000 new cases annually it represents 3% of cancer 
diagnoses. 
Currently renal cancers are distinguished by light microscopic appearance with 
three major subtypes of malignant tumour derived from the tubular epithelium of 
the proximal convoluted tubule, and a fourth derived from the collecting duct 
system
134. The most common subtype representing 75% of cases is conventional 
or clear cell renal cell carcinoma, so described due to the presence of a majority of 
cells containing clear cytoplasm. Papillary renal carcinoma represents 10-15% of 
cases with the majority of cells forming papillary architecture. Chromophobe 
tumours account of around 5% of cases and consist of cells which have condensed 
cytoplasm around the nucleus and vary in size. Finally collecting duct carcinomas 
represent less than 1% of renal cancers. Although these tumours vary in 
histological appearance they typically consist of cellular channels lined by 
abnormal epithelium. All of the above tumours may consist of areas of sarcomatoid 
appearance which is regarded as high grade tumour of the histological subtype of 
origin, rather than a distinct subtype of its own.  
Different genetic abnormalities have been associated with each different 
histological subtype, and as a greater understanding of the molecular defects 
underlying these tumours is achieved, so more effective therapies have been 
developed. 
Clear cell renal cell carcinomas are commonly associated with loss of material from 
chromosome 3p. The von Hippel-Lindau (VHL) tumour suppressor gene was   44 
identified as the germ line mutation in the von Hippel-Lindau cancer syndrome in 
which patients develop multiple bilateral clear cell renal tumours from a young age, 
as well as haemangioblastomas and tumours of the central nervous system, 
adrenals, pancreas and epididymis
135. The VHL gene is located at chromosome 
3p25 with frequent chromosomal loss in sporadic clear cell renal cancer
136 . 
Mutations in the VHL gene have subsequently been identified in up to 60%
137 of 
patients with sporadic clear cell kidney cancer, with up to a further 20% showing 
promoter hypermethylation
138. The deranged cellular signaling which occurs as a 
consequence is the target for several new therapies for advanced renal cancer. 
Under normoxic conditions VHL protein acts as a tumour suppressor by regulating 
HIF! transcription factors (HIF1! , HIF2!, HIF3!) in response to oxygen 
availability
139. HIF! contains an oxygen degradation domain (ODD)
140 where a 
proline residue can undergo hydroxylation, catalysed by HIF proline 
hydroxylase
141. Hydroxylated proline is recognised by a hydroxyproline binding 
pocket in VHL protein
142 as part of an E3 ubiquitin ligase complex together with 
Cul2, elongin B, elongin C
143 and Rbx1
144. Under hypoxic conditions HIF! is no 
longer proline hydroxylated and therefore does not bind to VHL and accumulates. 
When VHL is non-functioning or absent, either due to chromosomal loss, mutation, 
or hypermethylation, HIF! is no longer degraded and accumulates under normoxic 
conditions. HIF! is then able to bind one of the HIF" family to form an active 
transcription factor. This results in up-regulation of genes normally associated with 
hypoxic stress, including VEGF, platelet derived growth factor " (PDGF-B), 
transforming growth factor ! (TGF-!), glucose transporter 1 (Glut 1), carbonic 
anhydrase IX and erythropoietin
145 (fig 1:7). 
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Figure 1:7 HIF regulation by VHL 
Under normoxic conditions HIF! is hydroxylated, and thus targeted for 
ubiquitination by VHL and degraded within the proteosome. Under hypoxic 
conditions HIF! is no longer hydroxylated and therefore not targeted by VHL. HIF! 
accumulates and binds HIF" forming a transcription factor and upregulating target 
genes including vascular endothelial growth factor, platelet derived growth factor 
and transforming growth factor alpha. In clear cell renal cancers with VHL 
inactivation a pseudo-hypoxic phenotype is seen. 
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Study of a familial syndrome of multiple bilateral papillary renal cancers (hereditary 
papillary renal cancer carcinoma HRPC) has led to the identification of the MET 
oncogene as critical to the development of papillary renal cancers. Papillary 
tumours are characterised in cytogenetic studies by trisomies including 
chromosome 7. Activating mutations in the MET oncogene on chromosome 7 have 
been identified both in families with HRPC, and in sporadic cases of multiple 
papillary renal cancers
146,147. Although MET mutations have not been identified in 
all cases studied, the ligand of MET, hepatocyte growth factor/scatter factor 
(HGF/SF) is also located on chromosome 7, as are several other cytokines known 
to increase the expression of MET
148. MET is a receptor tyrosine kinase which 
undergoes dimerisation and phosphorylation in response to binding of its ligand 
HGF/SF, and subsequent signaling through the ERK MAPK cascade
149. This 
results in an increase in cell motility, invasiveness and proliferation
150. 
 
Early stage kidney cancer confined to a single kidney is conventionally treated by 
surgical resection, although organ preserving techniques such as partial 
nephrectomy, or ablative techniques such as cryoablation and radiofrequency 
ablation, are increasingly used. The outlook for early stage disease following 
surgical resection is stage dependent. Resected disease can be stratified as to 
recurrence risk using the Leibovich pathological scoring system
151, which takes into 
account nuclear grade, degree of histologically defined necrosis, tumour size, and 
tumour and nodal stage. Using this system patients may be stratified to good 
prognosis with a 97% 5 year metastasis free survival, compared with a poor risk 
group with 31.2% 5 year metastasis free survival. For advanced renal cancer, 
however the outlook is poor. Historically survival has been short with a median 
survival of 6 months in untreated patients. The only treatment option until recently 
was immunotherapy with interferon, with or without interleukin 2. Response rates 
were low with minimal effect on survival
152. 
The advent of VEGF targeted therapy has however made a significant difference to 
the management of advanced renal cancer. The multi-targeted kinase inhibitors 
sunitinib and sorafanib have both shown significant activity in advanced renal 
cancer in the first and second line respectively. These agents share target 
specificity towards VEGF receptors , PDGF receptors, and KIT, with sorafenib 
additionally targeting Raf and RET kinases. The median survival following   47 
treatment with sunitinib is 26 months
153. Similar results were seen with the 
combination of bevacizumab, a VEGF targeted monoclonal antibody, in 
combination with interferon
154. The two mTOR inhibitors temsirolimus and 
everolimus have also shown activity and are now licensed for use in advanced 
renal cancer. The phase III trial of temsirolimus specifically targeted a poor 
prognosis group of patients and although it only showed a median survival of 11 
months, this was significantly better than 7 months seen in the interferon treated 
control group
17. Everolimus is licensed in the second line after failure of tyrosine 
kinase inhibitor therapy having shown an improvement in progression free survival 
of an additional 2 months over placebo control. At the time of publication of the trial 
data in 2009 the median survival for the placebo group was 8.8 months and had 
not been reached in the everolimus group
18. 
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2. Aims 
Although significant advances in the management of advanced malignancies have 
been made in recent decades, even in the face of apparent curative surgery 
patients with early stages of disease may still relapse, and in the setting of 
advanced disease cures remain elusive for the majority of solid tumours. An 
imperative therefore exists both for a greater understanding of the biology 
underlying this disease, and for novel therapeutic options. 
The role of the MNK kinases in the transforming ability of cells has become 
apparent. It is clear that eIF4E is overexpressed in some solid tumours with 
enhanced expression being associated with inferior prognosis. Increasing data 
suggest that inhibition of eIF4E phosphorylation may be a valid therapeutic target 
in certain cancers. 
The aims of this project are four fold: 
Firstly to establish the effect of inhibition of eIF4E phosphorylation on the 
proliferation and survival of breast and kidney cancer cell lines. Limited data 
suggest that inhibition of the MNK proteins inhibits the proliferation of HER2 over-
expressing breast cancer cell lines, however this project aims to further investigate 
this effect in the wider context of the full spectrum of phenotypes of breast cancer. 
The effects of inhibition of eIF4E phosphorylation have not previously been 
investigated in renal cancer, however HIF has been established both as significant 
in the pathogenesis of the majority of clear cell renal cancers and as a target of 
eIF4E. 
Secondly the mechanisms underlying any effect on the proliferation or survival of 
these cancer cell lines will be investigated. In particular assays to assess the 
relative contribution of cell cycle control and induction of apoptosis will be 
performed. 
Thirdly the specificity of the chemical inhibitor of the MNK kinases, CGP57380, will 
be investigated by using alternative strategies to inhibit eIF4E phosphorylation. 
Finally the molecular mechanisms underlying the transcriptional and translational 
regulation of targets of eIF4E will be investigated, both by investigating the effects   49 
on established targets of eIF4E phosphorylation in breast and kidney cancer cell 
lines, and identifying novel targets.     50 
 
3. Materials and Methods 
3.1. Materials 
Solutions and Buffers 
Phosphate Buffered Saline  (30X) (PBS) NaCl 600 g 
            KCl 15 g 
Na2HPO4 108 g 
            KH2PO4 18 g 
            Water to 2.5 l 
            pH 7.4 
 
Tris Buffered Saline (10X)  (TBS)   Tris Base 24.2 g 
            NaCl 80 g 
            Water to 1 l 
            pH 7.6 
 
Urea Lysis Buffer        8 M Urea 
            10% Triton X-100 
            5 M NaCl 
            1 M HEPES pH 7.6 
            1 M DTT (in 0.01M NaAc pH 5.2)   51 
Polyacrylamide Gels 
Running Gel (12%)        40% Acrylamide-Bis (29:1) 3 ml 
            Water       5.35 ml 
            1.5 M Tris pH 8.8    2.5 ml 
            10% SDS      100 ml 
            10% APS      100 ml 
            TEMED      5 ml 
 
Stacking Gel         40% Acrylamide-Bis (29:1) 3 ml 
            Water       6.35 ml 
            1.5 M Tris pH 8.8    2.5 ml 
            10% SDS      100 ml 
            10% APS      100 ml 
            TEMED      10 ml 
 
SDS Sample Loading Buffer (4X)   EDTA 10 mM 
            SDS 4% (w/v) 
            Glycerol 20% (w/v) 
            Tris pH 6.8 20 mM 
            Bromophenol Blue Dye to colour 
            DTT 200 mM   52 
PAGE Running Buffer (10X stock)  Tris Base  30 g 
            Glycine  144 g 
            SDS    10 g 
            Water     to 1 l 
 
TG Buffer (10X stock)      Tris Base  29 g 
            Glycine  145 g 
            Water   to 1 l 
 
Propidium Iodide staining solution    PBS    10 ml 
            Triton X 100  0.2% 
            RNAse A  2 mg 
            Propidium Iodide 1mg/ml 20 ml 
 
Annexin V binding buffer (10X)    0.1 M Hepes/NaOH (pH 7.4) 
            1.4 M NaCl 
            25 mM CaCl2 
 
MPG Buffer          1 M NaCl 
            10 mM EDTA 
            100 mM Tris-Cl pH 7.4 
 
M
7GTP pulldown extraction buffer    25 mM Tris-Cl pH 7.6 
            50 mM !-glycerophosphate 
            0.2 mM EDTA 
            50 mM KCl 
Immediately before use added    20 X Protease inhibitor mix (Roche) 
            1% Triton X 100 
            0.5 mM NaVO3 
            50 mM NaF 
            100 mM DDT 
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Cell Culture 
The breast cancer cell lines, MCF7, T47D, ZR75.1, SKBr3, BT474 and MDA-MB-
231 were from Dr Blaydes laboratory. Cells were cultured in complete Dulbecco’s 
Modified Eagle Medium (DMEM) consisting of DMEM (Invitrogen) supplemented 
by Foetal Calf Serum (10% v/v Autogen Bioclear), penicillin G/streptomycin (100 
µg/ml), and L-glutamine (2 mM). Cells were maintained in exponential growth at 
37° in a CO2 controlled incubator at 10% (Hera cell, Haraeus). 
 
The renal cancer cell lines, Caki2, 786-O, 769-P, A498 and ACHN were a gift from 
Dr Sahota. A498 and ACHN cells were cultured in Eagle’s minimal essential 
medium (EMEM, Lonza), 37° 5% CO2. Caki-2 cells were cultured in McCoy’s 5a 
medium (Lonza), 37° 10% CO2.  786-O and 769-P cell lines were cultured in RPMI-
1640 (Lonza) 37° 5% CO2. All medium was supplemented with foetal calf serum, 
penicillin G/streptomycin and L-glutamine as above. 
 
siRNA 
The following siRNA oligonucleotides were obtained from Ambion 
MNK1 (s16321) 
  sense   GGAGUAGGGUGUUUCGAGA 
  antisense  UCUCGAAACACCCUACUCC 
MNK1 (s16319) 
sense     GCCCUUGACUUCCUGCAUA 
antisense   UAUGCAGGAAGUCAAGGGC 
MNK2 (s6095) 
  sense   GCCUUGGACUUUCUGCAU 
  antisense  UAUGCAGAAAGUCCAAGGC 
MNK2 (s6094) 
  sense   GCAGCGGCAUCAAACUCAA 
  antisense  UUGAGUUUGAUGCCGCUGC   54 
Antibodies 
The following antibodies were used for immunoblotting at dilutions as indicated. 
Antibodies were diluted as indicated in 3% fat free milk / 0.1% Tween 20 / TBS 
except for phospho-eIF4E which was diluted in 5% bovine serum albumin (fraction 
V) / 0.1% Tween 20 / TBS 
 
Target  Species  Manufacturer  Catalogue 
No 
Concentration 
Primary antibodies 
eIF4E  Rabbit polyclonal  Cell Signalling 
Technology 
9742  1:2000 
Phospho eIF4E 
(serine 209) 
Rabbit polyclonal  Cell Signalling 
Technology 
9741  1:400 
MNK1  Rabbit polyclonal  Cell Signalling 
Technology 
2196  1:2000 
MNK2  Rabbit polyclonal  Santa Cruz 
Biotechnology 
Sc-28781  1:500 
Cyclin D1  Mouse 
monoclonal (Ab-3) 
Calbiochem  CC12  1:500 
Mcl-1  Rabbit polyclonal  Santa Cruz 
Biotechnology 
SC819  1:500 
Actin  Rabbit polyclonal  Sigma  A5060  1:3000 
Secondary antibodies (Horse radish peroxidase (HRP) conjugated) 
anti rabbit  Goat  Dako  PO448  1:2000 
Anti mouse  Sheep  Amersham 
Bioscience 
  1:2000 
 
Table 3:1 Antibodies used for immunoblotting 
Taqman Gene Expression Assays 
The following Taqman gene expression assays were obtained from Applied 
Biosystems 
Cyclin D1 (CCND1) Hs00277039_m1 NM_053056.2 (FAM) 
GAPDH    4326317E NM_002046.3 (VIC)   55 
3.2. Methods 
3.2.1.  Cell Biology 
Cell Treatments 
Cells were plated to 60mm dishes at 0.5 X 10
6 cells per dish in 3 ml complete 
medium. At 24 h the medium was removed and the inhibitor of the MNK proteins, 
CGP57380 (Tocris bioscience) added at varying concentrations with a final 
concentration of 0.5% v/v DMSO vehicle, before returning the medium to the cells. 
At varying time points cells were rinsed once in PBS before being scraped, 
centrifuged at 1000g for 4 minutes at 4° and the pellets snap frozen in liquid 
nitrogen. 
 
MTS Proliferation Assay 
The MTS assay involves the conversion of a soluble tetrazolium compound 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(-4-sulfophenyl)-2H-
tetrazolium inner salt (MTS) to a water soluble formazan compound. This results in 
a colour change, with the Formosan compound absorbing light at 490 nm. This 
colour change can be used as a surrogate for cellular proliferation. The reaction 
relies on the reducing capacity of intracellular NADH in metabolically active cells. 
Cells were plated in triplicate with serial dilutions from 8000 to 500 cells per well in 
96 well plates in 120 µl medium. 24 h later 110 µl medium was removed from each 
well and pooled. CGP57380 (Tocris) was added to give a final concentration of 20 
µM and 0.5% v/v DMSO vehicle, and 100 µl was added back to each well. This 
was repeated on the same plate for CGP57380 concentrations of 10 µM and 5 µM, 
as well as for 0.5% DMSO control. After 72 h incubation 20 µl MTS reagent 
(CellTiter 96Aqueous One Solution, Promega) was added to each well and the 
plates incubated at 37° C for two h. Absorbance at 490 nm was measured on a 
Varioskan Flash plate reader (Thermo Electron Corporation). 
 
CyQuant Proliferation assay 
A second assay of cell proliferation was also used. The CyQuant Direct Cell 
Proliferation Assay (Invitrogen) uses a fluorescent nuclear stain as a surrogate for   56 
cell number. A second masking dye only permeable to dead cells with 
compromised cell membrane integrity prevents dead cells from being counted. 
To assess the ability of this assay to assess cell number, cells were plated at 
increasing number in triplicate wells of 96 well plates in 100 µl medium. 24 h later 
cell number was assayed as follows. 
The following were combined in a 15 ml tube: 
  11.7 ml PBS 
  48 µl CyQuant Direct nucleic acid stain 
  240 µl CyQuant Direct background suppressor I 
100 µl of the above mix was added to each well in the 96 well plate and incubated 
for 1 h at 37°C for 1h. Fluorescence was then measured on a bottom reading 
Varioskan Flash plate reader (Thermo Electron Corporation) using an excitation 
wave length of 480 nm and emission 535nm. Results were plotted as fluorescence 
intensity against cell number (Fig 2:2). 
 
 
Figure 3:1 Validation of CyQuant proliferation assay 
A498 cells were plated at the cell numbers as shown in 100 µl medium in 96 well 
plates. 24 h later proliferation was assayed using the CyQuant Direct assay. 
Results represent mean of triplicate wells. 
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Cell number   57 
For proliferation experiments 1000 cells per well were plated in 120 µl medium in 
96 well plates. 24 h later the medium was removed and CGP57380 added to give a 
final concentration of 20 µM in 0.5% DMSO. 100 µl was returned to each well. This 
was repeated for treatments at a final concentration of 10 µM, 5 µM and 0.5% 
DMSO vehicle control. Cells were incubated at 37° C for 72 h and proliferation 
assayed as described above. 
 
Live Cell Imaging 
Cells were plated in 24 well plates at 4000 cells per well in 1 ml medium. At 24 h 
the medium was removed and CGP57380 added to give a final concentration of 20 
µM in 0.5% DMSO, or 0.5% DMSO alone as a vehicle control. The medium was 
returned to the cells which were incubated for a further 24 h. Time-lapse 
photography was used to obtain 20X images at fifteen-minute intervals for a further 
twenty-four hours using an Olympus IX81 microscope with CO2 and temperature 
controlled environmental chamber, controlled by SIS Cell P software. Three fields 
were imaged for each well at each time point. The images were used to count cell 
numbers at the beginning and end of the time course. The number of apoptotic and 
mitotic events at each time point were identified, and the total number over the time 
course expressed as a fraction of the starting cell number (fig 2:3). 
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Figure 3:2 Live cell imaging of SKBr3 cells 
A photomicrograph at 20 X magnification of SKBr3 cells following treatment with 
CGP57380 at 20 µM for 24 h and then undergoing time lapse microscopy. Image 
indicates a cell undergoing mitosis (blue arrow) and apoptosis (red arrow).     59 
Cell Cycle Analysis 
Cells were plated in 60mm dishes with 25 x 10
4 cells per dish in 2 ml medium. 24 
hours after plating the medium was removed and CGP57380 added to give a final 
concentration of 20 µM or DMSO vehicle control at 0.5% v/v. The medium was 
returned and the cells incubated for 72 h. Cells were harvested by trypsinisation 
with retention of the original medium and washes. Cell suspensions were 
centrifuged at 1000g for 4 min and the supernatant aspirated. The cell pellet was 
resuspended in 1 ml ice cold PBS and the suspension once again centrifuged at 
1000g for 4 minutes with no braking. Again the supernatant was aspirated and the 
cells suspended in 300 µl ice cold  PBS. 700 µl ice cold ethanol was then added 
dropwise while gently vortexing the cell suspension. The cells were fixed for at 
least 2 h at 4° C. They were then centrifuged at 1000g for 4 min, washed once in 
PBS and then resuspended in propidium iodide staining solution and maintained at 
room temperature for 30 min. Analysis was performed using a FACScaliber 
(Becton Dickinson). 
siRNA Transfection 
Cells were plated to 60mm dishes at 0.5 X 10
6 cells per dish in 2.4 ml complete 
medium on the day prior to transfection. 
The transfection mix was created as follows: siRNA was added to 0.6 ml Optimem 
serum free medium (Invitrogen) at a volume to give the required final concentration 
of siRNA in 3 ml medium. 20 µl of Interferin reagent (Polyplus transfection) was 
added and the sample mixed by vortex. Following ten minutes incubation at room 
temperature the transfection mix was added dropwise to cells. Fresh medium was 
applied four hours later. 
 
siRNA Duplex  Stock concentration  Quantity added to 0.6 
ml optimem for final 
concentration: 
50 nM  100 nM 
MNK1 (i)  20 mM  3.75 µl  3.75 µl 
MNK1 (ii)  20 mM    3.75 µl 
MNK2 (i)  20 mM  3.75 µl  3.75 µl 
MNK2 (ii)  20 mM    3.75 µl 
 
Table 3:2 Transfection mix for siRNA transfections.   60 
Apoptosis assay using Annexin V and propidium iodide (PI) staining 
Cells were plated in 6 well plates at 0.2 x 10
6 cells per well in 2 ml medium. 24 h 
after plating cells were treated with CGP57380 at a final concentration of 20 µM in 
0.5% DMSO or 0.5% DMSO vehicle control alone. Cells were assayed for 
apoptosis at 8 h and 24 h time points using the following technique. 
Cells were trypsinised with all washes retained and centrifuged at 1000g for 4 min 
at 4° C. The medium was aspirated and cells washed twice in 1 ml cold PBS 
before being resuspended in 0.5 ml 1 X Annexin V binding buffer. 1.25 µl FITC 
conjugated Annexin V and 2.5 µl propidium iodide (1mg/ml) was added to each 
sample and incubated for 15 min at room temperature in the dark. Cells were 
analysed for Annexin V expression (FL1) and PI staining (FL2) using a 
FACScaliber (Becton Dickinson). 
 
Fluorescence microscopy 
Two coverslips cleaned with 100% ethanol were placed in each well of a 6 well 
plate. Cells were plated to 6 well plates at 0.1 x 10
6 cells in 2 ml medium. 24 h later 
the medium was removed from each well and the wells washed with cold PBS. 
Cells were fixed in the wells with 1 ml per well 4% paraformaldehyde in PBS for 15 
min. A further wash with PBS was performed and the paraformaldehyde quenched 
with 1 ml per well 100 mM glycine for 10 min. Following a further wash with PBS 
cells were permeabilised with 1 ml per well 0.2% Triton-X/PBS for 10 min. 50 µl 1 
µg/µl 4’,6-diamidino-2-phenylindole (DAPI) was added to each coverslip which 
were incubated in the dark for 10 min. Coverslips were washed twice with PBS and 
once with water before being mounted to microscope slides with fluorescence 
mounting solution (Dako). Slides were kept for at least 12h at 4 °C before being 
visualised with a fluorescence microscope (Zeiss Axiovert 200). Images were 
captured using an Orca-ER digital camera (Hamamatsu) and Openlab 3.5.1 
software (Improvision). 
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3.2.2.  Protein analysis 
Immunoblotting 
Total Protein Extraction 
Cell pellets were lysed with the addition of an equal volume of urea lysis buffer to 
frozen pellet on ice. The pellet was vortexed to disperse, and incubated on ice for 
15 minutes. The lysate underwent centrifugation for 10 minutes at 10500g at 4° C 
and the supernatant was aspirated and kept on ice. Protein quantification was 
performed using the Bio-Rad Bradford reagent and normalised to a known 
standard curve. Lysate concentrations were normalised to 20 mg/15 ml in SDS 
sample loading buffer. 
 
SDS PAGE and Protein Transfer 
Lysates were heated to 95° C for 4 min before being loaded onto a 12% 
polyacrylamide gel. Proteins were separated by electrophoresis using a Bio-Rad 
Mini-gel apparatus with SDS running buffer at 150 v. 
Proteins were transferred to Hybond nitrocellulose membrane (Amersham UK) 
using transfer buffer (1X TG, 20%v/v ethanol) at 100 v for 1 h. Protein transfer was 
verified using India ink staining (1:1000 India ink with 0.1% Tween / PBS) for 10 
min. 
 
Immunoblotting 
Membranes were blocked by incubating in 5% non fat dried milk / 0.1% Tween / 
TBS for 1 h at room temperature or overnight at 4° C. Primary antibodies were 
diluted in 3% non fat dried milk / 0.1% Tween / PBS and membranes incubated for 
1 h at room temperature or overnight at 4° C except for phospho-antibodies which 
were dissolved in 5% Bovine Serum Albumin (Fraction V) / 0.1% Tween / TBS and 
incubated overnight at 4° C. Membranes were then washed three times for five 
minutes in the appropriate wash buffer. HRP conjugated secondary antibodies 
were diluted in 3% non fat dried milk / 0.1% Tween / TBS and incubated for 1 h at 
room temperature. Three further washes in the appropriate wash buffer were 
performed for fifteen, ten and ten min. Immunocomplexes were identified using   62 
West Pico Supersignal Chemiluminescent Reagent and a chemiluminescent 
imager (Fluor S Max, Bio-Rad). 
Unless otherwise indicated membranes were not stripped or re-probed. 
Quantification of western blots was performed with Quantity One software 
(BioRad). Equal sized areas of interest (AOI) were created for each band analysed 
and the pixel density calculated for each area. A representative background AOI 
was calculated and subtracted from each band. To confirm the accuracy of this 
technique serial dilutions of quantified protein were run on a 12% polyacrylamide 
gel and separated by electrophoresis. MNK1 protein was identified by western 
blotting at each protein dilution and bands quantified. Band intensity was plotted 
against protein loaded (fig 2:1). 
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Figure 3:3 Quantification of immunoblotting  
Untreated SKBr3 cells were lysed with urea lysis buffer and clarified by 
centrifugation. Proteins were quantified with Bradford reagent and serial dilutions 
made with SDS loading buffer. Protein quantities as shown were loaded to 12% 
polyacrylamide gel and separated by PAGE. MNK1 protein was identified by 
immunoblotting and band intensity quantified using Quantity One 2D gel analysis 
software (BioRad). Graph shows band density plotted against amount of protein 
loaded for the immunoblot above.   
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3.2.3.  Nucleic acid analysis 
Taqman qRT-PCR 
Cells were plated at 0.5 X 10
6 cells per dish in 60mm dishes, and treated with 
CGP57380 or transfected with siRNA as above. Cells were harvested by washing 
once in PBS, scraped in PBS and pelleted by centrifugation at 1000g for 4 min at 
4° C. Pellets were snap frozen in liquid nitrogen. 
 
RNA extraction 
RNA was extracted at room temperature by solid phase extraction using a RNeasy 
Mini Kit (Qiagen). 
Cell pellets were homogenised and disrupted by vortex in 350 µl buffer RLT to 
which 1% ! mercaptoethanol had been added. Buffer RLT contains high salt and 
guanidine-thiocyanate and results in disruption of cells and denaturing of proteins 
including inactivation of ribonucleases. ! mercaptoethanol is added for its reducing 
capacity to further inhibit ribonuclease function. 350 µl 70% ethanol was then 
added and mixed by pipetting to establish optimum column binding conditions for 
RNA. 700 µl of the above lysate was then added to a spin column and centrifuged 
at 8000g for 15 s at room temperature to allow binding of RNA to the silica column. 
This binding occurs due to the high salt conditions allowing formation of a salt 
bridge between the negatively charged ribonucleic acid and silica. The column was 
then washed with 350 µl high salt buffer RW1 and centrifuged at 8000g for 15 s. 
An on-column DNA digestion was then performed. 10 µl DNase I was added to 70 
µl buffer RDD and mixed by inversion. 80 µl of the DNase I mix was then added 
directly to the column and incubated for 15 min at room temperature. A further high 
salt wash with 350 µl buffer RW1 was performed followed by being centrifuged at 
8000g for 15 s. Two washes were then performed with 500 µl buffer RPE to which 
4 volumes of ethanol had been added. Following the first wash, samples were 
centrifuged at 8000g for 15 s, and at 8000g for 2 min following the second. The 
column was then put in a new collection tube and the RNA eluted with 30 µl 
ribonuclease free water and centrifuged at 8000g for 1 min. The eluate was then 
re-applied to the column and a further centrifugation at 8000g for 1 min was 
performed.   65 
The RNA was quantified by photospectroscopic absorbance at 260 nm using a 
Nanodrop 1000 Spectrophotometer (Thermo Scientific), using the 260:280 nm 
absorbance ratio to confirm purity. Samples were stored at -80° C. 
 
cDNA synthesis 
Complementary DNA (cDNA) was synthesised using SuperScript II reverse 
transcriptase (Invitrogen). 
0.5 µg total RNA was added to a mixture containing 1 µl Olio dt primer (0.5 µg/ml 
Invitrogen), 1 µl dNTP mix (10mM Invitrogen) and deionised water to a final volume 
12 µl. This mixture was heated to 65° C for 5 min before being cooled on ice and 
pulse centrifuged at 8000g. A mixture of 4 µl 5X first strand buffer (Invitrogen), 2 µl 
0.1M dithiothreitol (DTT) and 1 µl ribonuclease inhibitor RNaseOut (40 units / µl 
Invitrogen) was added, mixed by pipetting and incubated at 42° C for 2 min. 1 µl 
(200 units) of SuperScript II reverse transcriptase (Invitrogen) was added and 
mixed by pipetting, followed by incubation at 42° for 50 min. The reaction was 
inactivated at 70° C for 15 min and the samples stored at -20° C. 
 
Taqman qRT-PCR 
Cyclin D1 reactions were performed in triplicate with GAPDH in duplicate. Standard 
curves were carried out for both genes using five known quantities of cDNA from 
T47D cells, starting at 15 ng with serial 1:5 dilutions. No cDNA negative controls 
were also performed in duplicate for each gene. All reactions were performed at a 
final volume of 20 µl and set up as follows. 
A mastermix for each reaction was made containing 10 µl 2 X Taqman Universal 
PCR Mastermix (Applied Biosystems), 1 µl GAPDH or Cyclin D1 20X primer/probe 
mix (Applied Biosystems), and 4 µl deionised water. The Universal PCR Mastermix 
contains AmpliTaq gold DNA polymerase, dNTPs and optimised buffers. 15 µl of 
the above mastermix was added to each well in a MicroAmp Optical 96 well 
reaction plate (Applied Biosystems). 5 µl cDNA at a concentration of 1 ng/µl was 
added to each well. The plate was then pulse centrifuged to 200g on a benchtop 
centrifuge (Sorvall Legend RT). PCR was performed using the ABI PRISM 7500 
Sequence Detection System (Applied Biosystems) using parameters as follows:   66 
94°C 10 min, 40 cycles 94°C for 15 s and 60°C for 1 min. Ct values were 
normalised to GAPDH, and absolute values obtained from the standard curve. 
 
Cell fractionation and polyribosome purification 
ACHN cells were plated at 1.5 x 10
6 cells in 10 ml medium in each of eight 90mm 
dishes. 24 h later cells were treated with CGP57380 at a final concentration of 20 
µM in 0.5% DMSO, or 0.5% DMSO vehicle control for 6h. Cells were washed once 
in cold serum free medium and then scraped into 2 ml cold serum free medium 
containing 10µg/ml cycloheximide with cells pooled from each treatment. A 1 ml 
aliquot was taken from each pooled cell suspension, centrifuged at 1000g for 4 min 
at 4 °C and snap frozen for total cellular RNA. The remaining cells were 
centrifuged at 1000g for 4 min at 4 °C and resuspended in 1 ml Fractionation buffer 
A before being incubated on ice for 5 min. Cells were homogenized using a dounce 
homogeniser with 20 strokes of the loose pestle before being incubated on ice for a 
further 5 min. Cells were then homogenized with 20 strokes of the tight pestle of 
the dounce homogeniser and once again incubated for 5 min on ice. A further 20 
strokes of the tight pestle were then used and the cells checked for lysis by 
microscopy. The cell suspension was then transferred to a 1.5 ml tube and 
centrifuged at 12,000g for 10 min at 4 °C. The supernatant was transferred to a 
fresh 1.5 ml tube as the cytoplasmic fraction. The pellet was resuspended in 200 µl 
fractionation buffer A and once again centrifuged at 12,000g for 10 min at 4 °C. 
The supernatant was removed and the pellet was snap frozen in liquid nitrogen as 
the nuclear fraction. The protein concentration of the cytoplasmic fraction was 
measured using Bio-Rad Bradford reagent. 
1.5 ml fractionation buffer A with 30% sucrose (w/v) was placed in each of two 2 ml 
Beckman centrifuge tubes. 0.5 ml of the cytoplasmic fraction with the lowest 
protein concentration was carefully layered over a sucrose cushion. A volume of 
the other cytoplasmic fraction to give equal protein was carefully layered over the 
other sucrose cushion, and the volume made up to 0.5 ml with fractionation buffer 
A. The remaining cytoplasmic fraction for each sample was snap frozen in liquid 
nitrogen. The samples were centrifuged at 130,000g for 2.5 h at 4 °C on a 
Beckman-Coulter Optima Max Ultracentrifuge using a TLS-55 rotor. All but the last   67 
100 µl sucrose cushion was removed and discarded. The final 100 µl was snap 
frozen in liquid nitrogen as the polyribosome fraction. 
 
RNA was extracted by phenol extraction using RNA Bee reagent (AMSbio) as 
follows: 
For the total and nuclear pellets 750 µl RNA Bee reagent was added and mixed by 
vortex. For the cytoplasmic and polysome fractions 1 ml RNA Bee reagent was 
added to 100 µl cell fraction and mixed by vortex. 0.1 vol chloroform was added to 
each sample and mixed thoroughly by vortex for 15 s and then incubated in ice for 
5 min. Samples were centrifuged at 10,500g for 15 min at 4 °C and the upper 
aqueous layer removed to a fresh 1.5 ml tube. RNA was precipitated by the 
addition of an equal volume of isopropanol and incubated on ice for 15 min. 
Samples were centrifuged at 10,000g for 10 min at 4 °C and the isopropanol 
aspirated to waste. The pellet was washed in 1 ml 75% ethanol, vortexing to break 
up the pellet. Samples were centrifuged at 7,500g for 8 min. The ethanol was 
aspirated to waste and the pellet allowed to air dry until semi-clear. The pellet was 
re-suspended in 40-100 µl RNAse free water and the RNA quantified using a 
Nanodrop 1000 Spectrophotometer (Thermo Scientific), using the 260:280 nm 
absorbance ratio to confirm purity. Samples were stored at -80° C. 
cDNA was synthesized as described above with the addition of 1 µl of 
oligonucleotide primer (table 2:3). 
Semi-quantitative reverse transcriptase PCR was used to assess fractionation 
using primers for small nuclear RNA U6 and GAPDH. Each reaction was set up in 
ice as follows, with 2 quantities of input cDNA to ensure reactions were within 
logarithmic range: 
 
  5 x GoTaq buffer (Promega)    10 µl 
  25 mM MgCl2        5 µl 
  10 mM dNTPs (ATGC)      1 µl each nucleotide 
  20 pmol primer        1 µl of each 
  GoTaq polymerase (Promega)    0.1 µl (0.5 units) 
  Water           to 48 µl 
  cDNA           2 µl   68 
Target  Primers  Product 
size 
Input 
cDNA (pg) 
Cycles 
snRNA 
U6 
F_CGC TTC GGC AGC ACA TAT AC 
R_TTC ACG AAT TTG CGT GTC AT 
100 bp  300/100  28 
GAPDH  F_GAA GGT GAA GGT CGG AGT 
R_GAA GAT GGT GAT GGG ATT TC 
200 bp  3000/1000  28 
 
Table 3:3 PCR conditions for cellular fractionation 
Reactions were run on a thermal cycler with the following parameters: 
  94 °C  3 min 
  94 °C 30 s  
  57 °C 30 s   cycles as per table 
  72 °C 30 s 
  72 °C 3 min 
 
4-thiouracil RNA labeling and pull down 
0.5 x 10
6 cells were plated to 60 mm dishes in 3 ml medium. 24 h later CGP57380 
was added to a final concentration of 20 µM in 0.5% DMSO, or 0.5% DMSO 
vehicle control alone. After 1 h 4-thiouracil (Sigma) was added to a final 
concentration of 50 mM and cells incubated for a further 6 h. Cells were then 
harvested by scraping and pelletted by centrifugation at 1000g for 4 min at 4 °C. 
RNA was extracted using RNA Bee as described above and quantified using a 
Nanodrop photospectrometer. 
4-thiouracil containing RNA was biotinylated as follows. A 1 mg/ml solution of EZ 
Link Biotin HPDP (Pierce) in dimethylformamide (DMF) was prepared. The 
following mixture was prepared with addition of Biotin-HPDP last, and incubated in 
the dark for 2 h at room temperature: 
  RNA (total)    10 µg 
  1M Tris (pH7.4)  0.5 µl 
0.5M EDTA    0.1 µl 
Biotin-HPDP   10 µl 
RNAse free water  up to final volume of 50 µl 
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Labelled RNA was precipitated by the addition of 5 µl 5M NaCl and 50 µl 
isopropranol followed by vortexing and incubation at room temperature for 5 min. 
Samples were then centrifuged at 10,500g for 20 min and the supernatant 
aspirated. The pellet was rinsed with 250 µl 75% ethanol and the samples once 
again centrifuged at 10,500g for 10 min. The ethanol was aspirated and the pellet 
allowed to air dry until semi-clear. The RNA was resuspended in 40 µl RNAse free 
water. 
Biotinylated 4-thiouracil labeled RNA was then purified as follows. Streptavidin 
beads (Dynabeads MyOneStreptavidin C1, Invitrogen) were first blocked with yeast 
tRNA (Invitrogen). Two aliquots of 40 µl beads were each blocked with 2 µg tRNA 
by rotating in a 1.5 ml tube for 20 min at room temperature. Tubes were then 
placed in a magnetic stand and the beads collected at the side of the tube for 2 
min. Beads were washed 3 times in 300 µl MPG buffer, collecting beads between 
washes by standing in a magnetic stand for 2 min, and then resuspended in 40 µl 
MPG buffer. The biotinylated RNA was added to the beads and mixed with rotation 
at room temperature for 30 min. The beads were then collected in a magnetic 
stand for 2 min. The supernatant was removed to a fresh tube and snap frozen in 
liquid nitrogen as unbound, non-4-thiouracil labeled RNA. The beads were then 
washed in MPG buffer as follows with pipetting to mix; twice in 250 µl MPG buffer 
at room temperature, once in 250 µl MPG buffer at 65 °C and once in 50 µl MPG 
buffer at room temperature, retaining the final wash to check flow through of 
unbound RNA. 
The bound, 4-thiouracil containing RNA was eluted by adding 40 µl of freshly 
prepared !-mecaptoethanol to the beads and incubating at room temperature for 
20 min with rotation, flicking the tube at 10 min to mix well. The beads were then 
collecting by placing the tube in a magnetic stand for 2 min and transferring the 
supernatant containing bound, 4-thiouracil to fresh tubes. 
RNA was precipitated from each fraction. An equal volume of isopropanol was 
added to each of the fractions. For the 4-thiouracil RNA fraction 1/10 volume of 5 M 
NaCl was also added. 5 µg glycogen (Fermentas) was added to each sample 
followed by incubation at room temperature for 5 min. The samples were 
centrifuged at 10,500g for 20 min. The supernatant was discarded and the 
precipitated RNA pellet washed in 250 µl 75% ethanol before being centrifuged at   70 
10,000g for 5 min. The pellet was air-dried until semi-clear and resuspended in 10 
µl RNAse free water. RNA was quantified using a Nanodrop photospectrometer. 
cDNA was made as above, and cyclin D1 RNA measured using Taqman qRT-PCR 
as described above. 
 
Luciferase reporter assay 
100,000 cells were plated to each well of a 24 well plate in 500 µl medium. 24 h 
later cells were transfected with 20 ng pRLSV40 renilla luciferase reporter vector 
together with 1 µl of firefly luciferase reporters containing either the complete 
CyclinD1 promoter (-1745CD1Luc)
155, a kind gift from Dr Richard Pestell, or pgl3 
basic control containing firefly luciferase with no promoter. Transfections were 
performed by the addition of vectors as above to 50 µl Opti-MEM serum free 
medium (Invitrogen). 2 µl Lipofectamine 2000 transfection reagent (Invitrogen) was 
added to 50 µl Opti-MEM per transfection and incubated at room temperature for 5 
min. 50 µl Lipofectamine mix was added to 50 µl plasmid mix, mixed by pipetting 
and incubated at room temperature for 20 min before being added dropwise to the 
cells. At 4 h post transfection the transfection mix was removed and replaced with 
1 ml complete medium containing either 20 µM CGP57380 in 0.5% v/v DMSO, or 
0.5% DMSO vehicle control. 
24 h post transfection renilla and firefly luciferase activity was assayed using the 
Dual-Glo luciferase assay system (Promega). Medium was removed from each 
well to leave 100 µl remaining. 100 µl Dual-Glo luciferase reagent was added to 
each well. Once cells had lysed 100 µl cell lysate was transferred to a white 
OptiPlate 96 well plate (Perkin Elmer) and firefly luminescence measured using a 
Varioskan Flash plate reader (Thermo Electron Corporation). 100 µl Dual-Glo Stop 
& Glo reagent was then added to each well to quench firefly luciferase activity and 
act as a substrate for renilla luciferase. After 10 min incubation renilla luciferase 
activity was measured using a plate reader as above. Results were expressed as 
firefly luciferase relative to renilla luciferase for each transfection. 
 
Site directed mutagenesis 
A plasmid vector encoding EYFP-eIF4E was mutated to give a positively charged 
aspartic acid at serine 209, the phosphorylation site of the MNK kinases in eIF4E.   71 
The EYFP-eIF4E plasmid was constructed by Mr Matthew Darley in Dr Blaydes 
laboratory using EYFP-C1 and the coding sequence for murine eIF4E which has 
close homology to human eIF4E. 
Oligonucleotide primers were designed such that the sequence of the forward 
primer matched that of the sequence of eIF4E at least 12 base pairs either side of 
the codon coding for serine 209. The S209 codon was changed to encode an 
aspartic acid giving the following primers: 
Forward – 5’-ACA AAG AGC GGC GAT ACC ACT AAA AAT AGG-3’ 
Reverse – 3’-CCT ATT TTT AGT GGT ATC GCC GCT CTT TGT-5’ 
A PCR Reaction was set up as follows using a Stratgene Quickchange SDM kit. 
  5 µl 10x pfu turbo reaction buffer 
  50 ng EYFP-eIF4E double stranded DNA template 
  1 ng forward primer 
  1 ng reverse primer 
  1 µl dNTP nucleotide mix 
  double distilled water to a final volume 50 µl 
1 µl Pfu turbo DNA polymerase was added immediately prior to running the 
following reaction in a thermal cycler: 
  Segment 1  1 cycle  95 °C  30 sec 
  Segment 2  18 cycles  95 °C  30 sec 
          55 °C  1 min 
          68 °C  18 min 
 
A Dpn1 digestion was then performed to digest the template plasmid DNA as 
follows: 
1 µl Dpn1 (Promega) restriction enzyme (10U/µl ) was added to the amplification 
reaction above and mixed by pipetting before being spun for 1 min in a 
microcentrifuge. The mixture was then incubated at 37 °C for 1 h and subsequently 
stored at -20 °C. 
The resulting plasmid DNA was then transformed into XL1-Blue supercompetent 
bacteria (made in the Blaydes lab by Mr Matthew Darley) as follows: 
XL1-Blue cells were thawed on ice 
15 µl cells were placed in a pre-chilled 15 ml Falcon tube (Becton-Dickinson)   72 
1 µl plasmid DNA was added to the cells, gently mixed and incubated in ice for 30 
min. 
The cells were placed in a waterbath at 42 °C for 45 s and then returned to ice for 
2 min. 
0.5 ml Luria-Bertani (LB) broth was added and incubated at 37 °C for 1 h shaking 
at 220 rpm. 
250 µl LB broth was then plated to each of 2 agar plates containing kanamycin at 
10 µg/ml and incubated overnight at 37 °C. 
5 colonies were picked from each plate and each placed in 5 ml LB broth 
containing 10 µg/ml kanamycin. These were subsequently incubated overnight at 
37 °C with shaking at 220 rpm. 
Plasmid DNA was isolated using a QIAprep spin miniprep kit (Qiagen) as follows: 
Bacterial cells were pelletted by centrifugation at 6000g for 15 min at 4 °C and the 
supernatant discarded to waste. 
The cells were resuspended in 250 µl buffer P1 to which RNase A had been pre-
added. 
The cell suspension was transferred to a 1.5 ml microcentrifuge tube to which 250 
µl buffer P2 (sodium hydroxide and SDS) was added and mixed by inverting, 
allowing the mixture to form a slightly viscous clear solution for a maximum of 5 
min. The alkaline buffer denatures the cell contents released following lysis of the 
cell though solubilisation of the membrane phospholipids by SDS. 
350 µl buffer P3 was added and once again mixed by inverting. This high salt 
buffer causes the precipitation of cellular proteins and chromosomal DNA. 
The suspension was centrifuged at 18,000g for 10 min following which the 
supernatant was placed in a QIAprep spin column. This was centrifuged at 18,000g 
for 60 s and the flow through discarded. 
The spin column was washed by the addition of 0.75 ml buffer PE followed by 
centrifugation at 18,000g for 60 s. The flow through was discarded and the column 
spun for a further 1 min at 18,000g to dry the column. The QIAprep column was 
then placed in a clean 1.5 ml microcentrifuge tube and 50 µl DNAse free water 
applied directly to the membrane at the centre of the column. The column was 
allowed to stand for 1 min and then spun at 18,000g for 1 min to elute the plasmid 
DNA.   73 
3 samples were sent for sequencing (Geneservice) using the EGFR-CR primer. 
Alignment of the sequencing data was checked and the mutation confirmed.  
The plasmid DNA was then amplified using tranformation of XL-1 Blue 
supercompetent bacteria and DNA extraction using a QIAfilter plasmid maxi kit 
(Qiagen). 
XL-1 Blue supercompetent bacteria were transformed as described above, plated 
to kanamycin-agar plates and colonies picked. Bacterial cultures were grown up to 
125 ml in LB broth by incubation overnight at 37 °C with shaking at 220 rpm. The 
bacterial cells were then pelletted by centrifugation at 6000g for 15 min at 4 °C. 
The pellet was resuspended in 10 ml buffer P1 following which 10 ml buffer P2 was 
added and mixed by inverting the tube 4-6 times. The cell suspension was then 
incubated at room temperature for 5 min. 10 ml chilled buffer P3 was added and 
the suspension mixed by inverting 4-6 times after which the suspension was 
poured into a QIAfilter cartridge and incubated at room temperature for 10 min. 
During this time a QIAGEN-tip was equilibrated by the addition of 10 ml buffer QBT 
which was allowed to drain through completely. A plunger was placed in the 
QIAfilter cartridge and the cell lysate filtered into the equilibrated QIAGEN-tip and 
allowed to pass into the resin. The resin was then washed twice with 30 ml buffer 
QC. The DNA was eluted into 10.5 ml isopropanol using 15 ml buffer QF. The 
eluted DNA was then precipitated by centrifugation at 6000g for 30 min at 4 °C. 
The supernatant was removed and the pellet re-suspended in 1 ml 70% ethanol to 
wash before being transferred to a 1.5 ml microcentrifuge tube. The DNA was once 
again precipitated by centrifugation at 10500g for 10 min at 4 °C and the 
supernatant removed. The DNA pellet was allowed to air dry, resuspended in 350 
µl 10% TE in RNase free water and quantified using a photospectrometer. 
 
Stable transfection 
For stable transfection of A498 cells with the EYFP-eIF4ESD209 vector and EYFP 
empty vector control, cells were first cultured in increasing concentrations of G418 
to establish the minimum concentration to kill all growing cells. This was 
established at 62.5 µg/ml. 
Cells were plated at 0.4 x 10
6 cells in 2 ml medium in 60 mm dishes. 24 h later 
cells were transfected using 2 µg vector DNA as follows.   74 
A plasmid mix was prepared by adding 2 µg plasmid vector to 0.5 ml Optimem 
serum free medium (Invitrogen). For each transfection a mix of 0.5 ml Optimem 
and 6 µl Lipofectamine 2000 transfection reagent (Invitrogen) was prepared, mixed 
thoroughly by vortex and incubated at room temperature for 5 min. The 
Lipofectamine mix was then added to the plasmid mix and vortexed thoroughly 
before incubation at room temperature for 20 min. The transfection mix was then 
added dropwise to the cells. The medium was replaced at 4 h after transfection. 
48 h after transfection the cells were trypsinised and replated to 90 mm dishes with 
10% of the trypsinised cells to one plate and 50% to another. 24 h later the 
medium was changed for complete medium containing G418 at 62.5 µg/ml. The 
medium was changed on alternate days until untransfected cells were seen to die 
and colonies of transfected cells form. Vector expression was confirmed by 
imaging the cells with a fluorescence microscope (Zeiss Axiovert 200) using 
excitation at 490 nm and an EYFP emission filter. 
Expressing colonies were picked from the 10% plates using cloning rings to 
selectively trypsinise individual colonies and transfer them to 96 well plates. 
Colonies were maintained in medium containing G418 at 62.5 µg/ml and grown up 
to 25cm
2 tissue culture flasks at which point pellets were frozen in liquid nitrogen 
for subsequent use, and protein lysates made for western blotting to confirm vector 
expression. 
Pooled transfectants were made from the 50% plates by serial trypsinisation and 
replating of all colonies on the plate in medium containing G418 at 62.5 µg/ml. 
 
M
7GTP pulldown of eIF4E 
To confirm the functionality of the transfected EYFP-eIF4ESD209 vector, synthetic 
m
7GTP linked to sepharose beads was used as a cap analogue to pull down the 
transfected eIF4E protein as follows. 
Transfected cells were plated to 90mm dishes in 10 ml medium and harvested 24 h 
later by scraping. Cell pellets were snap frozen. Proteins were extracted using 40 
µl extraction buffer for 15 min on ice. Lysates were clarified by centrifugation at 
10500g for 15 min at 4 °C and proteins quantified using Bradford reagent (BioRad). 
25 µl m
7GTP-sepharose beads (Amersham) were added to 1 ml extraction buffer, 
then pelleted by centrifugation at 1000g for 30 s and the supernatant removed. 180   75 
µg protein extract was added (with the volumes equalized to at least 100 µl with 
extraction buffer) and mixed by rotating for 1 h at 4 °C. The beads were then 
extracted by centrifugation at 1000g for 30 s and washed twice with 1 ml extraction 
buffer. 
18 µl of 100 µM m
7GTP (Amersham) was then added and incubated on ice for 15 
min, mixing every 2 min. The beads were then centrifuged at 1000g for 30 s and 
the supernatant retained. 
5 µl of 4 x SDS sample buffer was added to 15 µl pulldown supernatant and heated 
at 95 °C for 4 min before loading to wells on a 12% polyacrylamide gel and 
proteins separated by PAGE and western blotting as described above. 
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3.3. Statistical Analysis 
 
Statistical analysis was performed using GraphPad Prism software Version 4.0c. 
For comparing multiple groups of results, analysis of variance (ANOVA) was used 
with Tukey’s post test for subsequent comparison between single pairs of groups 
when p<0.05 for the overall analysis. For comparisons of pairs of groups Student’s 
t test was used. 
For microarray analysis GenePattern software was used for data processing and 
primary analysis. The database for annotation, visualisation and integrated 
discovery (DAVID) bioinformatics database was used to identify functional groups 
over-represented in the regulated genes.  77 
 
4. MNK kinase inhibition in breast cancer cell lines 
4.1. Introduction 
 
Approximately 25% of breast cancers are known to over-express the receptor 
HER2. HER2 over-expression can result in homo-dimerisation and subsequent 
activation of the tyrosine kinase resulting in signalling through both the 
PI3K/AKT/mTOR and MAPK signaling cascades and activation of cell proliferation 
and survival pathways. Thus blockade of a node of signalling with input from both 
of these pathways such as eIF4E may be an active therapeutic target. Although a 
single HER2 over-expressing breast cancer cell line has been shown to be 
sensitive to inhibition of proliferation by the MNK inhibitor CGP57380
65, it is not 
clear whether this effect is limited to cells of this phenotype or whether other breast 
cancers may be sensitive. To investigate this, a panel of breast cancer cell lines 
representing a spectrum of phenotypes of clinical breast cancer cases was used to 
establish the significance of phosphorylated eIF4E on proliferation (table 4:1). 
 
Cell line  MCF7  ZR75.1  T47D  BT474  SKBr3 
MDA-MB-
231 
Oestrogen 
Receptor 
+  +  +  +  -  - 
HER2 
overexpression 
-  -  -  +  +  - 
p53  Wildtype  Wildtype  Mutant  Mutant  Mutant  Mutant 
Phenotype  Luminal  Luminal  Luminal  HER2  HER2  Basal 
 
Table 4:1 Characteristics of breast cancer cell lines 
+ overexpression, - no overexpression. 
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4.2. Basal levels of eIF4E phosphorylation 
In order to investigate whether the presence of significant amounts of 
phosphorylated eIF4E in unstimulated cells varied between the different cell lines 
immunoblotting was performed. Protein lysates for all lines were made from 
exponentially growing cells, to which fresh medium had been applied 24 hours 
previously and analysed by immunoblotting. Bands were quantified and 
phosphorylated eIF4E expressed as a proportion of eIF4E, as well as being 
normalised to actin (fig 4.1). 
There was a clear variation in the amount of phosophorylated eIF4E between cell 
lines, and in the ratio of phosphorylated eIF4E to unphosphorylated eIF4E. Low 
levels of both eIF4E and phosphorylated eIF4E were seen in MCF7 cells, with a 
low ratio of phosphorylated to unphosphorylated protein. The two other luminal 
phenotype cell lines showed higher levels of eIF4E phosphorylation which was 
more pronounced in ZR75.1 cells. Lower levels of unphosphorylated eIF4E in 
T47D cells however resulted in a higher ratio of phosphorylated to 
unphosphorylated protein in this cell line. 
Both the HER2 phenotype cell lines, BT474 and SKBr3, showed high levels of 
phosphorylated eIF4E, although when normalised to actin the levels of 
phosphorylated eIF4E in BT474 cells was one of the lowest of the cell lines 
investigated. The pattern of bands for actin for this cell line, as noted previously
62, 
is however unusual with multiple bands seen making interpretation of normalised 
data for this cell line more difficult. The basal phenotype line, MDA-MB-231 
showed an intermediate level of both eIF4E and phosphorylated eIF4E, with a ratio 
similar to that seen in the BT474 line. 
 
In order to compare levels of phosphorylated eIF4E in breast cell lines with primary 
breast tissue, protein lysates from ten breast tumour tissue samples were also 
assessed (fig 4:2). The pathological characteristics of the breast tumours sampled, 
are shown in table 4:2. Again variation was seen between samples. Most samples 
which had measurable levels of eIF4E, also had higher levels of the 
phosphorylated form (samples 4,8-10), however two samples had measureable 
eIF4E with barely detectable levels of peIF4E (samples 4,7) and one had low 
levels of unphosphorylated eIF4E with higher levels of the phosphorylated form   79 
(sample 3). Although the sample size is too small to draw any firm conclusions, 
there did not appear to be any relationship between those tumour samples with the 
highest ratio of phosphorylated eIF4E to unphosphorylated eIF4E and tumour size, 
grade, nodal status or ER status. 
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Figure 4:1 eIF4E phosphorylation in unstimulated breast cancer cells 
Exponentially growing cells with fresh medium applied 24 h prior to sampling were 
pelleted and snap frozen. Samples were lysed by urea lysis. Equal amounts of 
protein were separated by PAGE, and individual proteins identified with 
immunoblotting. Bands were quantified with Quantity One software (BioRad) and 
expressed as a ratio of phosphorylated eIF4E to actin, and as a ratio of 
phosphorylated eIF4E to unphosphorylated eIF4E. 
   
0 
1 
2 
3 
4 
MCF7  ZR75.1  T47D  BT474  SKBr3  MDA-
MB-231 
p
e
I
F
4
E
 
r
e
l
a
t
i
v
e
 
t
o
 
a
c
t
i
n
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
 
0 
1 
2 
3 
4 
5 
MCF7  ZR75.1  T47D  BT474  SKBr3  MDA-
MB-231 
p
e
I
F
4
E
 
r
e
l
a
t
i
v
e
 
t
o
 
e
I
F
4
E
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
!
   81 
 
 
 
Figure 4:2 eIF4E phosphorylation in breast tissue samples 
Proteins were extracted from human breast tissue samples by urea lysis and 
quantified. Equal amounts of protein were separated by PAGE and individual 
proteins identified with immunoblotting. Bands were quantified using Quantity One 
software (BioRad) and expressed as a proportion of phosphorylated eIF4E to total 
eIF4E. * no detectable phosphorylated eIF4E beyond background. 
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Tumour 
sample 
Surgery  Tumour 
type 
Tumour 
size 
Nodal 
involvement 
Grade  ER 
status 
1  Mastectomy  IDC  5mm  0/8  2  ++ 
2  Mastectomy  IDC  87mm  7/11  2  + 
3  WLE  IDC  14mm  0/13  1  + 
4  WLE  IDC  30mm  0/15  2  ++ 
5  Mastectomy  IDC  40mm  1/8  3  + 
6  Mastectomy  IDC  45mm  3/24  3  - 
7  Mastectomy  ILC  55mm  2/7  2  ++ 
8  Mastectomy  IDC  55mm  10/12  2  + 
9  WLE  IDC  25mm  0/19  3  - 
10  WLE  IDC  30mm  1/9  2  ++ 
 
Table 4:2 Histological characteristics of breast tissue samples 
The histological characteristics of each tumour were obtained from the diagnostic 
pathology report. These samples pre-date routine diagnostic testing for HER2 by 
either immunohistochemistry or fluorescence in situ hybridisation. WLE Wide local 
excision; IDC invasive ductal carcinoma; ILC invasive lobular carcinoma; nodal 
involvement - involved nodes/sampled nodes; ER - no expression, + weak to 
moderate expression, ++ strong expression by immunohistochemistry. 
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4.3.  Effects of CGP57380 on eIF4E phosphorylation 
In order to ensure CGP57380 was indeed inhibiting phosphorylation of eIF4E, cells 
were treated with increasing concentrations of CGP57380 or 0.5% DMSO control 
for 24 h and immunoblotting used to measure effects on eIF4E phosphorylation. 
Both SKBr3 and BT474 cell lines showed inhibition of eIF4E phosphorylation with 
20 µM CGP57380 (fig 4:3). 
A time course was also performed with cells treated for 72 h with CGP57380 at 20 
µM, and protein lystates obtained at various time points (fig 4:4). BT474 cells were 
most sensitive to CGP57380, with inhibition of eIF4E phosphorylation by 15 min, 
which was sustained for 72 h. SKBr3 cells showed reduced levels of eIF4E 
phosphorylation by 4 h, however by 24 h this was starting to return, and had 
returned to baseline levels by 72 h. MDA-MB-231 cells were less sensitive to 
CGP57380 with partial loss of eIF4E phosphorylation at 1 h, which persisted to 72 
h, when both eIF4E and phosphorylated eIF4E levels were almost undetectable. 
T47D cells showed a rapid loss of eIF4E within 2 hours. Although phosphorylated 
protein was visible at 24 h, it otherwise remained inhibited until 72 h.  84 
 
 
Figure 4:3 eIF4E phosphorylation following treatment with CGP57380 
0.5 X 10
6 SKBr3 (a), and BT474 (b) cells were plated to 60mm dishes. 24 h later cells were treated with CGP57380 at the 
concentrations as indicated in DMSO vehicle control 0.5% v/v for 24 h. Cells were pelleted and lysed with urea lysis buffer. Equal 
amounts of protein were separated by PAGE. Individual proteins were identified by Immunoblotting.   85 
 
Figure 4:4 eIF4E phosphorylation following treatment with CGP57380 
MDA-MB-231 (a), BT474 (b), SKBr3 (c) and T47D (d) cell lines were treated with CGP57380 at 20 µM for times as indicated. 
Equal amounts of protein were loaded and separated by PAGE. Individual proteins were identified by immunoblotting. Time 0 
represents 0.5% DMSO vehicle control.  86 
4.4. Effects of CGP57380 on proliferation 
Having established that variation exists between the unstimulated level of eIF4E 
phosphorylation between cell lines, and that CGP57380 is able to inhibit eIF4E 
phosphorylation at a concentration of 20 µM, the effects of CGP57380 were 
investigated on the proliferation of the panel of breast cancer cell lines. 
Initially the MTS assay of cell proliferation was used to assess proliferation over a 
72 h time period. Initial escalating cell number experiments in each cell line, using 
the MTS assay to assess proliferation, revealed differences in the effect of 
proliferation dependent on the cell number plated. It was shown that beyond a 
certain number of cells plated, no further increase in output from the MTS assay, 
and no effect on proliferation was seen, whatever the dose of CGP57380 with 
which the cells were treated. Equally if too few cells were plated then little effect on 
proliferation was seen. Therefore a point on the cell number plating graph just 
before the curve plateaued was taken to assess the effects of proliferation (fig 4.5). 
Three experiments were performed for each cell line, with wells plated in triplicate. 
The mean MTS result was obtained for each triplicate plating, and the background 
MTS result for medium only was subtracted. Results for each experiment were 
normalised by adding the total MTS results for each experiment and dividing by the 
number of wells. This value was used to generate a correction factor to apply to 
each result for that experiment. At the cell number used to define proliferation, the 
results from three experiments were combined, and normalised to DMSO vehicle 
control (fig 4.6).  
With this experiment no effect on proliferation at any cell number or dose of 
CGP57380 was seen in MCF7 cells. This was consistent with the low levels of 
unstimulated eIF4E phosphorylation seen in this cell line. Surprisingly no effect 
was seen in T47D cells either, which was not expected on the basis of the 
relatively high unstimulated levels of eIF4E phosphorylation in this line. More 
surprising was an apparent increase in proliferation seen in ZR75.1 cells at all 
doses of CGP57380 tested. Both of the cell lines with a HER2 phenotype showed 
a trend to reduction in proliferation compared to control, consistent with previously 
published data
73. The MDA-MB-231 cell line which has a basal phenotype, and 
does not express estrogen receptor or the HER2 receptor also showed a response 
to CGP57380. This cell line is known to harbour an activating mutation of k-RAS
156,   87 
and therefore may be expected to have increased signaling through MNK1 and be 
sensitive to its inhibition. 
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Figure 4:5 Proliferation in response to CGP57380 
BT474 cells were plated at the numbers shown in 120 µl medium. 24 hours later 
110 µl medium was removed from each well and DMSO or CGP57380 added to 
give a final concentration as shown with 0.5% v/v DMSO vehicle control. 100 µl 
medium was returned to the well, and proliferation assessed 72 h later by the MTS 
assay. Results represent the mean of three separate experiments performed in 
triplicate. Highlighted results are those used for subsequent statistical analysis.   89 
 
Figure 4:6 Proliferation in response to CGP57380 
Cells were plated to 96 well plates in 120 µl medium. 24 h later 110µl medium was 
removed and CGP57380 added to give a final concentration as shown in 0.5% v/v 
DMSO vehicle. Proliferation was assessed using the MTS assay 72 h later. Results 
represent the mean of 3 experiments at plating cell numbers immediately below 
peaking of the MTS/cell number response curve. Statistical analysis: ANOVA with 
Tukey post test *=p<0.05 **=p<0.001 
   
MCF7
0
10
20
30
40
50
60
70
80
90
100
110
120
ZR75.1
0
50
100
150
T47D
0
10
20
30
40
50
60
70
80
90
100
110
120
BT474
0
10
20
30
40
50
60
70
80
90
100
110
SKBr3
0
10
20
30
40
50
60
70
80
90
100
110
MDA-MB-231
0
10
20
30
40
50
60
70
80
90
100
110
** *  90 
The effects seen on proliferation in the HER2 cell lines were relatively modest with 
this assay and did not reach statistical significance. 
In order to assess the effects of CGP57380 on proliferation under conditions of 
cellular stress, CGP57380 was combined with etoposide in SKBr3 cells. A dose 
response curve to etoposide was performed with and without CGP57380. This 
showed that CGP57380 was in fact protective from the effects of etoposide, rather 
than showing increased sensitivity (fig 4:7) with more growth inhibition seen in 
those cells treated with etoposide combined with DMSO vehicle control, than seen 
in combination with CGP57380.     91 
 
 
 
 
 
 
Figure 4:7 Proliferation in response to CGP57380 with etoposide 
SKBr3 cells were plated at 4000 cells/well in 120 µl medium in 96 well plates. 24 h 
later 110 µl medium was removed from each well and pooled for triplicate repeats. 
Concentrations of etoposide were added as shown, with CGP57380 20 µM or 0.5% 
DMSO vehicle control, and 100 µl added to each well. Proliferation was measured 
at 72 h using the MTS assay. 
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Given the surprising results of the MTS assay with respect to the ZR75.1 and T47D 
cell lines, a colony-forming assay of proliferation was performed (fig 3:8). This 
assay also puts the cells under additional stress by creating a single cell 
environment. It investigates the long term survival capacity of a single cell with both 
senescence and death giving a definitive result. 
Using this assay, once again MCF7 cells showed little response to CGP57380 at 
20 µM with a similar number of colonies grown with both treatment and control. All 
of the three lines showing a response in the MTS assay, also showed a response 
in the colony assay with almost complete inhibition of growth in the treated cells. 
Contrary to the MTS assay, T47D cells, which had not previously shown a 
response, showed a marked reduction in colony forming ability in the treated cells. 
In addition the ZR75.1 cell line, which showed an apparent proliferative effect in the 
MTS assay, also showed a reduction in colony number with the colony assay. 
One possible explanation for the discrepancy between the two assays in the 
ZR75.1 cell line may lie in the way in which the MTS assay measures cellular 
proliferation. This assay uses the reducing ability of cells as a measure of 
metabolic activity, and therefore as a surrogate for proliferation. MuItiple 
cytoplasmic and mitochondrial enzymes are able to achieve this
157. It is 
conceivable that applying a compound to the cell which has effects on cellular 
metabolism may lead to differential effects on the readout of the MTS assay 
compared to actual cellular proliferation as measured by the colony forming ability 
of the cells. 
Using the colony assay as the main readout for proliferation it therefore becomes 
apparent that all the cell lines with higher constitutive levels of eIF4E 
phosphorylation, which includes lines of luminal, HER2 and basal phenotype, have 
their growth inhibited by CGP57380.  93 
 
 
 
Figure 4:8 Colony forming assay in response to CGP57380 
0.5 X 10
6 cells were plated in 3 ml complete medium. At 24 h cell lines as indicated were treated with 0.5% DMSO vehicle control 
(upper wells) or CGP57380 20 µM (lower wells) for 24 h. Cells were then trypsinised, counted and re-plated at 1000 cells/well in 6 
well plates, in medium containing CGP57380 20 µM or 0.5% DMSO as previously. At 9-12 days colonies were fixed in methanol 
and stained with Geimsa. Pictures are representative of triplicate wells.  94 
 
4.5. Effects of CGP57380 on targets of eIF4E phosphorylation 
As the BT474 breast cancer cell line appeared the most sensitive to CGP57380, 
both in terms of inhibition of eIF4E phosphorylation, and inhibition of proliferation, 
this cell line was chosen to examine the effects of CGP57380 on downstream 
targets of eIF4E phosphorylation. Following exposure of cells to CGP57380 at 20 
µM for 72 h, immunoblotting was used to probe protein lysates for cyclin D1 and 
Mcl-1. A sustained inhibition of cyclin D1 protein was seen from 24 hours onwards, 
however no change in levels of the anti-apoptotic Mcl-1 was seen. In a repeat 
experiment examining intermediate time points from 1-8 h, once again an 
immediate and sustained inhibition of eIF4E phosphorylation was seen, however 
there was a less marked effect on cyclin D1 at the time points examined (fig 4:9).   95 
 
 
 
Figure 4:9 Downstream targets of phosphorylated eIF4E 
BT474 cells were treated with CGP57380 at 20 µM for times as indicated. Time 0 
represents untreated control. Equal amounts of protein were separated by PAGE. 
Immunoblotting was used to identify individual proteins. *These blots were re-
probed. The lower bands represent eIF4E/actin respectively. 
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4.6.  Mechanisms of inhibition of proliferation 
The marked effect on proliferation seen in the colony forming assay may be due 
either to senescence or cell death in those cells exposed to CGP57380. To 
investigate this, live cell imaging was used to assess changes in mitotic and 
apoptotic events over a time period of exposure to either CGP57380 or DMSO 
control. Using this technique SKBR3 and MDA-MB-231 cell lines were 
investigated. Cells were imaged for 24 h after 24 h pre treatment with CGP57380. 
Images were recorded every 15 min. Cells undergoing mitosis and apoptosis were 
identified by reviewing sequential images, and the number of events counted over 
the 24 h period. 
A differential effect was seen between cell lines. Over the 24 h time period SKBr3 
cells showed a reduction in mitotic events from 33.3±1.9 per 100 cells in the DMSO 
treated cells to 13.4± 1.5 per 100 cells in the CGP57380 treated cells (p<0.0001). 
Apoptotic events were low in both treated and untreated samples, however there 
was an increase from 0.4±0.3 events per 100 cells in the DMSO treated cells to 
2.1±0.5 events per 100 cells the CGP57380 treated over 24 h in the CGP57380 
treated cells compared with the DMSO controls (p=0.01). 
In MDA-MB-231 cells there was also a reduction in mitoses in the CGP57380 
treated cells. There was a reduction in mitotic events from 36.0±1.2 events per 100 
cells in the DMSO treated cells, to 21.9± 0.7 events per 100 cells in the CGP57380 
treated cells (p=0.009). Again there were low numbers of apoptotic events with a 
small increase from 3.3±0.4 events per 100 cells in the DMSO treated cells to 
3.8±0.5 events per 100 cells in the CGP57380 treated cells (p=0.5) (fig 4:10).   97 
 
Figure 4:10 Live cell imaging following treatment with CGP57380 
MDA-MB-231 cells (a) and SKBr3 cells (b) were assessed with live cell imaging. 
Cells were treated with 0.5% DMSO control or CGP57380 20µM for 24 h prior to 
imaging for 24 h with micrographs taken at 15 min intervals. The number of cells at 
the beginning and end of the time period, as well as the number of mitotic and 
apoptotic events were counted. Statistical analysis by Student’s t test *=p<0.05.   98 
The above results would suggest that cell cycle control may be involved in the 
response of breast cancer cells to MNK inhibition by CGP57380. To further 
investigate this as the underlying mechanism of inhibition of proliferation, cell cycle 
analysis using DNA staining with propidium iodide was used. A flow cytometry plot 
of fluorescence against events shows two peaks of fluorescence representing 2n 
and 4n DNA content, and hence cells and G1 and G2/M of the cell cycle 
respectively. Those events falling between the two peaks represent cells in S 
phase. Following 24 hours treatment with CGP57380 at 20 µM, MDA-MB-231 cells 
showed an accumulation in G1 compared with DMSO treated controls (Fig 4:11). 
Cells were lost from both S phase and G2/M. This result is consistent with 
immunoblotting of BT474 cells, showing a reduction in one of the key regulators of 
the transition from G1 to S phase; cyclin D1.   99 
a 
 
 
b 
 
 
Figure 4:11 Cell cycle analysis following treatment with CGP57380 
MDA-MB-231 cells were treated with CGP57380 20 µM, or DMSO vehicle control 
for 24 h. Cells were trypsinised with all washes retained and fixed in cold ethanol. 
Cells were resuspended in PBS, stained with propidium iodide and analysed by 
flow cytometry. a Example flow cytometry plots of fluorescence (FL2-A) against 
events. b quantification of cell cycle distribution from triplicate repeat experiments. 
Error bars represent standard error of the mean. Statistical analysis by Student's t-
test.   100 
4.7.  Discussion 
These results have shown that CGP57380 can inhibit the proliferation of a range of 
breast cancer cell lines, including those of luminal, HER2 and basal phenotypes. 
This both supports the results of Chrestensen et al
73, and extends the findings of 
sensitivity to inhibition of the MNK proteins in breast cancer cells to include 
additional phenotypes. Within the relative limitations of the number of cell lines 
investigated it appears that the presence of the target of CGP57380, 
phosphorylated eIF4E, predicts for sensitivity to MNK inhibition, rather than an 
individual phenotype per se. This also supports the assertion that the growth 
inhibitory effects of CGP57380 are specific to its inhibition of the MNK kinases
60, 
despite the concerns that additional kinases may be targeted by this reagent
124. 
The effect of proliferation is modest when using the MTS proliferation assay, which 
also appears to be misleading in certain cell lines, showing an apparent 
proliferative effect in ZR75.1 cells. This may be related to the use of an assay 
which measures metabolic activity as a surrogate for proliferation, which may be 
inappropriate in the context of inhibition of pathways which regulate critical cellular 
functions. 
A more marked effect was seen using a colony forming assay. This may be due to 
the increased cellular stress involved in re-plating the cells at low density through 
anoikis. It is recognised that lack of cell-matrix interaction has the ability to induce 
apoptosis in a specific manner through the process termed anoikis
158. Many 
intracellular signaling pathways are involved in the maintenance of cell survival via 
interactions with the extra-cellular matrix. These include both the MAPK
159 and 
PI3K/AKT
160 signaling pathways both of which interact through eIF4E. It may be 
therefore that intact signaling through one or both of these pathways is required to 
maintain cell integrity during periods of cellular stress due to lack of either cell-cell 
interaction or contact with extra-cellular matrix, conditions which may be mimicked 
by plating at extreme low density. Thus interruption of normal eIF4E function 
through inhibition of the MNK kinases may result in increased sensitivity to anoikis. 
This may manifest as a more marked effect on proliferation when using an assay 
such as the colony forming assay investigated in the experiments described above. 
The combination of CGP57380 with a cytotoxic chemotherapy drug shows a 
protective effect, with less effect on growth inhibition from the combination of   101 
etoposide and CGP57380 than seen with etoposide alone. This result would be 
consistent with CGP57380 having a cytostatic rather than a cytotoxic effect. If 
CGP57380 were to cause cell cycle arrest, then this may protect the cells from the 
effects of etoposide, a topoisomerase II inhibitor, which increases in cytotoxicity as 
cells progress through S and G2/M phases of the cell cycle
161. 
These findings are consistent with both live cell imaging experiments and cell cycle 
analysis which show a dominant effect on mitotic events and cell cycle arrest, 
rather than an increase in apoptosis. 
Immunoblotting confirmed inhibition of eIF4E phosphorylation at the dose of 
CGP57380 used. The kinetics of inhibition of eIF4E phosphorylation varied 
between cell lines with BT474 cells showing inhibition of phosphorylation within 15 
min, whereas MDA-MB-231 cells showed a gradual inhibition over the 72 h time 
period investigated. Several mechanisms may explain this difference, for example 
variation in intracellular handling of CGP57380, either through degradation, or 
export. The recent identification of the phosphatase for eIF4E, protein phosphatase 
2A
76, may provide an alternative explanation for the difference with differential 
expression of this phosphatase between cell lines representing another possible 
explanation for the varying kinetics of dephosphorylation. These experiments 
additionally confirmed inhibition of cyclin D1 protein, a key regulator of the cell 
cycle. Other groups have shown eIF4E phosphorylation to be critical in cyclin D1 
regulation through promoting mRNA nuclear export
12,13. In these experiments 
inhibition of eIF4E phosphorylation has been linked to both a reduction in cyclin D1 
protein, and subsequent G1 cell cycle arrest. 
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5.  MNK kinase inhibition in renal cancer cell lines 
5.1. Introduction 
Renal cancer is an attractive target in which to investigate sensitivity to inhibition of 
the MNK proteins. The majority of clear cell renal cancers harbour mutations, 
deletions or hypermethylation of the VHL gene, causing a constitutive up-regulation 
of HIF!
137,138. This is already a therapeutic target in clinical use via inhibition of 
mTOR with temsirolimus
17 and everolimus
18, however inhibition of mTOR can lead 
to increased eIF4E phosphorylation in cell culture model systems
20. Of note, the 
rapalog mTOR inhibitors such as those described above are allosteric inhibitors of 
mTOR function and not ATP competitive inhibitors of mTOR kinase. As such they 
have specific activity against mTORC1 (Rictor) with no activity against mTORC2. 
S6kinase, a target of activated mTOR has a negative feedback role in inhibiting 
insulin receptor substrate 1 activity, however when inhibited with agents such as 
the rapalogs this feedback is lost. As a result increased signalling through 
mTORC2 can result in increased AKT activity, and may explain the relatively 
modest activity of the rapalogs in advanced renal cancer. mTOR kinase inhibitors 
currently in pre-clinical development have a dual effect on both mTORC1 and 
mTORC2 and thus may have more promising activity in the clinical setting. 
Stabilisation of disease rather than measurable reductions in disease burden are 
usually seen with currently available mTOR inhibitors, and the impact on survival is 
modest. Temsirolimus has shown an increase in survival from 7.3 to 10 .9 months 
when compared with interferon alpha in patients with poor risk advanced renal 
cancer
17. 
HIF! mRNA has been identified as being regulated by eIF4E phosphorylation
74. In 
addition a screen for novel agents showing inhibition of HIF1! revealed a 
quassinoid compound able to inhibit HIF1! protein via translation control though 
eIF4E phosphorylation
162. Thus inhibition of the MNKs may also inhibit proliferation 
in kidney cancer cell lines. 
Clear cell renal cell cancers exhibit high levels of VEGF
163, a gene regulated by 
HIF activity. Inhibition of VEGF is a current therapeutic strategy with the 
monoclonal antibody bevacizumab
154, which binds circulating VEGF, preventing 
binding to the VEGF receptor. Sunitinib, a multi targeted kinase inhibitor has   103 
activity against the kinase domains of both VEGF and PDGF receptors and as 
such is another proven therapeutic strategy targeting VEGF signaling
164. Sorafenib, 
a multi-targeted agent with activity against VEGF also has activity against RAF and 
is active in advanced renal cancer in patients who have failed first line interferon 
therapy
165. Additional agents are in development including pazopanib, a multi 
targeted agent active against VEGF, PDGF and c-KIT
166, and axitinib which has an 
increased potency specifically for the VEFG receptors 1, 2 and 3
167. 
Following activation of VEGF receptors, signaling occurs through both the MAPK 
and PI3K pathways. As such targeting kinases such as the MNKs which act at a 
node of convergence of these cascades is an attractive therapeutic strategy. 
 
Growth inhibition of CGP57380 was investigated in a panel of kidney cancer cell 
lines representing VHL wild-type and VHL mutant tumours. 
 
Cell line  ACHN  CAKI 2  786-O  769-P  A-498 
VHL status  WT  WT  Null  Null  Null 
Mutation      1 bp deletion  Promoter 
hypermethylation 
Point mutation 
4 bp deletion 
Effect      Stop codon  Inhibition of transcription 
Proline-Serine codon 2 
Stop codon 
 
Table 5:1 Characteristics of renal cancer cell lines 
VHL Von Hippel Lindau, WT Wild type, bp base pair
168 
 
5.2.  Effects of CGP57380 on eIF4E phosphorylation 
 
To confirm the activity of CGP57380 on inhibiting eIF4E phosphorylation, ACHN 
and A498 cell lines were chosen as examples of VHL wild-type and null cancers 
respectively. Immunoblotting was used to investigate the effects of CGP57380 on 
eIF4E phosphorylation, and known downstream targets. ACHN cells showed a 
rapid reduction in eIF4E phosphorylation after 1 hour of treatment with CGP57380 
at 20 µM which was sustained for 8 hours, with no change in eIF4E 
phosphorylation in control cells assessed untreated at baseline, and with DMSO 
vehicle control at 4 and 8 h. A reduction in both cyclin D1 and Mcl-1 was seen after   104 
4 h of treatment. This was sustained for both proteins to 8 h by which time there 
was almost complete loss of Cyclin D1 protein (fig 5:1). 
A498 cells were less sensitive to inhibition of eIF4E phosphorylation. eIF4E 
phosphorylation was inhibited after 1 h, and remained undetectable for 8 h. A 
reduction in Cyclin D1 was seen by 3 h, but was less pronounced than that seen in 
ACHN cells. An apparent increase in cyclin D1 protein is seen in the three control 
samples and as such when each control time point is compared with the treated 
sample at the same time point, a reduction in cyclin D1 is indeed noted. A more 
marked reduction in Mcl-1 was seen, first apparent by 3 h and then sustained until 
8h. (fig 5:2).  105 
 
 
 
Figure 5:1 Phosphorylated eIF4E and downstream 
targets 
ACHN cells were treated with CGP57380 at 20 µM or 0.5% 
DMSO vehicle control for times as indicated. Time 0 
represents untreated control. Cells were lysed with urea lysis 
buffer and proteins quantified. Equal amounts of protein were 
separated by PAGE. Immunoblotting was used to identify 
individual proteins as indicated. 
 
Figure 5:2 Phosphorylated eIF4E and downstream 
targets 
A498 cells were treated with CGP57380 at 20 µM or 0.5% 
DMSO vehicle control for times as indicated. Time 0 
represents untreated control. Cells were lysed with urea lysis 
buffer and proteins quantified. Equal amounts of protein were 
separated by PAGE. Immunoblotting was used to identify 
individual proteins as indicated.    106 
5.3. Effects of CGP57380 on proliferation 
 
Having demonstrated an effect on the cell cycle regulatory protein cyclin D1, and 
the anti-apoptotic protein MCl-1, the effect of MNK inhibition with CGP57380 on 
proliferation was assessed. As with the breast cancer cell lines, increasing 
numbers of cells were plated in 96 well plates and treated with CGP57380 at a 
variety of concentrations. The MTS assay was used to assess proliferation at 72 h 
(fig 5:3). Pre-confluent cell numbers were chosen for statistical analysis (fig 5:4). 
Although an apparently greater response was seen in all renal cancer lines than 
the breast cancer lines, statistically significant differences were only seen in the 
two VHL null lines, 786-O and 769-P. 
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Figure 5:3 Proliferation in response to CGP57380 
ACHN cells were plated at the numbers shown in 120 µl medium. 24 h later 110 µl 
medium was removed from each well and DMSO or CGP57380 added to give a 
final concentration as shown with 0.5% v/v DMSO vehicle control. 100 µl medium 
was returned to the well, and proliferation assessed 72 h later by the MTS assay. 
Results represent the mean of three separate experiments performed in triplicate. 
Highlighted results are those used for subsequent statistical analysis.   108 
 
Figure 5:4 Proliferation in response to CGP57380 
Cells were plated to 96 well plates in 120 µl medium. 24 h later 110µl medium was 
removed and CGP57380 added to give a final concentration as shown in 0.5% v/v 
DMSO vehicle. Proliferation was assessed using the MTS assay 72 h later. Results 
represent the mean of 3 experiments at plating cell numbers immediately below 
peaking of the MTS/cell number response curve. *=p<0.05. Statistical analysis was 
by ANOVA with Tukey post test.   109 
Due to uncertainty about the results obtained with the MTS assay in the context of 
CGP57380 an alternative proliferation assay was investigated. The CyQuant Direct 
assay uses a cell permeable nucleic acid stain to identify viable cells. A second 
quenching dye which is only permeable in dead or dying cells which have lost 
membrane integrity is added to exclude dead cells. 
Using this assay the effects of proliferation on A498 cells was investigated in 
response to increasing concentrations of CGP57380. Maximal inhibition of 
proliferation occurred with CGP57380 20 µM with a small amount of inhibition at 10 
µM but no effect on proliferation with 5 µM (fig 5:5). 
Although all renal cell lines investigated with the MTS assay showed an anti-
proliferative response following treatment with CGP57380, once again a colony 
forming assay was used as a more sensitive measure of proliferation. All of the cell 
lines investigated, both VHL wildtype (CAKI2 and ACHN) and VHL null (A498, 769-
P and 786-0) showed a marked anti-proliferative response to CGP57380 with 
either a reduction in, or complete absence of, colony formation in the CGP57380 
treated cells (fig 5:6). 
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Figure 5:5 Proliferation in response to CGP57380. A498 cell line 
A498 cells were plated at 1000 cells per well in 120 µl medium in 96 well plates. 24 
h later 110 µl medium was removed from each well and pooled for triplicate 
repeats. CGP57380 was added to the medium to give a final concentration as 
indicated with 0.5% v/v DMSO. 100 µl was returned to each well. At 72 h 
proliferation was analysed using the CyQuant assay. Results represent triplicate 
repeats in a single experiment. Statistical analysis by ANOVA with Tukey post test. 
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Figure 5:6 Colony assay in response to CGP57380 
0.5 X 10
6 cells were plated in 3 ml complete medium. At 24 h cell lines as indicated were treated with 0.5% DMSO vehicle control 
or CGP57380 20 µM for 24 h. Cells were then trypsinised, counted and re-plated at 1000 cells/well in 6 well plates, in medium 
containing CGP57380 20µM or 0.5% DMSO as previously. At 9-12 days, according to growth kinetics between lines, colonies 
were fixed in methanol and stained with Giemsa. Pictures are representative of triplicate wells.   112 
5.4. Mechanisms of inhibition of proliferation by CGP57380 
 
As both the short term proliferation assays (MTS and CyQuant) and the colony 
assay may represent effects of either cell cycle arrest, or apoptosis, cell cycle 
analysis using flow cytometry was used to assess the predominant mechanism of 
growth inhibition. Both ACHN and A498 cell lines were investigated. Cells were 
plated and subsequently treated for 24 h with either CGP57380 at 20 µM, or 
DMSO control. Cells were then assessed for cell cycle distribution by harvesting, 
fixing in ethanol and staining with propidium iodide. DNA content was assessed by 
flow cytometry. In both cases cells accumulated in G1 with no significant change in 
the sub-G1 fraction, representing fragmented, apoptotic cells (fig 5:7 and fig 5:8). 
The accumulation in G1 is consistent with the results of immunoblotting in these 
cell lines, showing a reduction in the cell cycle regulatory protein cyclin D1. Both 
ACHN and A498 cells showed a reduction in Mcl-1 protein on immunoblotting in 
response to CGP57380, however this was not associated with an accumulation of 
cells in the sub-G1 fraction on cell cycle analysis. 
   113 
 
 
 
Figure 5:7 Cell cycle analysis following treatment with CGP57380 
ACHN cells were treated with CGP57380 20 µM, or DMSO vehicle control for 24 h. 
Cells were trypsinised with all washes retained and fixed in cold ethanol. Cells 
were resuspended in PBS, stained with propidium iodide and analysed by flow 
cytometry. Upper panel shows representative flow cytometry plots from single 
experiment. Results are mean of triplicate repeat experiments. Statistical analysis 
by Student's t test.   
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Figure 5:8 Cell cycle analysis following treatment with CGP57380 
A498 cells were treated with CGP57380 20 µM, or DMSO vehicle control for 24 h. 
Cells were trypsinised with all washes retained and fixed in cold ethanol. Cells 
were resuspended in PBS, stained with propidium iodide and analysed by flow 
cytometry. Statistical analysis by t-test. No comparisons reached statistical 
significance.   115 
Although no accumulation in the sub G1 fraction was seen during cell cycle 
analysis, a more specific assay for the investigation of apoptosis was used. Cells 
were treated with either CGP57380 or DMSO vehicle control and then co-stained 
with FITC conjugated Annexin-V and propidium iodide (PI). During early apoptosis 
phosphotidylserine translocates from the inner to the outer cell membrane. 
Annexin-V has a high affinity for phosphotidylserine and therefore stains cells in 
early apoptosis. Cells in later apoptosis, and those undergoing necrosis, lose 
membrane integrity and become permeable to the DNA binding dye propidium 
iodide. Thus when stained with both compounds, live cells stain with neither 
annexin-V or propidium iodide, early apoptotic cells stain with Annexin V alone, 
and cells in late apoptosis or undergoing necrosis stain with both Annexin-V and 
PI. 
Both A498 and ACHN cells were treated with either CGP57380 at 20 µM or DMSO 
vehicle control for 8 h and 24 h. Staurospaurine was used as a positive control. In 
both cell lines no increase in either early or late apoptosis was seen at either time 
point, confirming the predominant mechanism of inhibition of proliferation as cell 
cycle arrest (fig 5.9).  116 
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Figure 5:9 Effects of CGP57380 on induction of apoptosis 
A498 and ACHN renal cancer cells were treated with CGP57380 20 µM, 0.5% DMSO vehicle control or staurosporine 20nM. 
Following harvesting by trypsinisation and dual staining with Annexin V and propidium iodide, cells were analysed by flow 
cytometry at time points as indicated. A) example FACS plots following 8 h treatment. B) percentage of cells alive (FL1/FL2 
negative), early apoptosis (FL2 positive only) and late apoptosis (FL1/FL2 positive). Bars represent mean and standard error of 
triplicate samples.
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5.5. CGP57380 in combination with mTOR inhibition 
Previous work has shown an increase in eIF4E phosphorylation in lung cancer 
cells following inhibition of mTOR with rapamycin
20. mTOR inhibition is now an 
established therapeutic strategy in renal cancer with the rapalogue mTOR 
inhibitors temsirolimus
17 and everolimus
18. It is possible that the increase in eIF4E 
phosphorylation induced by mTOR inhibition could attenuate the anti-proliferative 
effects of mTOR inhibition in renal cancer cells, and as such the combination of 
mTOR inhibition with inhibition of the MNKs may induce enhanced antiproliferative 
effects in renal cancer cells. 
A498 and CAKI 2 renal cancer cells were investigated following treatment with the 
mTOR inhibitor rapamycin, or CGP57380 or both compounds in combination. 
Western blot analysis was used to investigate the effect of each compound on 
eIF4E phosphorylation, and 4E-BP phosphorylation (fig 5:10). In A498 cells there 
was no increase in eIF4E phosphorylation seen in response to treatment with 
rapamycin, however eIF4E phosphorylation was inhibited by both CGP57380 alone 
and in combination with rapamycin. Loss of 4E-BP phosphorylation was seen in 
response to treatment with rapamycin both alone and in combination with 
CGP57380 as indicated by loss of the higher molecular weight bands, suggesting 
that rapamycin was inhibiting mTOR at the concentration used. In CAKI 2 cells 
there was an increase in eIF4E phosphorylation seen following treatment of cells 
with rapamycin, however this was inhibited by the addition of CGP57380. Once 
again loss of 4E-BP phosphorylation was seen in response to treatment with 
rapamycin, both alone and in combination with CGP57380. 
Subsequently the antiproliferative effects of treatment with rapamycin and 
CGP57380 were investigated in these cell lines (fig 5:11). Both lines showed an 
inhibition of proliferation in response to CGP57380 as previously documented. 
A498 cells were sensitive to treatment with rapamycin with a similar anti-
proliferative effect to that seen with CGP57380. When cells were treated with both 
compounds in combination a modestly enhanced effect was seen on proliferation 
compared to either compound used alone. 
CAKI 2 cells showed no effect on proliferation when treated with rapamycin alone, 
however when treated with both rapamycin and CGP57380 an anti-proliferative   118 
effect at least as substantial as that seen with CGP57380 alone was seen with the 
suggestion of an enhanced effect.  119 
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Figure 5:10 A498 and CAKI 2 cells treated with rapamycin and CGP57380 
A498 (A) and CAKI 2 (B) cells were treated with 0.5% DMSO vehicle control, rapamycin, CGP57380, or both in combination for 
24 h at concentrations as indicated. Cells were harvested and proteins extracted by urea lysis. Equal amounts of protein were 
separated by PAGE and individual proteins identified by western blotting. 4E-BP was probed with a non-phospho antibody. The 
upper two bands represent higher molecular weight phosphorylated protein and the lower band un-phosphorylated 4E-BP 
(Experiment performed by GB)   120 
 
Figure 5:11 Proliferation following treatment with rapamycin and CGP57380 
A498 (A) and CAKI 2 (B) cells were treated with 0.5% DMSO vehicle control, rapamycin, CGP57380 or the combination at 
concentrations as indicated. Proliferation was measured at 72 h using the CyQuant assay. Results are mean and standard error 
of triplicate wells normalised to DMSO control. (Experiment performed by GB)  121 
 
5.6. Specificity of CGP57380 
MNK inhibition with siRNA 
Bain et al have investigated the specificity of a panel of protein kinase inhibitors, 
including CGP57380, and have raised concerns about the specificity of the 
compound for the MNK proteins
124. With this in mind alternative strategies of 
inhibiting the MNK proteins, and thus eIF4E phosphorylation have been sought in 
order to demonstrate that the specificity of the effects of CGP57380 are through 
inhibition of eIF4E phosphorylation. 
One strategy to achieve this is the use of RNA interference with siRNA duplexes. 
By inhibiting the MNK proteins at the RNA level and repeating the assays 
described above it may be possible to confirm that the growth inhibitory effects of 
CGP57380 are indeed through inhibition of eIF4E phosphorylation by the MNKs. 
Two siRNA duplexes were obtained for each of MNK1 and MNK2. ACHN cells 
were transfected with a final concentration of siRNA of 50nM. Initially a time course 
was performed to confirm the effects of the siRNA both on their target molecules 
and eIF4E phosphorylation. Using a combination of a single MNK1 and single 
MNK2 duplex, partial inhibition of MNK1 was seen by 24 h which was complete at 
48 h and persisted to 120 h (fig 5.12). A MNK2 antibody was obtained from Santa 
Cruz biotechnology, however despite attempts to optimise the antibody, multiple 
bands were seen throughout the membrane. A band at the predicted size of 50kDa 
was however identified which showed a reduced intensity at 24 h and 48 h, but 
less than that seen for MNK1 (fig 5:12). eIF4E phosphorylation was reduced at 48 
h, but never reduced to the extent of that seen through MNK kinase inhibition with 
CGP57380. 
In order to clarify the specificity of the MNK2 antibody, HEK293 human embryonal 
kidney cells were transfected with a MNK2 vector (pCMVMNK2-HA) or control 
vector (pCMV) at two vector concentrations, and MNK2 protein measured at 48 h 
by western blotting. Two clear bands were identified close to the expected size for 
MNK2, with the band intensity proportional to the concentration of vector 
transfected. It would be anticipated that the band seen would be slightly larger than 
the size of endogenous MNK2 (50 kDa) due to the HA tag.  The upper of the two   122 
bands correlates with that seen in the cells treated with MNK1 and MNK2 directed 
siRNA and would suggest that this does indeed represent MNK2. 
In order to generate maximal inhibition of the MNK proteins, all four siRNA 
duplexes were combined in a single experiment to give a final concentration of 
siRNA of 100 nM. ACHN cells were transfected and samples were assessed at 72 
h for inhibition of MNK1 with no band detected in the MNK1/2 transfected cells. No 
eIF4E phosphorylation was seen in the MNK1/2 transfected cells and a reduction 
in cyclin D1 protein was also identified, although this was not as marked as that 
seen with CGP57380 (fig 5:14). 
ACHN cells transfected with this combination of four siRNA duplexes were 
assayed for both proliferation, and cell cycle distribution. Using the CyQuant assay, 
a small but non-significant effect on proliferation was seen following siRNA 
transfection (fig 5.15).  
Using the colony assay, which was a more sensitive marker of proliferation in both 
the renal and breast cancer cell lines following treatment with GGP57380, no 
change in colony forming ability was seen following transfection with siRNA (fig 
5:16). Equally the accumulation of cells in G1 of the cell cycle seen with 
CGP57380 was not seen following siRNA transfection (fig 5:17). 
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Figure 5:12 ACHN cells transfected with MNK siRNA 
0.25 X 10
6 ACHN cells were plated in 6 well plates. 24 h later 
cells were transfected with a pair of MNK1 and MNK2 siRNA 
duplexes to a final concentration of 50 nM in 2 combinations 
(i and ii). Cells were harvested every 24 h, pelleted and snap 
frozen. Proteins were extracted by urea lysis and quantified. 
Equal amounts of protein were separated by PAGE and 
individual proteins identified with immunoblotting. Lanes 
represent control siRNA (C), MNK1 and MNK2 siRNA 
combination 1 (M(i)) and MNK1 and MNK2 siRNA 
combination 2 (M(ii)). Arrow indicates expected size for 
MNK2. 
 
 
 
Figure 5:13 HEK293 cells transfected with MNK2 vector 
HEK293 cells were transfected with pcmvMNK2-HA or pcmv 
parent vector using Lipofectamine 2000 transfection reagent 
(Invitrogen) at vector quantities as shown. Cells were 
harvested at 48 h and proteins extracted with urea lysis 
buffer and quantified. Equal quantities of protein were 
separated by PAGE and transferred to a nitrocellulose 
membrane. The membrane was probed for MNK2 (expected 
size 50kDa).  124 
 
 
 
 
 
 
 
Figure 5:14 ACHN cell line transfected wtih MNK siRNA 
siRNA transfection of ACHN cell line at final concentration 100 nM. 
0.5 X 10
6 ACHN cells were plated to 60mm dishes. At 24 h cells were transfected 
with 2 MNK1 and 2 MNK2 siRNA duplexes to a final concentration of 100 nM. 72 h 
later cells were harvested and proteins extracted by urea lysis. Equal amounts of 
protein were separated by PAGE and individual proteins were identified with 
immunoblotting.   125 
  
 
Figure 5:15 Proliferation in ACHN cells following MNK siRNA transfection 
Cells were transfected in 6 well plates with 2 siRNA duplexes targeting each of 
MNK1and MNK2 to a final siRNA concentration of 100 nM. 48 h post transfection 
cells were trypsinised, counted and replated in 120 µl fresh medium at 1000 cells 
per well in 96 well plates. 72 h later proliferation was assessed using the Cyquant 
assay. Results represent mean and standard error of triplicate experiments, each 
performed with triplicate wells. 
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Figure 5:16 Colony assay following MNK1/MNK2 siRNA 
0.5 X 10
6 ACHN cells were plated to 60mm dishes. At 24 h cells were transfected 
with 2 MNK1 and 2 MNK2 siRNA duplexes to a final concentration of 100 nM. At 
48 h post transfection cells were trypsinised, counted and re-plated at 1000 
cells/well in 6 well plates. At 10 days colonies were fixed in methanol and stained 
with Giemsa. Pictures are representative of triplicate wells.   127 
 
Figure 5:17 Cell cycle analysis following MNK1/MNK2 siRNA 
ACHN cells were transfected with 2 duplexes of each of MNK1 and MNK2 siRNA, 
or control siRNA at a final concentration of 100 nM. At 72 h cells were trypsinised 
with all washes retained and fixed in cold ethanol. Cells were resuspended in PBS, 
stained with propidium iodide and analysed by flow cytometry. 
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Combination of CGP57380 with MNK1 and MNK2 directed siRNA 
CGP57380 alone has shown significant effects on the proliferation of kidney cancer 
cell lines, however siRNA targeted at the MNK proteins has failed to replicate these 
results. A series of experiments was therefore performed in which the siRNA 
duplexes were combined with CGP57380, the hypothesis being that removal of the 
target for CGP57380 might abrogate its effect on proliferation. Cells were 
transfected with either control siRNA or a combination of four siRNA duplexes 
targeted at MNK1 and MNK2 at a final concentration of 100 nM. Following this cells 
were treated with increasing concentrations of CGP57380, and cell pellets 
harvested at 24 h for protein extraction. Western blotting was used to assess levels 
of eIF4E phosphorylation in the treated cells. Lower levels of eIF4E 
phosphorylation were seen in the MNK siRNA treated cells such that no eIF4E 
phosphorylation could be detected in cells treated with CGP57380 at 5 µM. This 
was compared with control transfected cells where low levels of eIF4E 
phosphorylation were still detected following treatment with CGP57380 at 10 µM. 
(fig 5:18). 
     129 
 
Figure 5:18 eIF4E phosphorylation in response to CGP57380 in MNK directed 
siRNA transfected cells 
Cells were transfected in 6 well plates with a combination of 2 MNK1 directed, and 
2 MNK2 directed siRNA duplexes to a final concentration of 100 nM. 48 h post 
transfection cells were harvested and replated to 6 well plates. 24 h later cells were 
treated with concentrations of CGP57380 or DMSO vehicle control as shown. At 24 
h cells were harvested and proteins extracted by urea lysis. Lysates were 
quantified and proteins separated by PAGE. Individual proteins were identified by 
immunoblotting.   130 
Similar experiments were performed to assess the effect on proliferation of adding 
CGP57380 to control or MNK1 and MNK2 directed siRNA transfected cells. 
Following transfection with either control, or a combination of 2 MNK1 directed and 
2 MNK2 directed siRNA duplexes, cells were re-plated and treated with 
CGP587380 at increasing concentrations. No differential effect on proliferation was 
seen between either transfection, either without the addition of CGP57380, or at 
any of the treated concentrations (fig 5:19) 
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Figure 5:19 Proliferation in ACHN cells transfected with MNK directed siRNA 
and treated with CGP57380 
Cells were transfected in 60mm dishes with either control siRNA at 100 nM, or a 
combination of 2 MNK1 and 2 MNK2 siRNA duplexes at a final concentration of 
100 nM. After 48 h cells were trypsinised, counted and re-plated to 96 well plates 
at 1000 cells/well. 24 h later cells were treated with CGP57380 at concentrations 
as shown, or DMSO vehicle control. Proliferation was assessed at 72 h using the 
CyQuant assay. Results indicate mean and standard error of triplicate wells. 
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Stable transfection with mutated eIF4E 
An alternative strategy to demonstrate the specificity of the CGP57380 compound 
was to generate stable transfectants of one of the renal cancer cell lines in which 
the phosphorylation site of eIF4E, serine 209, was mutated to an aspartic acid. The 
negatively charged aspartate is able to act as a phosphomimetic; in a murine 
lymphoma model transfection with either wild-type or S209D mutated eIF4E 
resulted in formation of tumours with a similar latency, whereas mutation of serine 
209 to a phosphoresistant alanine resulted in impaired tumour formation
69. Stable 
transfection of cancer cells with the eIF4E S209D mutant should make them at 
least partially resistant to the effects on proliferation of CGP57380. 
A498 cells were stably transfected either with parent vector (EYFP-C1) or EYFP-
eIF4ES209D and clones selected with G418. Initial screening was performed using 
fluorescence microscopy to identify EYFP expressing clones. Subsequently cell 
pellets were lysed for each clone, and eIF4E expression analysed with western 
blotting (Fig 5:20).  
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Figure 5:20 Immunoblotting of A498 eIF4E stable clones 
A498 cells were stably transfected with EYFP-C1, or an EYFP-eIF4E construct in 
which serine 209 had been mutated to aspartate (SD). Clones were selected with 
G418 and individual colonies picked from EYFP-eIF4E-SD transfected cells. For 
EYFP transfected cells colonies were pooled. Parental cells (A498), pooled 
transfectants with EYFP, and clones SD2.3, 2.5 and 1.2 were harvested and 
proteins extracted by urea lysis and quantified. Equal protein was loaded to 
polyacrylamide gels and separated by PAGE. Individual proteins were identified by 
immunoblotting. 
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Both endogenous eIF4E at the expected size of 25 kDa, and the EYFP-eIF4E 
construct at a predicted size of approximately 50 kDa were detected. There was 
variation in both expression of the construct and endogenous eIF4E between the 
clones. Two clones eIF4ESD2.5 and eIF4ESD1.2 had lower levels of cyclin D 
protein than either another clone, eIf4ESD2.3, or untransfected parental controls. 
Pooled transfectants with both the EYFP parent vector and EYFP-eIF4ES209D 
vector were also made. Of interest when the eIF4ESD pool was assayed for eIF4E 
expression, no second band at the expected size for the construct was seen. When 
the expression of EYFP was measured in these cells, the size of the band detected 
with an EYFP antibody was slightly smaller than that seen with the parent EYFP 
vector. This would suggest not only that the vector had been cut when incorporated 
stably into the transfected cells, but also a negative selection pressure against the 
full length eIF4ESD vector, leading to absence of expression in the pooled 
population (Fig 5:21). 
 
eIF4E is predominantly cytoplasmic in its localisation
12. To ensure that the EYFP-
eIF4E construct was distributed in the expected fashion within the cell, stable 
tranfectants of EYFP-eIF4ES209D, and EYFP parent were fixed and EYFP 
subcellular distribution assessed with fluorescence microscopy. Cells expressing 
the EYFP parent vector showed equal distribution of fluorescence through both 
nuclear and cytoplasmic compartments, however cells expressing the mutated 
eIF4E construct showed clear evidence of nuclear exclusion of the fluorescence 
signal (fig 5:22).  135 
 
 
 
 
 
 
Figure 5:21 Immunoblotting of pooled stable transfectants from A498 cells 
A498 cells were transfected with parent EYFP-C1 vector or eIF4E-EYFP with 
mutation of serine 209 to aspartate (SD). Colonies were selected with G418 and 
pooled. Cells were harvested and proteins extracted by urea lysis and quantified. 
Equal protein was loaded to polyacrylamide gels and separated by PAGE. Individual 
proteins were identified by immunoblotting.  136 
 
 
Figure 5:22 Cellular distribution of eIF4ESD protein in stable transfected cells 
Stable transfectants of A498 cells were fixed with methanol and counterstained with the nuclear stain DAPI. 2 fields of cells at 100 
X magnification were visualised for each tranfectant using fluorescence microscopy, and imaged using a greyscale camera. 
Green and blue colour was superimposed and merged images created.  137 
The functionality of the construct was additionally investigated using m
7GTP pull 
down. Functional eIF4E is able to bind the cap analogue m
7GTP, and thus m
7GTP 
beads were used to extract eIF4E from clarified protein lysates from parent cells, 
and cells expressing the EYFP-eIF4ES209D construct. Following pulldown the 
lysates were separated by PAGE and membranes probed with antibody directed at 
eIF4E. Endogenous eIF4E could be detected in both parent and transfected cells, 
however in transfected cells the construct at the predicted size of 50 kDa could 
also be detected confirming the ability to bind the m
7GTP cap. The lack of actin in 
the pulled down lysates confirms the specificity of the pulldown (fig 5:23). 
 
To investigate the impact of variable eIF4E expression on the growth 
characteristics of the clones, cells were plated to 96 well plates in triplicate, and 
growth assessed at 24 h, 48 h, and 96 h using the CyQuant assay. Variability in 
growth characteristics was seen such that the eIF4ESD2.3 clone in which higher 
baseline levels of cyclin D1 was seen, grew more quickly than either the 
untransfected parent cells, or the eIF4ESD2.5 and eIF4ESD1.2 clones. In addition 
these latter two clones grew more slowly than the untransfected parent cells, in 
keeping with the lower baseline levels of cyclin D1 protein in these clones (fig 
5:24). 
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Figure 5:23 m
7GTP pulldown of eIF4ESD mutant clones 
A498 parental cells, A498_EYFP pooled clones and A498SD2.2 clone cells were 
harvested, pelleted and snap frozen. Proteins were extracted with extraction buffer, 
clarified by centrifugation and quantified. Equal amounts of protein were mixed with 
m
7GTP-sepharose. Beads were extracted by centrifugation and washed. m
7GTP 
was used to elute the bound proteins, and the beads pelleted by centrifugation. 
Equal volumes of supernatant were separated by PAGE, and individual proteins 
identified with immunoblotting. Whole cell lysates were run as a comparison. 
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Figure 5:24 Proliferation in A498 stable transfectants 
A498 parental cells, pooled stable transfectants transfected with either EYFP alone 
(A498_EYFP pool) or EYFPeIF4ES209D (A498_SD pool), and stable clones 
transfected with EYFPeIF4ES209D (A498_SD2.3, A498_SD2.5, A498_SD1.2) 
were plated to 96 well plates at equal densities. Proliferation was assessed at 24, 
48 and 96 h using the CyQuant proliferation assay. Error bars represent standard 
error of the mean for triplicate wells. 
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The effect of CGP57380 on proliferation was investigated for each of the eIF4ESD 
clones using the CyQuant short term proliferation assay, the hypothesis being that 
stably transfected cells would be at least partially insensitive to CGP57380. 
Following 72 h treatment of the EYFP pooled population, a reduction in 
proliferation was seen with treatment at both 10 µM and 20 µM concentrations. In 
the two stable clones eIF4ESD1.2 and eIF4ESD2.5, although inhibition of 
proliferation was seen with CGP57380 at 20 µM, no inhibition was seen with 
CGP57380 at 10 µM. The third clone however, which differed both in growth 
characteristics and baseline levels of cyclin D1 protein, responded in the 
proliferation assay in a similar way to control cells at both CGP57380 10 µM and 
20 µM (fig 5:25).   141 
 
 
 
 
Figure 5:25 Proliferation in A498 stable transfectants exposed to CGP57380 
Stable transfectants were plated to 96 wells plates and 24 h later treated with CGP57380 at concentrations as indicated, or 0.5% 
DMSO vehicle control. Proliferation was assessed at 72 h using the CyQuant assay. Error bars represent standard error of the 
mean for three experiments each performed in triplicate wells. Statistical analysis was with ANOVA with Tukey's post test.   142 
The results of the above experiment using proliferation as an output to assess the 
effects of CGP57380 on the stable transfected clones would suggest that in clones 
SD1.2 and SD2.3 then some resistance to the effects of CGP57380 exists. Further 
experiments were performed in which cell cycle analysis was used as the endpoint, 
to see if this would correlate with the proliferation experiments, providing additional 
weight to the conclusion that mutating serine 209 to aspartate does indeed provide 
some resistance to the effects of CGP57380. Thus stable transfectants were 
treated with CGP57380 at 10 and 20 µM or 0.5% DMSO vehicle control. 24 h later 
cell cycle distribution was assessed using flow cytometry. Both A498 and 
A498_EYFP showed an accumulation in G1 following treatment with both 10 and 
20 µM CGP57380. In a similar pattern to the proliferation experiment, A498SD2.5 
cells remained sensitive to CGP57380 at both concentrations of CGP57380, 
however no effect on cell cycle distribution was seen with the A498SD1.2 and 
A498SD2.3 clones when exposed to either 10 µM or 20 µM CGP57380 (fig 5:26).  143 
 
Figure 5:26 Cell cycle analysis in A498 clones treated with CGP57380 
Parental A498 cells, control A498_EYFP pooled transfectants and A498 clones (A498SD1.2, A498SD2.3 and A498SD2.5) were 
plated to 6 well plates. At 24 h cells were treated with CGP57380 at concentrations as indicated or 0.5% DMSO vehicle control. 
At 24 h cells were harvested by trypsinisation, washed once in ice cold PBS, and fixed in ice cold ethanol. Cells were stained with 
propidium iodide staining solution and cell cycle analysis performed by flow cytometry.  144 
5.7. Discussion 
Investigation of the effects of CGP57380 on the proliferation of renal cell lines has 
shown inhibition of proliferation in all of the cell lines studied. This includes cell 
lines of both VHL null and VHL wildtype phenotype, with those of null phenotype 
including cell lines with somatic mutation of VHL, and those with promoter 
hypermethylation, representing the spectrum of clinical phenotypes of clear cell 
renal cell carcinoma
137,138. Inhibition was seen in a short-term assay, with similar 
results using both the MTS assay, and the CyQuant assay. Additionally a longer 
term assay of cell proliferation by colony formation, during which the cells undergo 
additional stress through low density plating, showed a marked anti-proliferative 
effect in response to CGP57380. This anti-proliferative effect is similar to that 
previously documented in other cell types including breast
73, lung
20 and prostate 
cancers
74, and similar to those seen in breast cancer cell lines in this work. 
Immunoblotting has confirmed inhibition of eIF4E phosphorylation and down 
regulation of known targets of eIF4E phosphorylation. Two proteins were 
specifically investigated which are regulated by phosphorylated eIF4E, cyclin D1 
through control of mRNA export, and Mcl-1 through translation control. The 
changes in cyclin D1 protein were more marked in the VHL null than the VHL 
wildtype cell line investigated, however Mcl-1 protein was reduced following 
treatment with CGP57380 in both cell types. 
With a reduction seen in both a cell cycle regulatory protein and an anti-apoptotic 
protein, it might be anticipated that either cell cycle arrest or apoptosis may be the 
underlying mechanism for the growth inhibitory properties of CGP57380. 
Subsequent investigation showed a G1 cell cycle arrest following treatment with 
CGP57380, with no induction of apoptosis, either as an accumulation in the sub G1 
cell fraction on cell cycle analysis, or through annexin V/PI staining. Investigation of 
the effects of MNK inhibition in prostate cancer cells have also shown a cell cycle 
inhibitory rather than a pro-apoptotic effect
74. It is possible that renal cancer cells 
are less dependent on Mcl-1 for survival than some other cell types where 
inhibition would be expected to induce apoptosis. Alternatively the time points 
examined may have been too early to see evidence of apoptosis. Previous studies 
of a Raf kinase inhibitor able to inhibit Mcl-1 through post translational control,   145 
showed an early reduction in Mcl-1 protein as assessed by immunoblotting, but no 
induction of apoptosis until 4-5 days exposure to the compound
169. 
Although several groups have used CGP57380 as a specific inhibitor of the MNK 
proteins and demonstrated anti-proliferative effects, there has been some criticism 
of the use of this agent on the basis of its ability to target other kinases when 
tested in an in vitro kinase assay
124. Although the reduction in known targets of 
regulation by the MNK proteins such as cyclin D1, and an associated anti-
proliferative effect mediated through cell cycle arrest, would support specificity of 
action of CGP57380, alternative strategies have been investigated to demonstrate 
the specificity of the effects seen. 
Using siRNA targeted at both the MNK1 and MNK2 genes, knockdown of both 
proteins has been shown, with associated reduction in phosphorylated eIF4E. In 
order to demonstrate a reduction in downstream targets of eIF4E phosphorylation, 
relatively high concentrations of siRNA were required with two siRNA duplexes 
targeted at each gene. The reduction in cyclin D1 protein was partial, and less 
marked than that seen when using the kinase inhibitor CGP57380. Using this 
technique the reduction in cyclin D1 protein achieved did not translate into a 
change in either proliferation or cell cycle distribution. It therefore remains possible 
that the effects of CGP57380 on proliferation are not specific to its activity through 
the MNK proteins. Equally it may be that an insufficient reduction either in eIF4E 
phosphorylation, or in cyclin D1 was seen to replicate the effects of the kinase 
inhibitor. Alternatively the prolonged dynamics of achieving a reduction in eIF4E 
phosphorylation with siRNA, may lead to the induction of compensatory pathways 
allowing the cell to continue to proliferate and prevent cell cycle arrest. 
An alternative strategy was pursued to demonstrate the specificity of the anti-
proliferative effects of CGP57380 to the MNK kinases. A phosphomimetic mutation 
of eIF4E can be created by substitution of serine 209 to a positively charged 
aspartic acid
69. It was hypothesised that cells with stable integration of mutant 
eIF4E would develop resistance to the effects of the CGP57380 kinase inhibitor. 
A498 cells with stable integration of a construct containing mutated eIF4E (serine 
209 to aspartic acid) and EYFP showed expected subcellular distribution of 
eIF4E
12 with nuclear exclusion not seen with EYFP transfected cells. The 
functionality of the construct was further demonstrated with m
7GTP pulldown of the 
EYFP-eIF4E fusion protein confirming the ability of the transfected eIF4E to bind   146 
the mRNA cap. Of the three mutant eIF4E expressing clones tested, two had 
similar proliferation patterns with similar levels of cyclin D1. Of interest a third clone 
had significantly higher levels of cyclin D1 and a much faster proliferation than the 
other two. An anti-proliferative response was still seen in the two clones with 
similar levels of cyclin D1 protein with 20 µM CGP57380. When cell cycle analysis 
was investigated, a G1 arrest following treatment with CGP57380 was seen in 
EYFP containing cells. No effect was seen at either 10 µM or 20 µM CGP57380 in 
the two similar eIF4E mutants, however the effect seen in untransfected A498 cells 
was not statistically significant. The third eIF4E mutant containing higher levels of 
cyclin D1 behaved in a similar fashion to the EYFP transfected cells in both 
proliferation and cell cycle assays with an effect seen at both concentrations of 
CGP57380. A lack of effect seen on inhibiting the effects of CGP57380 may have 
several explanations. The most likely may be that the effects of CGP57380 are 
through both inhibition of eIF4E phosphorylation, but also through other undefined 
pathways due to inhibition of additional kinases. Alternatively it may be that the 
proliferation of the clones containing mutated eIF4E is partially dependent on the 
transfected, mutated eIF4E, but that endogenous eIF4E also has an ongoing role. 
The endogenous eIF4E would continue to be sensitive to the effects of CGP57380, 
therefore resulting in a degree of inhibition of proliferation on treatment with the 
compound, but less so than that seen in parental cells due to the presence of the 
resistant mutated eIF4E. 
Overall these results show an anti-proliferative effect of CGP57380 in a panel of 
renal cancer cell lines of both VHL wild-type and null phenotype covering the 
clinical spectrum of clear cell renal cancer. This appeared to be a cytostatic rather 
than a cytotoxic effect with no induction of apoptosis at the time points investigated 
despite a reduction in Mcl-1 protein. The induction of cell cycle arrest is however 
correlative with the demonstrated reduction in cyclin D1 protein, a key regulator of 
the G1/S transition. Although MNK directed siRNA was able to show a reduction in 
eIF4E phosphorylation, and a modest effect on cyclin D1 protein, this did not 
translate into an effect on proliferation. The generation of A498 clones with stable 
integration of S209D mutated eIF4E had little effect on the anti-proliferative and 
cell cycle inhibitory effects of CGP57380, suggesting that CGP57380 is likely to 
have additional targets beyond the phosphorylation of eIF4E.   147 
6. MNK mediated control of transcription and translation 
6.1. Introduction 
The experimental data described so far has identified the anti-proliferative effect of 
CGP57380 in breast and renal cancer cell lines. This effect has been shown to be 
largely due to inhibitory effects on cell cycle progression, with an accumulation of 
cells in G1, and an associated reduction in cyclin D1 protein. The regulation of 
cyclin D1 protein in response to eIF4E phosphorylation has been previously 
described as mediated through the inhibition of cyclin D1 mRNA export with an 
associated reduction in translation but no effect on total cellular cyclin D1 mRNA
12. 
It is proposed that the phosphorylation of eIF4E also modulates the affinity of 
mRNA cap binding
59, and therefore polysome recruitment of regulated mRNAs. 
In order to further investigate the influences of eIF4E phosphorylation on the 
regulation of cyclin D1 RNA a series of experiments was proposed to assess the 
impact of inhibition of eIF4E phosphorylation using CGP57380 on RNA 
abundance. Current data would support no change in total cyclin D1 RNA 
abundance in response to inhibition of eIF4E phosphorylation, and rather an 
accumulation of RNA within the nuclear compartment. With this in mind 
experiments were performed both to investigate the levels of total cyclin D1 RNA in 
response to inhibition of the MNK proteins, but also to assess the distribution of 
RNA within subcellular fractions. 
 
6.2. Effects of MNK inhibition on RNA abundance 
Previous work has identified RNA export to be the mechanism of control of cyclin 
D1 protein through eIF4E phosphorylation
12. It may therefore be expected that 
there would be no change in total RNA in response to treatment with CGP57380. 
To confirm this to be the case, qRT-PCR was used to measure total cyclin D1 RNA 
normalised to GAPDH RNA following treatment with CGP57380 at 20 µM. 
Following treatment of ACHN cells with CGP57380, total RNA was measured at 
time points up to 24 h, with DMSO vehicle control samples at each time point. 
Unexpectedly a fall in total RNA was seen over the time course (fig 6:1). A 
progressive reduction in total cyclin D1 RNA was seen, with a 1.7 fold reduction 
compared with untreated control at 4 h, 2.5 fold by 6 h and 6.8 fold at 24 h.   148 
Although some reduction in cyclin D1 total RNA was seen in control cells at 24 h, 
possibly due to the lack of new growth factors for 48 h by this time point, a much 
greater reduction was seen in those cells treated with CGP57380, at both earlier 
time points and 24 h. This would suggest additional regulation of RNA beyond 
simply re-distribution within the cell. Possible explanations for the changes seen 
might include either a change in RNA synthesis through regulation of transcription, 
of altered degradation of RNA, perhaps related to the movement of RNA between 
cell compartments. 
Although no change in proliferation or cell cycle distribution was seen following 
siRNA transfection with MNK1 and MNK2 duplexes at 100 nM, a change in cyclin 
D1 protein was seen, albeit less so than in response to CGP57380. The specificity 
of the changes in total cyclin D1 RNA was therefore additionally investigated using 
siRNA to modulate eIF4E phosphorylation through knockdown of the MNK1 and 
MNK2 RNA transcripts. The effects of MNK1 and MNK2 siRNA on total cyclin D1 
RNA was investigated using qRT-PCR. Again a fall in total cyclin D1 RNA was 
seen, normalised to GAPDH, suggesting that this effect is indeed specific to the 
activity of the MNK proteins, and therefore likely to be related to phosphorylation of 
eIF4E (fig 6:2). 
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Figure 6:1 Cyclin D1 RNA following treatment with CGP57380 
ACHN cells were treated with CGP57380 or DMSO vehicle control for times as 
indicated. Cells were harvested by pelletting and snap frozen. RNA was extracted 
and cDNA synthsesised as described. Cyclin D1 cDNA was measured using qRT-
PCR and normalised to GAPDH. Time 0 = untreated control. Values are mean of 
triplicate repeat qRT-PCR reactions. Error bars represent standard error of the 
mean. 
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Figure 6:2 Cyclin D1 RNA following MNK1/MNK2 siRNA 
ACHN cells were transfected with with 2 duplexes of each of MNK1 and MNK2 
siRNA, or control siRNA at a final concentration of 100 nM. At 48 h cells were 
harvested by pelletting and snap frozen. RNA was extracted and cDNA 
synthsesised as described. Cyclin D1 cDNA was measured using qRT-PCR and 
normalised to GAPDH. Values are expressed as a proportion of untreated control 
and are mean of triplicate repeat qRT-PCR reactions. 
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Having established a reduction in total cellular cyclin D1 RNA following both 
inhibition of eIF4E phosphorylation with CGP57380, and using siRNA knockdown 
of the MNK proteins, experiments were performed to investigate the underlying 
mechanisms of this reduction. As outlined above, changes in total cellular RNA for 
a given transcript may be due to reduced production of new RNA through inhibition 
of transcription, or if transcription remains unchanged, then through enhanced 
degradation of an existing pool of RNA molecules. 
For inhibition of transcription to cause the reduction in cyclin D1 RNA seen, the half 
life of the RNA transcript would have to be such that on inhibiting transcription, the 
existing pool of RNA would be degraded at a rate fast enough to account for the 
changes in total RNA seen. As such an experiment was performed to assess the 
stability of cyclin D1 mRNA following treatment of cells with Actinomycin D. By 
forming DNA adducts, Actinomycin D prevents the activity of RNA polymerase, and 
thus inhibits transcription. Cells were treated with either 0.5% DMSO vehicle 
control, Actinomycin D or CGP57380 for 6 h, and cyclin D1 RNA assessed by qRT-
PCR. Whereas those cells treated with CGP57380 showed a reduction in cyclin D1 
RNA as previously, those cells in which transcription was inhibited by Actinomycin 
D showed no reduction in cyclin D1 RNA (fig 6:3). This would indicate that the 
cyclin D1 RNA transcript is stable for at least 6 h, and that therefore regulation of 
transcription alone is not responsible for the reduction in cyclin D1 RNA seen with 
CGP57380. 
This question was subsequently investigated by examining the effects of 
CGP57380 on cyclin D1 transcription using a reporter construct consisting of the 
cyclinD1 promoter within a luciferase reporter plasmid. It would be anticipated that 
should eIF4E phosphorylation be a regulator of cyclin D1 transcription, treatment of 
cells with CGP57380 would result in a reduction in cyclin D1 promoter activity, and 
thus a reduction in firefly luciferase activity. 
ACHN renal cancer cells were transfected with either an empty luciferase reporter 
(pGl3 basic) or the cyclin D1 promoter construct
155, in each case together with the 
Renilla luciferase plasmid pRLSV40 as a transfection control. 4 h post transfection 
the cells were treated with either CGP57380 at 20 µM, or DMSO vehicle control, 
and luciferase activity measured at 48 h post transfection. Both firefly and Renilla 
luciferase activity were measured using the dualglo system (Promega) and results   152 
expressed as firefly luciferase activity normalised to Renilla luciferase. In cells 
transfected with the empty firefly luciferase vector (pGl3) no luciferase activity was 
seen. In those cell transfected with the cyclin D1 promoter plasmid, firefly 
luciferase activity was seen, however subsequent treatment with CGP57380 
resulted in an increase in cyclin D1 promoter activity (fig 6:4). This would indicate 
that regulation of transcription is not the mechanism underlying the reduction in 
cyclin D1 RNA seen with inhibition of eIF4E phosphorylation.   153 
 
 
Figure 6:3 Cyclin D1 RNA expression following Actinomyin D 
ACHN cells were treated for 6 h with 0.5% DMSO vehicle control, Actinomycin D 
(5µg/ml), or CGP57380 20µM. Cells were harvested and RNA extracted. Cyclin D1 
RNA was measured by qRT-PCR and normalised to GAPDH. Results indicate 
mean and standard error of triplicate qRT-PCR reactions. (Experiment performed 
by AD)   
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Figure 6:4 The effects of eIF4E phosphorylation on cyclin D1 transcription 
ACHN renal cancer cells were transfected with the Renilla luciferase reporter 
vector under the control of the SV40 promoter (pRLSV40) together with the firefly 
luciferase vector pGl3 with no promoter (pGl3 basic) or the cyclin D1 promoter. 4h 
following transfection new medium was applied containing either 0.5% DMSO 
vehicle control or CGP57380 at 20 µM. Luciferase activity was measured 48 h post 
transfection using the DualGlo system. Results are expressed as firefly luciferase 
activity relative to Renilla luciferase activity in relative light units (RLU). Results 
represent the mean of triplicate transfections. Error bars represent standard error 
of the mean. 
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6.3. Effects of CGP57380 on mRNA subcellular localisation 
The results from the above experiment may therefore suggest that degradation of 
RNA may be the mechanism for the reduction in total cellular RNA seen following 
both treatment with CGP57380, and transfection with MNK1 and MNK2 directed 
siRNA. It may be postulated that in the face of known data showing that 
phosphorylated eIF4E can regulate the nuclear export of a subset of RNA 
molecules
170, cyclin D1 RNA may accumulate in the nucleus, and then become 
degraded in the nuclear compartment, resulting in an overall decrease in total 
RNA. 
An insight into the distribution of cyclin D1 RNA within the cell following inhibition of 
eIF4E phosphorylation may be gained by fractionating cells into nuclear, 
cytoplasmic and polysome fractions after treatment with CGP57380. Subsequent 
measurement of the amount of cyclin D1 RNA in each compartment may therefore 
provide an indication of the fate of transcribed RNA. Therefore ACHN cells were 
treated with CGP57380 or DMSO vehicle control for 6 h before undergoing 
fractionation. RNA was then extracted from each cell fraction, and the amount of 
cyclin D1 RNA measured and normalised to the housekeeping gene GAPDH. 
Fractionation was confirmed using semi-quantitative RT-PCR to measure the small 
nuclear RNA U6 in each fraction, which confirmed enrichment of the nuclear 
compared to the cytoplasmic fraction (fig 6:5). 
     156 
 
 
 
 
 
 
Figure 6:5 Fractionation of ACHN cell line 
ACHN cells were fractionated using fractionation buffer A and a Dounce 
homogeniser as described. RNA was extracted from each fraction using phenol 
and cDNA synthesised. PCR was performed with two quantities of input cDNA for 
each sample, the second reaction representing one third of the input cDNA of the 
first. The upper bands show U6 small nuclear RNA and the lower GAPDH control 
for total (unfractionated) nuclear and cytoplasmic samples. 
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Subsequently qRT-PCR was used to measure cyclin D1 RNA in each of the 
fractionated samples including the polysome fraction (fig 6:6). This confirmed a 
reduction in the total RNA in cells treated with CGP57380 consistent with previous 
experiments. A global reduction was therefore also seen in all of the cell fractions 
from the samples treated with the MNK inhibitor. To provide a clearer indication of 
the relative distribution of the cyclin D1 RNA the results were normalised to the 
amount of total cyclin D1 RNA. This showed a relative accumulation of RNA in the 
nuclear fraction compared with either the cytoplasmic or polysome fractions in 
those cells treated with CGP58380.  158 
 
 
 
Figure 6:6 Cyclin D1 RNA in ACHN cell fractions 
ACHN cells were treated with CGP57380 20 µM or 0.5% DMSO vehicle control for 6 h. Cells were harvested by scraping and 
fractionated as described with fractionation buffer A and a Dounce homogeniser. RNA was extracted from each fraction, cDNA 
synthesised and cyclinD1 RNA quantified with qRT-PCR. Left panel represents absolute cyclin D1 RNA levels in each fraction 
normalised to GAPDH. Bars are mean and standard error of triplicate repeat qRT-PCR reactions. The right panel represents 
values normalised to the levels of cyclin D1 RNA in the unfractionated (total) sample for each condition.
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Together these results suggest that cyclin D1 RNA is not regulated at the 
transcriptional level by treatment with CGP57380, and that there is a relative 
accumulation of cyclin D1 RNA in the nucleus in the context of a decrease in total 
cellular cyclin D1 RNA. Possible explanations for these findings include either an 
accumulation and subsequent degradation of RNA within the nucleus, or 
degradation of RNA in the cytoplasm.  
A further method of investigating the fate of RNA in response to inhibition of the 
MNK proteins with CGP57380 is to label newly synthesized RNA, and measure the 
effects of the compound on the relative levels of both total and newly synthesised 
transcripts. RNA can be labelled by incorporating 4-thiouracil, such that when RNA 
is extracted, the sulfhydryl groups can be biotinylated and the newly synthesized 
RNA extracted by binding to strepdavadin labelled magnetic beads. Thus ACHN 
cells were treated with CGP57380 or DMSO vehicle control for 1 h before the 
addition of 4-thiouracil and incubation for a further 6 h. Following this the 4-
thiouracil labelled, newly synthesized RNA was extracted, and cyclin D1 RNA 
measured in both the newly synthesized fraction, and the unlabelled fraction using 
qRT-PCR. A reduction in cyclin D1 RNA was seen in the CGP57380 treated cells 
for both the labelled and unlabelled RNA, however the reduction seen in the 
unlabelled RNA was greater than that seen in the newly synthesized labelled 
samples (fig 6:7)
The more significant reduction in cyclin D1 RNA from the unlabelled RNA fraction 
would suggest that this may be the driver of the overall reduction in cyclin D1 RNA 
leading to a reduction in cyclin D1 protein. This would further support a hypothesis 
that existing RNA in the cell accumulates within the nucleus and is subsequently 
degraded, and that subsequently newly synthesised RNA which would also lie 
within the nucleus also starts to be degraded leading to a reduction in 4TU labelled 
RNA, but one less significant than that seen for the existing pool. This could be 
further investigated by performing a series of labeling experiments over a time 
course to identify the time points at which a reduction in 4TU labelled and 4TU 
unlabelled RNA are seen.  160 
 
Figure 6:7 4-Thiouracil labeling of cyclin D1 RNA 
ACHN cells were plated and treated with CGP57380 20 µM or 0.5% DMSO vehicle control. 1 h later 4-thiouracil was added to 
each dish and incubated for a further 6 h. Cells were harvested and the 4-thiouracil biotinylated. Strepdavidin beads were used to 
extract the biotinylated RNA. cDNA was synthsesised from the extracted biotinylated RNA (4TU Labelled), and the un-labelled 
RNA (4TU Unlabelled). qRT-PCR was used to measure the amount of cyclin D1 RNA in each sample normalised to GAPDH. 
Results represent the mean of triplicate qRT-PCR reactions from a single biotinylation experiment.
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
DMSO    CGP57380 
C
y
c
l
i
n
 
D
1
 
m
R
N
A
 
 
(
n
o
r
m
a
l
i
s
e
d
 
G
A
P
D
H
)
 
Cell treatment 
4TU Unlabelled 
0 
20 
40 
60 
80 
100 
120 
140 
160 
DMSO    CGP57380 
C
y
c
l
i
n
 
D
1
 
R
N
A
 
(
n
o
r
m
a
l
i
s
e
d
 
G
A
P
D
H
)
 
Cell treatment 
4TU Labelled   161 
6.4. Novel targets of regulation of RNA in response to CGP57380 
Studies in prostate cancer have used a microarray platform with 263 genes specific 
to prostate cancer to assess the impact of CGP57380 on polysome recruitment. 
Eight genes were identified in which polysome recruitment was down-regulated. 
These including cell cycle regulatory genes, the cyclin dependent kinases CDK2, 
CDK8, CDK9, and the CDK inhibitor KAP1
74. Genome wide array analysis provides 
a platform whereby genes across the whole human genome can be investigated in 
a single experiment. This provides the potential to investigate additional targets of 
CGP57380. By measuring the effects of MNK inhibition on gene expression in total 
cellular mRNA extracts, additional genes in which total mRNA may be reduced 
might be identified. 
Phosphorylation of eIF4E can play a dual role in the regulation of protein synthesis, 
both through regulation of RNA export and regulation of cap binding. It has been 
postulated through the experiments described in this work that retention of RNA 
within the nucleus and subsequent degradation may be the explanation for the 
changes in total RNA seen. Measurement of total cellular mRNA would not 
however directly measure the effects of CGP57380 on translation, which is rather 
most closely represented by the degree of polysome recruitment of mRNA 
molecules. Thus by additionally analysing the changes in RNA in the polysome cell 
fraction, those genes regulated through cap binding, and subsequently ribosome 
loading, might be identified. 
Thus data may be obtained regarding the regulation of both cyclin D1, and other 
mRNAs at multiple levels. By comparing the gene expression in whole cell RNA 
extracts (total mRNA) following treatment with CGP57380, changes may be seen 
which might be accounted for either by reduced transcription or enhanced 
degradation. The work described so far would suggest that this is due to 
degradation. The closest correlate to protein expression however would be 
obtained from the expression of genes in the polysome cell fraction ie those RNA 
molecules actively undergoing translation. Changes in polysome recruitment may 
simply be a consequence of changes in either transcription or degradation as 
identified through analysis of total mRNA samples, however additionally direct 
regulation of translation, for example through polysome loading, would also 
influence this result. The combination of these two data sets may therefore provide   162 
the most powerful analysis by indicating a shift in mRNA to or from the polysome. 
By examining the ratio of polysome associated to total mRNA in untreated cells, an 
indication of baseline translational efficacy may be obtained. Any change in this 
ratio seen on repeating this analysis following treatment of cells with CGP57380 
may indicate a change in polysome association due to translational control, 
providing that an absolute decrease in expression in the polysome fractions 
between control and treated cell is seen. Should the change in the ratio be due to 
an increase in total cellular mRNA, this could be explained by enhanced 
transcription which has not yet affected polysome loading, but would be apparent 
due to an absolute change in total rather polysome associated mRNA. 
ACHN cells, in which cyclin D1 protein and mRNA down regulation has been 
consistently identified were used for these experiments. Previous time course 
experiments have identified 6 h as a time by which a marked reduction in cyclin D1 
mRNA was seen. Thus ACHN cells were treated for 6 h with CGP57380 at 20 µM 
following which cells were harvested and fractionated into nuclear, cytoplasmic and 
polysome fractions, with retention of whole cell samples prior to fractionation. Two 
independent experiments were performed, and RNA extracted from both whole 
cells and each cell fraction using phenol extraction. Qiagen RNeasy spin columns 
were then used as a clean up step to obtain purified RNA which was snap frozen 
and stored at -80 °C. 
The Affymetrix GeneChip Human Genome U133 plus 2 array was used for these 
experiments. This array chip includes 38,500 characterised human genes, with 11 
pairs of oligonucleotide probes for each gene. RNA samples were couriered on dry 
ice and array experiments were performed by the Patterson Institute Micro-array 
Service (Manchester). 
cDNA synthesis was performed as a 2 step process using a NuGen WT Ovation 
Pico RNA amplification and labeling protocol. Newly synthesised cDNA was 
purified using RNAClean magnetic beads followed by an amplification step with a 
SPIA amplification protocol and a further purification step. Quantified cDNA was 
then fragmented and labeled with biotin using a NuGen Encore Biotin module. 
Biotin labeled cDNA was hybridised to the HG-U133 gene chip array during a 16 h 
incubation and then washed and stained with a strepdavidin-phycoerythrin   163 
conjugate. The chip was read using a GeneChip Scanner 3000 with emission 
intensity at 570nm proportional to bound target cDNA. 
Data manipulation was performed using Genepattern software hosted by the Broad 
Institute
171. The raw data from the array experiments showing individual probe 
fluorescence was uploaded as cel files. Pre-processing was performed using 
Robust Multi-Array analysis (RMA). This three component protocol incorporates 
background correction to account for optical noise and low level non-specific 
hybridisation to probes. Normalisation between samples allows comparison 
between chips. Finally summarisation combines the corrected and normalised data 
from each probe set to give a single expresssion measure for each gene. 
Comparisons between treatment conditions were made using differential 
expression analysis. A two-sided t-test was used to assess differences in individual 
genes. A p value !0.05 and a greater than 2 fold absolute change in expression 
was used to define genes of interest. 
 
An initial analysis was made of those genes differentially expressed in the total 
mRNA samples. 1791 features were identified with a significant difference in 
expression (p!0.05). When this analysis was limited to those with an absolute fold 
change of >2 a subset of 169 features was identified (fig 6:8). Of these 61 were 
down regulated, representing 53 known genes, and 108 up regulated, representing 
72 known genes. 
Of note the list of genes which were downregulated included cyclin D1. Two probe 
sets for this gene are represented on the HG-U133 chip, one showing a 3.8 and 
the other showing a 3.5 fold reduction in expression, comparable to the data 
obtained from qRT-PCR. 
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Figure 6:8 Genes differentially expressed in total RNA samples 
Fold change in RNA expression for 169 features showing a significant difference 
(p!0.05) in expression between CGP57380 treated and untreated cells with a fold 
change of at least 2. 
 
Within the gene set showing differential expression in the total mRNA samples, 
several genes were identified with critical regulatory functions in cellular 
metabolism (table 6:1). Two genes which encode enzymes with rate limiting effects 
in the glycolytic pathway were identified, with a decrease in expression following 
treatment of cells with CGP57380. Hexokinase (HK) catalyses the conversion of 
glucose to glucose-6-phosphate as the initial step in the glycolysis pathway, and is 
associated with the outer mitochondrial membrane. Although catalysing an 
anaerobic metabolic pathway, it consumes ATP generated through oxidative 
phosphorylation within the mitochondria. It is the rate-limiting step in glycolysis in 
fast growing tumour cells
172. 6-phosphofructo 2-kinase (PFKB3) catalyses the 
conversion of fructose-6-phosphate to fructose-2,6-bisphosphate (F2,6BP). 
Although not itself an intermediary in the glycolytic chain, F2,6BP is an allosteric 
promoter of the activity of phospho-fructokinase-1, a component of the glycolytic 
pathway. PFKB3 is highly expressed in tumours, and indeed shows high 
expression in the ACHN renal cancer cell samples examined in these experiments. 
It is highly inducible both by hypoxia, and its activity is induced by growth factors, 
and as such has been suggested as a potential anti-neoplastic target
173. 
In contrast, phosphoenolpyruvate carboxykinase 2 was up regulated and has a key 
role in gluconeogenesis, suggesting a switch from a glycolytic metabolic pathway. 
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This would be supported by an increase in other genes associated with the TCA 
cycle including Isocitrate dehydrogenase 1 and acyl-CoA synthetase medium-chain 
family member 3.  166 
 
Feature ID  Gene 
abbreviation 
Gene name  Fold change  P 
222305_at  HK2  Hexokinase 2  -2.9  0.04 
202464_s_at  PFKFB3  6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 
-2.5  0.03 
242001_at  IDH1  Isocitrate dehydrogenase 1  2.4  0.01 
205942_s_at  ACSM3  acyl-CoA synthetase medium-chain family 
member 3 
2.2  0.01 
202847_at  PCK2  phosphoenolpyruvate carboxykinase 2 
(mitochondrial) 
3.9  0.02 
205047_s_at  ASNS 
 
asparagine synthetase (glutamine-hydrolyzing) 
 
3.4  0.05 
 
 
Table 6:1 Genes with cellular metabolic functions and altered expression following treatment with CGP57380 
Genes with significant up or down-regulation of expression and at least a 2 fold change in expression following treatment of 
ACHN cells with CGP57380. Total RNA samples.  167 
 
Online software was used to look for enrichment of particular functional categories 
within the regulated genes identified. The database for annotation, visualisation 
and integrated discovery (DAVID http://david.abcc.ncifcrf.gov) allows comparison 
of an uploaded geneset with the background incidence of functional groups within 
the genes represented on a specified array platform. By using a modified Fisher's 
exact test (EASE Expression Analysis Systematic Explorer) a statistical value is 
given to the strength of association of a functional class of genes within the 
geneset analysed. 
The top functional groups identified within the set of genes regulated in the total 
RNA samples were genes encoding phosphoproteins, genes of the Sprouty family, 
genes involved in response to oxidative stress, and genes encoding sequence 
specific DNA binding domains (table 6:2). The group of phosphoproteins was the 
largest at 71 genes, representing over 50% of the genes identified as significantly 
altered in expression, and was not therefore helpful in identifying patterns of gene 
expression. 
The sprouty (Spry) and sprouty related proteins (Spred) are negative regulators of 
MAPK signaling. Spry2 is a target of MNK1
66, which is able to phosphorylate and 
hence stabilise Spry2, potentially creating a negative feedback loop in the MAPK 
signaling pathway. Although there is no known link between Spry or Spred 
transcription and MNK activity, the link with a known target of MNK1 would support 
the activity of CGP57380 through the MNK kinases. 
Several genes were identified with a function involved in the response to oxidative 
stress. Signaling through the MAPK signaling cascade is involved in the cellular 
response to oxidative stress, in particular the balance between ERK and JNK 
signaling pathways
174. The MNKs are activated by ERK and p38 MAPK but not 
JNK, and it may be that by inhibiting MNK activity a change in the balance of 
signaling through these different aspects of the MAPK signaling pathway is 
achieved, manifesting in altered regulation of genes involved in oxidative stress. It 
must also be born in mind that DMSO vehicle control was used to treat the cells in 
these experiments, which itself has anti-oxidant properties. Both treated and 
control cells were exposed to the same concentration of DMSO for the same time 
course, so differential expression of genes related to DMSO exposure should not 
be seen.   168 
The third functional group identified was sequence specific DNA binding, 
representing several transcription factors (table 6:2). The gene within this group 
with the highest level of fold change was fos-like antigen 1 (FOSL1) which was 
also represented in the oxidative stress group. FOSL1 binds members of the JUN 
family to form the AP-1 transcription factor. AP-1 has been identified as a regulator 
of both c-MYC and cyclin D1 transcription, and can be itself be regulated through 
inhibition of mTOR in cells with activated AKT
175. It is therefore possible that cyclin 
D1 transcription could also be regulated at a transcriptional level by the MNK 
proteins through this mechanism.     169 
Functional Group/ 
Feature ID 
Gene symbol/name  EASE 
Fold Change 
Sprouty  p<0.01 
212558_at  SPRY1/sprouty homolog 1  -2.1 
235074_at    SPRED1/sprouty-related, EVH1 domain containing 
1 
-2.4 
214026_s_at    SPRED2/sprouty-related, EVH1 domain containing 
2 
-2.2 
Response to oxidative stress  p<0.01 
204420_at    FOSL1/FOS-like antigen 1  -6.6 
230711_at    EPAS1/endothelial PAS domain protein 1  +2.2 
218120_s_at    HMOX2/heme oxygenase (decycling) 2  -2.9 
242956_at    IDH1/isocitrate dehydrogenase 1 (NADP+), soluble  +2.4 
238408_at    OXR1/oxidation resistance 1  +2.0 
232375_at    STAT1/signal transducer and activator of 
transcription 1 
+2.2 
201008_s_at    TXNIP/thioredoxin interacting protein  +3.9 
Sequence Specific DNA Binding  p<0.01 
212501_at    CEBPB/ CCAAT/enhancer binding protein (C/EBP), 
beta 
+3.4 
203973_s_at    CEBPD/ CCAAT/enhancer binding protein (C/EBP), 
delta 
+2.3 
204420_at    FOSL1/FOS-like antigen 1  -6.6 
205313_at    HNF1B/HNF1 homeobox B  -2.1 
202672_s_at    ATF3/activating transcription factor 3  +2.9 
230711_at    EPAS1/endothelial PAS domain protein 1  +2.2 
1553613_s_at  FOXC1/forkhead box C1  -2.4 
208025_s_at    HMGA2/high mobility group AT-hook 2  -4.6 
214639_s_at    HOXA1/homeobox A1  -2.0 
232375_at    STAT1/signal transducer and activator of 
transcription 1 
+2.2 
244521_at    TSHZ2/teashirt zinc finger homeobox 2  +2.9 
217367_s_at    ZHX3/zinc fingers and homeoboxes 3  -2.1 
 
Table 6:2 Functional groups statistically over-represented within genes with 
altered expression following treatment with CG57380. Total RNA samples   170 
Analysis of those genes differentially expressed in the polysome fraction revealed 
1155 features with a significant difference in expression (p!0.05). Limiting this to 
those with at least a 2 fold change revealed 264 features, 142 of which were down 
regulated and 122 up regulated (Fig 6:9). This gene set included MCL-1 with a 3.8 
fold reduction in the polysome fraction between treated and untreated cells. This is 
consistent with a reduction of translation of this transcript, and with the findings of 
protein analysis in response to treatment of cells with CGP57380. 
 
 
 
Figure 6:9 Genes differentially expressed in polysome associated RNA 
samples 
Fold change for 264 features showing a significant difference (p!0.05) in 
expression between CGP57380 treated and untreated cells with a fold change of at 
least 2. 
 
The highest changing gene in the polysome fraction was MAFF with a decrease of 
16 fold. The Maf proteins are transcriptional regulators which are able to form 
homo-dimers, or heterodimers with other transcription factors including the collar 
and cuff (CNC) family
176. This includes the Nrf proteins which act as transcription 
factors, binding antioxidant response elements (AREs) in the nucleus to induce 
antioxidant genes when cells are exposed to oxidative and electrophile stresses. 
Nrf2 has been implicated both in carcinogenesis, such that induction of Nrf2 is 
protective against the development of the malignant phenotype, but also in the 
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resistance to cancer therapy, with induction of Nrf2 in response to 
chemotherapeutics
177. 
 
In order to explore the changes in regulation of translation due to treatment of cells 
with CGP57380, an analysis of the shift in mRNA from the total to the polysome 
fraction was made, based on previous analyses by Bushell et al
178. The ratio of 
polysome associated to total mRNA was calculated for each gene to define the 
level of translation. In this calculation, genes with a higher level of expression in the 
polysome fraction i.e. being actively translated, compared to the total sample i.e. 
being transcribed, would be regarded as being more efficiently translated. A 
percent rank function was used to define the position of each gene within the 
genome with respect to its translational efficiency. In order to exclude genes in 
which changes in transcription rather than translation were the cause of changes in 
the ratio, only those genes with a significant absolute change in polysome 
associated mRNA were selected. The change in position within the percent rank 
was then calculated for each gene. In order to exclude genes in which small 
changes in low levels of expression (therefore appearing to have a large relative 
change) were seen, only those genes with a change in percent rank (delta percent 
rank) of greater than 20 were included. Two populations of genes were 
established, those with a negative value for delta percent rank, i.e. those in which 
inhibition of MNK proteins resulted in a reduction in translational efficiency, and 
those with a positive delta percent rank in which inhibition of the MNKs resulted in 
an enhanced level of transcriptional efficiency. 203 genes were identified in which 
translation appeared to have decreased, with a further 284 genes with a positive 
delta percent rank of greater than 20, where translational efficiency appeared to 
have increased giving a total of 487 genes in which translation seemed to have 
been significantly altered by treatment of the cells with CGP57380.  
Using functional annotation clustering as described above, 55 functional groups 
were identified with a significant EASE score. Due to the redundancy within 
functional groups, these can be combined into higher order groups containing 
similar functions. In this way a broader group containing multiple similar functional 
subgroups is obtained. Using this method, the top three clusters contained genes 
associated with; intracellular non-membrane bound organelles, post-transcriptional   172 
gene silencing, and transition metal ion binding. These three groups contained 77, 
4 and 83 genes respectively (table 6:3). 
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Functional Group Cluster / Gene Name    Delta percent rank 
Intracellular non-membrane bound organelles 
AT rich interactive domain 4B (RBP1-like)  -20.5 
CDC14 cell division cycle 14 homolog A (S. cerevisiae)  +28.9 
CDC5 cell division cycle 5-like (S. pombe)  -55.6 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 20  -40.8 
Post-transcriptional gene silencing 
Mov10, Moloney leukemia virus 10, homolog (mouse)  +45.6 
lin-28 homolog B (C. elegans)  -24.1 
protein kinase, interferon-inducible double stranded RNA dependent 
activator 
-38.0 
zinc finger, CCHC domain containing 11  +46.5 
Transition metal ion binding     
ADAM metallopeptidase domain 5 pseudogene  +35.4 
ADAM metallopeptidase with thrombospondin type 1 motif, 2  -32.9 
ATP/GTP binding protein-like 5  +26.7 
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2  +22.7 
 
Table 6:3 Functional annotation clustering of genes with delta percent rank 
greater than 20 
Genes in which the ratio of polysome to total expression is altered. Three gene 
clusters were identified. The top 4 ranked genes for each cluster are shown. 
 
A relatively large number of genes are clearly influenced by CGP57380 at the 
translational level with both increases and decreases in delta percent rank seen 
suggesting the ability of this compound to both promote and inhibit translation. Of 
note several genes involved in cell cycle regulation have been identified in the 
intracellular non-membrane bound organelle cluster. AT rich interactive domain 4B 
is often over-expressed in breast cancer, and has a dual role in the regulation of 
cell proliferation, through an ability to bind retinoblastoma protein, and also to from 
part of a histone deacetylase-dependent transcriptional co-repressor complex
179. 
CDC14 is a homolog of a gene well described in S. cerevisiae with an important 
function in the exit from mitosis. CDC14 is a phosphatase and is responsible for 
inactivation of cyclin dependent kinases at the end of mitosis
180. Equally in the 
post-transcriptional gene silencing group, Mov10 is a putative RNA helicase, with 
activity against INK4a, itself an inhibitor of cell cycle progression
181. 
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6.5. Discussion 
Having established in earlier chapters that inhibition of the MNK proteins with 
CGP57380 can inhibit cell cycle progression in association with a reduction in 
cyclin D1 protein, the work in this chapter has investigated in more detail the 
mechanisms underlying the regulation of cyclin D1 at a transcriptional and 
translational level. In addition novel targets for regulation by the MNK proteins have 
been investigated. 
Previous work has identified nuclear export of cyclin D1 RNA as the method of 
regulation of cyclin D1 protein in response to inhibition of the MNKs with 
CGP57380
12. The work in this chapter has however clearly shown that on treating 
cells with CGP57380 not only is a reduction in cyclin D1 protein seen, but also in 
total cellular cyclin D1 RNA as measured using quantitative RT-PCR. This effect 
has been reproduced using siRNA targeted at the MNK proteins suggesting that it 
is indeed specific to an effect of CGP57380 on eIF4E phosphorylation, rather than 
an off target effect on other kinases identified in in vitro kinase screening assays
124. 
Potential mechanisms for a reduction in total cyclin D1 cellular RNA would have to 
result from either a reduction in newly synthesised cyclin D1 RNA, i.e. regulation of 
transcription, or through enhanced degradation. In order for transcriptional 
regulation of cyclin D1 RNA to solely account for the reduction seen, the stability of 
the existing pool of RNA would have to be such that on complete inhibition of 
transcription, existing RNA would rapidly degrade. Treating cells with Actinomycin 
D in order to inhibit transcription however, showed stability of cyclin D1 RNA at 6 h, 
the time point in which a reduction in cyclin D1 RNA was seen on treatment with 
CGP57380. A reporter assay was performed to directly investigate the effect of 
CGP57380 on transcription. Surprisingly this assay demonstrated enhanced cyclin 
D1 promoter activity in response to CGP57380, compatible with increased rather 
than decreased transcription, but contrary to the effects of CGP57380 seen on 
cyclin D1 protein and RNA as investigated by western blotting and qRT-PCR 
respectively. 
Further evidence for enhanced degradation of RNA rather than reduced 
transcription was seen when cells were treated with 4-thiouracil in order to label 
newly synthesised RNA. Although treatment with CGP57380 showed a reduction in 
both labelled (newly synthesised) and unlabelled RNA, the larger reduction in   175 
unlabelled RNA would suggest this to be the driver of the reduction in total RNA 
seen. A model could therefore be suggested where degradation of RNA 
predominantly effects the existing pool, with some degradation of newly 
synthesised RNA also occurring, at a rate greater than transcription. 
In order to investigate the localisation of cyclin D1 RNA within the cell following 
treatment of cells with CGP57380, cellular fractionation was performed. This 
showed a reduction in cyclin D1 RNA in all cellular compartments, however when 
the absolute levels of RNA were normalised to the levels of total cellular RNA, a 
relative accumulation of cyclin D1 RNA was seen within the nuclear compartment. 
Existing data shows an effect of inhibition of cyclin D1 RNA on nuclear export. The 
results described above suggest that to account for a reduction in total RNA in the 
absence of an effect on transcription, enhanced RNA degradation must occur. 
Thus on inhibition of eIF4E phosphorylation, RNA messages regulated by 
CGP57380 may first be retained within the nucleus, and then undergo degradation.  
This hypothesis would be supported by the data shown. 
A limited analysis of genes regulated in the polysome cell fraction was carried out 
by Bianchini et al
74 using a gene microarray limited to a geneset associated with 
prostate cancer. This identified several genes associated with cell cycle control to 
be reduced in the polysome fraction. Within the polysome fractions examined by 
geneome wide analysis in the experiments described above cdc5 was identified as 
having a 2 fold reduction in the polysome fraction, a gene involved in G2/M 
transition
182, however other cell cycle regulatory proteins were not identified in the 
polysome fraction. Within the total RNA samples, however cyclin D1 was identified 
as down regulated, with two probes for this gene showing 3.5 and 3.8 fold down 
regulation respectively, a similar change to that seen in previous qRT-PCR 
experiments. Additional genes with cell cycle regulatory roles were also identified 
which were regulated at the level of translation, as identified by changes in relative 
polysome loading (delta percent rank). These included genes directly involved in 
cell cycle regulation such as CDC14, and those with indirect action such as Mov10. 
Large numbers of genes have been identified within this genome wide array 
analysis which are influenced by CGP57380, both in respect to the total amount of 
RNA which can be measured in the cell, but also in polysome recruitment. This 
would support the hypothesis that eIF4E controls a regulon of mRNA molecules, 
with activity both at the level of nuclear export, but also initiation of translation
14.   176 
Analysis of these results raises a number of issues. Although many genes were 
identified with statistically significant results using a two sided t test, when 
analysing such a large number of data points, statistical correction for multiple 
testing should be made. A variety of methods exist for such corrected analysis 
including the false discovery rate
183, which accounts for the large numbers of 
statistical tests involved in analysis of an array experiment. When the results 
obtained from the array experiments described in this chapter were subjected to a 
false discovery rate analysis, the level of statistical significance was >0.05 in all 
cases. There may be a variety of explanations for this. It is possible that all of the 
results obtained could be false positives due to multiple testing. However the fact 
that genes previously identified as regulated both at the protein level through 
immunoblotting, and RNA level through qRT-PCR, were identified in the array 
experiment would suggest that this is not universally the case. The experiments 
performed were duplicate rather than triplicate repeats due to the cost of 
performing such analyses. When using an inherently unstable molecule such as 
RNA, the inter-experimental variation is likely to be high, and it may be that larger 
numbers of repeat samples are required to obtain sufficient statistical power to 
show significance in a false discovery rate calculation. Although some of the array 
results can be retrospectively validated, as the changes in cyclin D1 RNA seen in 
qRT-PCR experiments are replicated in the array dataset, clearly further validation 
of these results is required with qRT-PCR analysis of additional targets identified 
from this experiment. Several interesting targets are however identified which 
would be worthy of further analysis. 
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7. Final discussion and future work 
 
The work described in this thesis has confirmed the ability of CGP57380, through 
inhibition of the MNK proteins, to inhibit the proliferation of both breast and kidney 
cancer cell lines. This would suggest that the MNK proteins are a therapeutic target 
worthy of further investigation in these cancer types. 
 
Although previous work has identified the ability of CGP57380 to inhibit the 
proliferation of HER2 overexpressing breast cancer cells
73, this work has extended 
this growth inhibitory effect to breast cancer cells of all clinical phenotypes, 
including HER2 overexpressing, oestrogen receptor positive, and triple negative 
cell lines. Within the cell lines investigated there was a correlation between the 
basal levels of phosphorylated eIF4E and the ability of CGP57380 to inhibit 
proliferation, such that the line with low levels of eIF4E phosphorylation (MCF7) 
showed no growth inhibitory effect. Within the breast tumour tissue samples 
examined there was significant variation in the levels of phosphorylated eIF4E. 
These two features together would suggest that levels of phosphorylated eIF4E 
could be investigated further as a biomarker of response to inhibition of the MNK 
proteins should this be taken forward as a therapeutic strategy in breast cancer. 
 
The role of eIF4E phosphorylation in the proliferation of renal cancer cell lines has 
not previously been investigated. Previous work in prostate cancer cell lines has 
however identified HIF! as a target for regulation by phosphorylated eIF4E
74. Thus 
as HIF! has been identified as critical in the pathogensis of VHL mutant clear cell 
renal cell cancer
184, this would appear an attractive disease to target with inhibition 
of the MNK proteins. Not only has this work identified the ability of inhibition of the 
MNK proteins to inhibit the proliferation of renal cancer cell lines, it has shown this 
effect in both VHL wild-type and mutant cell lines. This would suggest therefore 
that HIF! is not the relevant target of the MNK kinases in renal cancer cell lines, for 
the regulation of proliferation. 
 
The mechanisms underlying inhibition of proliferation in both breast and renal 
cancer cell lines have been investigated. Both cyclin D1 and Mcl-1 have previously   178 
been identified as targets for regulation by phosphorylated eIF4E
12,69,170, and have 
been shown in this work to be inhibited on treatment of cells with an inhibitor of the 
MNK proteins. Thus both inhibition of cell cycle progression and induction of 
apoptosis are potential mechanisms underlying the anti-proliferative effects seen in 
breast and kidney cancer cells. Using a combination of techniques, cell cycle arrest 
has been identified as the dominant mechanism of inhibition of proliferation, with 
little or no effect on induction of apoptosis in either of the cancer types 
investigated. This correlates with other work where the effects of treatment of solid 
tumour cells with CGP57380 have been investigated 
74. The effects of CGP57380 
on the proliferation of B cell lymphoma cells has previously been investigated
75. 
This is the only published work in which CGP57380 has been used as an anti-
cancer agent in an animal model, and confirmed the ability of this compound to 
inhibit the growth of a lymphoma xenograft. The effects of inhibition of eIF4E 
phosphorylation on cyclin D1 protein were confirmed in these cells, however an 
increase in apoptosis in lymphoma cells treated with CGP57380 was also 
identified. Mcl-1 is however highly expressed in high grade lymphomas and is 
implicated in the survival of lymphoma cells
185. Thus although a reduction in cyclin 
D1 was identified in this study, it is likely that Mcl-1 is the dominant regulator of cell 
survival in this cell type, and as such the use of an agent known to inhibit Mcl-1 
translation would be likely to induce apoptosis in these circumstances. 
 
The specificity of CGP57380 for the MNK proteins has been questioned using in 
vitro protein kinase assays
124. Criteria have also been suggested for the 
demonstration of the specificity of kinase inhibitors for in vivo experiments
186. 
These include the ability of the kinase inhibitor to induce cellular effects at a 
concentration shown to induce inhibition of phosphorylation of known targets of the 
kinase of interest. The proliferation experiments described in breast and kidney 
cancer cells have indeed been at doses in which inhibition of eIF4E 
phosphorylation has been demonstrated. Additional criteria include that no effect of 
the compound should be seen in cells in which a drug resistant mutant of the 
protein kinase has been induced. In this work a phospho-mimetic mutant of eIF4E 
was induced to generate resistance to CGP57380 and showed partial resistance in 
proliferation and cell cycle assays, again supporting the specificity of the action of 
CGP57380 through the MNK proteins.   179 
 
The effect of inhibition of eIF4E phosphorylation on cyclin D1 protein has been 
highly reproducible both in this work and in other groups investigating the effects of 
CGP57380
12,20,75. eIF4E is able to regulate translation of mRNA both through 
translation initiation, and mRNA nuclear export
14, and it is the latter which has been 
identified as regulating cyclin D1
13. Inhibition of eIF4E phosphorylation has not 
however previously been shown to impact on total cyclin D1 RNA. Having 
established a reduction in cyclin D1 RNA in renal cancer cell lines, no effect has 
been shown on inhibition of transcription using a reporter assay. By demonstrating 
the stability of cyclin D1 RNA to be longer than the time period over which a 
reduction in cyclin D1 RNA is seen after treatment with CGP57380, a hypothesis is 
generated in which enhanced degradation of RNA is induced. When taken together 
with experimental data showing a relative accumulation of cyclin D1 RNA within the 
nuclear compartment, this hypothesis can be extended to suggest that inhibition of 
eIF4E phosphorylation leads to a nuclear accumulation of cyclin D1 RNA, and 
subsequent degradation within the nuclear compartment. Further work is clearly 
required to prove this hypothesis, which could be achieved by combining some of 
the assays used in the work described in this thesis. By labeling newly synthesised 
RNA with 4-thiouracil, treating cells with CGP57380, and then fractionating cells at 
sequential time points, a clearer picture of the fate of both existing and newly 
synthesised RNA could be achieved. 
 
The final part of this project has investigated novel targets under the control of 
phosphorylated eIF4E using genome wide microarray. Multiple targets have been 
identified. Identifying changes in total cellular RNA would suggest regulation prior 
to translation, with the hypothesis suggested above that this is through RNA 
degradation within the nucleus. As has been previously alluded to, the results of 
this assay reached a level of statistical significance with a conventional t-test, but 
this did not hold up using false discovery rate. The results of this assay are 
therefore purely hypothesis generating, although did correlate with earlier qRT-
PCR analysis of cyclin D1 RNA. Several genes with key functions in cell 
metabolism were identified in this group suggesting the induction of a metabolic 
switch from aerobic glycolysis to oxidative phosphorylation, a reversal of the 
Warburg effect
179, and a therapeutic strategy increasingly being investigated in   180 
cancer
175. By investigating changes in RNA within the polysome fraction, and in 
particular shifts in the ratio of total to polysome associated RNA a picture of those 
genes regulated at the translational level can be obtained. Clearly a change in the 
expression of multiple genes is seen at this level, and of particular note both up-
regulation and down-regulation of gene expression at the level of translation is 
seen. Given the proposed established mechanisms of eIF4E function, either 
through induction of cap binding, or control of nuclear export, it would seen unlikely 
that a direct effect in up-regulating gene expression would be achieved by blocking 
the phosphorylation of eIF4E. It is more likely however that following the down-
regulation of transcription and other factors involved in the regulation of gene 
expression by inhibiting eIF4E phosphorylation, subsequent events may result in 
an up-regulation of gene expression. 
 
Although CGP57380 is active in inhibition of eIF4E phosphorylation and induction 
of cell cycle arrest at relatively high concentrations, it is certainly not sufficiently 
potent to be used as a therapeutic agent. Work is underway by other groups to 
develop more active inhibitors of the MNK proteins. A compound has recently been 
identified via high throughput screening with inhibition of the MNK kinases in the 
nanomolar range, and a preferential inhibitory effect on MNK2. This agent, 
cercosporamide, is orally active in animal models, and has shown the ability to 
prevent the growth of colon cancer and melanoma human xenografts in a mouse 
model
187. The MNK kinases should thus be pursued for further development as 
therapeutic targets and their inhibitors should ultimately enter the arsenal of 
molecularly targeted agents as cancer therapy enters the age of personalised 
medicine. 
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